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Abstract
Food allergy, defined as an adverse immune response to food, is increasing in preva-
lence. It can be broadly separated into phases of sensitization, in which allergy-
triggering Immunoglobulin E (IgE) is generated, and the post-sensitization allergic
response, in which the allergic response is triggered by sensitizing allergen. While
much is known about the specific mediators that cause allergies, the immune pro-
cesses that underlie disease progression are less clear. This project has employed
mouse models of Th2 immunity to clarify the factors involved in the initiation and
maintenance of allergic disease.
At the centre of allergic disease is the Interleukin (IL)-4-producing CD4+ T helper
type 2 (Th2) cell. One of the key inducers of Th2 cell development in vitro is IL-4,
but its involvement in Th2 cell development in vivo is controversial. In our studies,
we saw that Th2 cell development could be initiated in vivo by primary, adjuvant-free
allergen immunisation in the absence of IL-4. However, Th2 cells were more frequent
in IL-4-sufficient conditions. We also determined that genetic lesions that result in
loss of one, or both, IL-4 alleles impaired the Th2 cell-mediated allergic process, such
that IL-4-heterozygous mice can be considered haplo-insufficient for IL-4 in allergic
disease contexts.
In addition to the generation of IgE antibody, Th2 cells are implicated in the post-
sensitization phase of allergy. Multiple oral challenges of sensitized mice induces
elevations in Th2-associated cytokines and elevates intestinal mast cell frequencies.
It was the second aim of this project to clarify the role of CD4+ T cells in the post-
i
sensitization intestinal allergic process. We demonstrate a key role for CD4+ T cells
in this jejunal mast cell recruitment, and identify that this is required in addition
to their established contribution to IgE production. Our investigations also reveal
a previously unappreciated role for the CD4+ T cell-derived cytokine IL-3 in oral
food allergy. These findings suggest that intestinally localised mast cell-inducer Th2
(Th2m) cells are required for allergic responses generated in the intestine.
We also investigated whether specific components of ruminant milks influence the al-
lergic process. While goat and cow milks share significant protein homology, goat milk
has lower sensitizing and response-evoking capacity, or allergenicity, than cow milk,
in numerous experimental systems. In this project, we compared dominant allergens
purified from cow and goat milks for their ability to initiate Th2 cell development.
We also examined the ability of one of these allergens to initiate the intestinal allergic
process. In these studies, we observed similar Th2 cell development and intestinal
mast cell activity in response to both cow and goat milk proteins. These responses
indicate that the intrinsic allergenicity of the proteins analysed is not sufficient to
explain the differential allergenicity attributed to cow and goat milk.
These studies examine the endogenous and exogenous factors that contribute to the
development of allergic disease. This project clarifies the role of IL-4 in in vivo Th2
cell development, identifies functional segregation of CD4+ Th2 cells in the intestinal
allergic process and further illustrates some of the similarities in the allergenicity of
isolated cow and goat milk proteins. Collectively, these studies uncover fundamental
aspects of the allergic process which may be useful targets for disease intervention in
both prophylactic and therapeutic settings.
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Chapter 1
General Introduction
1.1 Thesis overview
Food allergy remains a life-threatening problem in society today. One in twenty
children will have an allergic episode before they turn three, and the majority of these
will be invoked by a common dietary protein. Over 90% of these will be induced by
one of six foods: cows milk, egg, peanut, tree nuts, wheat or soy. It is still unclear why
these six foods are common allergens, and further more, why only some people will
develop an allergy at all. This project aimed to clarify the basic immune processes
that result in allergic disease.
Research over the past hundred years has made great advances in the field of allergic
disease research. The key mediators of the allergic response have been elucidated; the
cell types involved in the response are known; and a number of risk factors have been
identified. However, our current understanding of the allergic process is inadequate.
We don’t know the first steps that lead to allergic sensitization; we are not able to
predict with reasonable certainty which children will become allergic; we don’t know
how to prevent an allergy from developing; and most critically, we don’t know how to
turn an established allergy off.
This thesis begins with a general introduction into the field of allergy. In this in-
troduction, knowledge of the role of mast cells and the immunological processes that
underlie allergic sensitivity are outlined. Some of the epidemiology of allergy is cov-
ered and is also used as evidence that supports the concept of intrinsic allergenicity,
which is subsequently investigated for some common allergens. As interleukin(IL)-4
producing, CD4+ T helper type 2 (Th2) cells are heavily implicated in the allergic
process and are a major focus of this thesis, their development and contribution to
the allergic process are discussed in depth. Chapter two provides details of the meth-
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ods that were used during this project. Chapters 3-6 present the project findings
regarding Th2 cell development and function in allergic immunity.
The focus on the Th2 cell arose from previous studies in our lab that broke the
historically accepted view that IL-4 is required to initiate Th2 cell development[1].
From these earlier studies, questions pertaining to the true contribution of IL-4 to
Th2 cell development naturally evolved and were accordingly investigated. These
studies, in turn, gave rise to the question of how genetic defects in IL-4 production
affect not only Th2 cell development, but also their function. These concepts are the
focus of Chapter four. Chapter five aims to clarify the role of CD4+ T cells in the
post-sensitisation phase of food allergy, and in the final results chapter, a series of
tests are performed that aim to clarify why goats milk is a less allergenic food than
cows milk. Future directions and potential implications of our findings are covered at
the end of each chapter, and a general overview of the concepts contained within are
discussed in Chapter seven.
My dissertation covers the reasons that I think allergies are still problematic. It out-
lines our attempts to clarify unknown facets of Th2 cell development and function, and
in this, specifically addresses some fundamental aspects of the allergic process. Under-
standing the immunological processes that lead to the physiological allergic response
has great potential to reduce the burden of allergic disease in society today.
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1.2 Allergy and food induced allergic reactions
1.2.1 What is allergy?
Allergy, or type I hypersensitivity, is an acute adverse immune response to a generally
innocuous protein or substance. The current paradigm of allergy links back to the
1800s[2], with the first direct tests carried out 100 years ago in dogs[3]. Portier and
Richet[3] determined that when dogs are immunised with two additively non-lethal
doses of poisonous Physalia man o’ war tentacle extract, if the second injection is
given two weeks after the first, the dogs will collapse, develop cyanosis and in many
cases, die. These studies gave rise to the concept that underpins allergy as it is under-
stood today. More general allergic symptoms include vomiting, diarrhoea, wheal and
flare, urticaria, wheezing and bronchospasm and some or all of these symptoms can
be triggered simultaneously during an allergic response[4–6]. Fatal allergic anaphy-
laxis is usually attributed to complications involving the respiratory and circulatory
system, caused by either hypovolaemic systemic shock and inadequate organ perfu-
sion or difficulties with breathing[5–8]. Food allergy is defined as an adverse immune
response to food[9, 10]. To manage an allergy, people are advised to practise aller-
gen avoidance[10, 11]. However, the rapid onset and potential severity of an allergic
episode make it necessary to develop new strategies to deal with allergies. This is
particularly important because one in four cases of fatal anaphylaxis is caused by un-
intended allergen ingestion, and immediate adrenalin administration, which is the best
current intervention, does not prevent death in every case[7, 8]. There is currently
no treatment available that is entirely sufficient for the prevention of anaphylactic
death[5, 7, 8]. Food allergy is thought to be increasing in prevalence[9, 10, 12] and
understanding ways to subvert the immune processes that precede allergic responses
are key directions of current medical research.
1.2.2 IgE is at the centre of allergic disease
Food allergies are distinguished from food intolerances because an allergy is caused
by an active immune response against a specific food[10]. Food intolerances can be
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caused by specific food components, but are not immune mediated. For example,
an inability to absorb and breakdown fructose or lactose is associated with gastroin-
testinal discomfort and diarrhoea that disappears with elimination of the sugars from
the diet[13–15]. Toxins in foods and pharmocologically active molecules like caffeine
can also cause food allergy-like symptoms[5]. The food allergy response is also acute,
which helps distinguish it from other chronic forms of gastrointestinal disorder, like
inflammatory bowel disease or functional diarrhoea[16–18]. The current view of al-
lergy is that on first allergen exposure, either in utero or soon after birth[19, 20],
sensitization occurs such that subsequent exposures can trigger an allergic response.
The culmination of the sensitization phase is the generation of allergen-specific Im-
munoglobulin E (IgE) antibody. Fifty-sixty percent of food allergies can be attributed
to IgE dependent processes[11, 21, 22].
IgE was first discovered and designated as the reaginic antibody in a series of studies
by Ishizaka and Ishizaka[23–25]. In their studies, serum from people with ragweed
pollen allergy was depleted of the major known antibody isotypes (IgM, IgD, IgG and
IgA) and shown to retain its ability to passively sensitize skin[23, 25]. These investi-
gations further determined that it was possible to remove the reaginic activity from
10/10 studied sera by depleting a component that specifically recognised the ragweed
allergen[25]. This component had detectable antibody light chains but none of the
IgM, IgD, IgG or IgA isotypic regions, and had distinct electrophoretic properties to
the other antibody isotypes[23, 24, 24]. The isotype class was proposed and accepted
as γE antibody, or IgE.
Although the specificity of the allergic response is provided by IgE, the allergic re-
sponse is caused by vasoactive mediators released by IgE-bound mast cells and ba-
sophils. IgE is bound to the surface of mast cells and basophils by direct interac-
tions with the alpha subunit of the high-affinity IgE receptor, FceRI[26–29]. When
cell-bound IgE is ligated by allergen, the cells release granules containing vasoactive
mediators that cause the allergic symptoms[5, 30]. Clinical allergic symptoms are
generally more severe, and allergies are far less likely to resolve in individuals with
high titre IgE[31–35]. In experimental systems, the severity of the allergic response
correlates with the amount of IgE and level of mastocytosis[36–39]. In some murine
experimental systems, alternate cell types and an alternate antibody isotype, IgG1,
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are now known to play important roles in antigen-specific anaphylactic and allergic
responses[40–42]. However, IgE-mediated experimental anaphylaxis initiated by the
intravenous or the oral route is attributed to mast cell activity[37, 43, 44]. Therefore,
IgE and mast cells are central to the allergic response.
1.2.3 Physiological changes that occur during systemic ana-
phylaxis
The vasoactive mediators released by mast cells are diverse. These include prostaglandins,
leukotrienes, mast cell proteases, histamine, serotonin and platelet-activating factor
(PAF)[5, 30, 37, 45]. Histamine and proteases are preformed mediators, whereas PAF,
leukotrienes and prostaglandins are synthesised after activation[30]. Appropriately
activated mast cells are also reported to produce a number of cytokines, including
Interleukin (IL)-4 and IL-13[30]. The mediators generally act in a co-ordinated fash-
ion, but some manifestations of allergy can be prevented by treatment with specific
mediator antagonists and this has been examined in terms of the inhibition of the
physiological allergic response.
Experimental systemic anaphylaxis induces measurable physiological changes medi-
ated predominantly by histamine and PAF. IgE-mediated mast cell-dependent[43]
systemic anaphylaxis causes smooth muscle contraction and vascular leak[46, 47], re-
sulting in loss of plasma volume, loss of blood pressure and a drop in core body
temperature[43, 48]. Isotonic fluid perfusion of anaphylactic mice is sufficient to
prevent haemaconcentration, ameliorate temperature loss and prevent anaphylactic
death[48], indicating that hypovolaemia is a major cause of anaphylactic death in
mice. The systemic drop in temperature in mice can be prevented by administra-
tion of anti-histamines or combined histamine and PAF antagonism, as the tem-
perature nadir is reduced and vascular leak is reduced when these pathways are
inhibited[37, 48, 49]. Conversely, serotonin inhibitors, and 5-lipoxygenase inhibitors
that prevent prostaglandin synthesis are unable to prevent allergen-specific systemic
anaphylaxis in mice[37, 49]. This indicates that histamine and PAF mediate the
systemic allergic reaction. Histamine- and PAF-induced anaphylaxis are also exacer-
bated by IL-4 and IL-13[48, 50]. Additionally, PAF-induced anaphylaxis causes more
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haemaconcentration when the amount of mediator introduced induces equivalent hy-
pothermia, suggesting that distinct mechanisms may be involved in each part of the
anaphylactic response[48]. However, both PAF and histamine can cause anaphylac-
tic death and are important for mast cell- and IgE-mediated experimental systemic
anaphylactic responses.
Currently, there is no universal clinical definition of anaphylaxis[4, 6]. In humans,
anaphylaxis is generally considered severe when cyanosis is observed, when the in-
dividual collapses, or when soluble oxygen levels in the blood fall below 92 per-
cent saturation[6]. More general changes include a drop in blood pressure, and a
range of physical symptoms indicating respiratory or gastrointestinal involvement[4,
6]. Intramuscular adrenalin administration is the best recommended treatment for
anaphylaxis[6], and its delayed or improper administration is a common cause of ana-
phylactic death[7, 8, 10, 11]. One of the most frequent presentations of food allergy,
and a secondary diagnostic feature of anaphylaxis, is diarrhoea[4] and some of the
physiological mechanisms of allergic diarrhoea induced by intestinal allergen exposure
have been investigated.
1.2.4 Physiological processes during fasting and allergic in-
testinal responses
The normal physiological motility of the intestine is disrupted during an intestinal
allergic response. In the fasted state, the major contractions of the intestine are pe-
riodic coordinated phasic contractions that begin in the stomach and pass along the
length of the small intestine to maintain uni-directional gastric transit[51]. This pro-
cess, called peristalsis, occurs in most mammals[51]. Introduction of allergen to the
small intestine of sensitized rats disrupts fasting peristaltic movements and induces
a rapid increase in phasic contractile frequency of both smooth muscle layers along
the entire length of the small intestine, causing increased allergen transit through the
small intestine[52, 53]. Similarly, when specific allergen is deposited onto colonic sec-
tions from sensitized rats, a tonic contraction of both smooth muscle layers is induced
and the colonic contents are transported more rapidly in vivo[44, 54]. Not only is
motility increased, but net sodium, chloride and water absorption are impaired and
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concomitant active luminal secretion of water and ions increased following allergen
exposure[55, 56]. Oral allergen exposure in sensitized mice also causes acute loss
of blood plasma volume analogous to that occuring during systemic anaphylaxis in
sensitized intravenously-challenged mice[48, 57], suggesting that the net change in in-
testinal fluid secretion can affect homeostatic blood volume as well. Collectively, these
processes expedite allergen transit and ultimately result in profuse watery diarrhoea
soon after intestinal allergen exposure[37, 44, 53, 58, 59].
The processes occurring in allergic humans are similar to those in experimental sys-
tems and have been concisely summarised by Hugh Sampson[60]. In the stomach of
allergic individuals, allergen transit is slowed, but once in the small intestine, intesti-
nal motility is enhanced, peristalsis is interrupted, intestinal vasodilatation and mucus
hypersecretion occur[60]. Diarrhoea and sometimes vomiting follow[5, 60]. Mice and
rats are non-emetic species[61] so diarrhoea is the major presentation of intestinal
allergic responses in rats and mice. Much of the physiology of the intestinal allergic
response is known.
1.2.5 IgE and mast cells mediate intestinal allergen-induced
allergic responses
Investigations have demonstrated that intestinal allergic responses are IgE- and mast
cell-dependent. Mast cell degranulation is observed upon intestinal allergen exposure[37,
54]. The response is mediated by IgE, as demonstrated by colonic contractile responses
being specific for the sensitising antigen and passively transferrable to naive intesti-
nal sections via immune sera, but like passive skin immunisations[62], this activity
is lost if sera is first heat-inactivated[44, 54]. Similarly, treating mice with an anti-
IgE antibody, ablating mast cell (and the intestinal pace-maker interstitial cells of
Cajal) populations with anti-cKit antibodies, cKit-inhibiting drugs[63] or monitoring
allergic disease development in FceRI-deficient mice, all result in reduced diarrhoea
incidence[37]. In humans, positive oral food challenges also cause intestinal mast cell
degranulation and in greater than 95 percent of cases this correlates with antigen-
specific skin prick sensitization[60], indicative of antigen-specific IgE sensitization.
Collectively, the data provide strong evidence that oral allergen-induced diarrhoea is
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mast cell- and IgE-mediated.
The mast cell products that cause diarrhoea differ from those that cause systemic
anaphylaxis. Colonic circular muscle contraction can be induced by exogenous admin-
istration of a range of mast cell vasoactive mediators: 5-hydroxytryptamine (5-HT;
i.e., serotonin) and leukotriene D4 are particularly potent, and contractility can be
partially induced by histamine, PAF or prostaglandin D2[44]. However, the antigen-
specific response of both smooth muscle layers along the entire length of the intes-
tine is prevented by mast cell stabilization with doxantrazole, and some responses
with disodium cromoglycate, but histamine antagonists have no effect[44, 54, 64, 65].
Leukotriene D4 antagonists and PAF blockade prevent contraction of both layers of
the colon in the rat[44, 54], whereas, 5-HT1 and 5-HT2 receptor blockade and in-
domethacin, which inhibits the cyclooxygenase pathway and inhibits prostaglandin
synthesis, prevent allergen-induced jejunal smooth muscle contractility[64, 65]. Addi-
tionally, in live animals, prostaglandins and serotonin have been implicated in altering
jejunal contractility by modifying neuronal innervation[52]. Concomitant blockade
of multiple mediators is the best means to inhibit antigen-induced colonic contrac-
tion and diarrhoea[37, 54]. Specifically, concomitant blockade of PAF and serotonin
can inhibit allergic diarrhoea in mice[37]. In addition to these vasoactive media-
tors, cytokines can also influence the intestinal allergic response: IL-4 and IL-13
directly enhance intestinal smooth muscle contractility[50, 66]. IL-4 can also affect
intestinal ion flux and tissue responsiveness to mast cell vasoactive mediators[50].
Thus, while histamine is a key trigger for systemic anaphylaxis, histamine- and his-
tamine receptor-antagonists do not prevent intestinal anaphylaxis, whereas, PAF,
serotonin, leukotrienes and prostaglandins are implicated in the intestinal response[37,
47, 54].
In summary, while both intestinal and systemic allergic responses are mediated by
mast cells, and systemic and intestinal anaphylactic responses are exacerbated by IL-4
and IL-13[48, 50, 66] when antigen is deposited in the intestine, distinct mediators are
implicated in the response. The similarities and differences that are attributed to sys-
temic and intestinal anaphylactic responses are summarised in figure 1.1. Histamine
and PAF are key to the systemic anaphylactic response; PAF, serotonin, and poten-
tially prostaglandins and leukotrienes are involved in intestinal responses[37, 52, 64].
8
There is also evidence that systemic and intestinal manifestations of disease can
exist independently of each other, even when allergen is administered by the oral
route[37, 67, 68]. Therefore, it is possible that the immunological mechanisms that
permit allergic responses in the intestine are distinct from those that drive systemic
anaphylaxis.
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6-11
Anaphylaxis Response: Major Mediators
Systemic Vascular smooth muscle contraction
Vascular leak
Plasma volume
Blood pressure
hypoxia
Gastrointestinal Intestinal smooth muscle contraction
Fluid absorption
Lumenal ion/water secretion
plasma volume
Intestinal permeability
mucus hypersecretion
Histamine + PAF
PAF + Serotonin
12
13
14
14,15
16
1-3,15,17
prostaglandins & leukotrienes
6-8,10,11,15
Figure 1.1: Symptoms and mediators of systemic and intestinal anaphylaxis.
Mast cell-dependent responses that result in systemic or intestinal (not including the
stomach) allergic responses in rodents and/or humans. Superscript numbers denote
references, which are listed in the table-specific bibliography in the appendices.
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1.2.6 Management of food allergy
The current advice given for the prevention of allergic responses in sensitized indi-
viduals is allergen avoidance[10, 11], however, a number of alternative strategies are
also used. Therapies can target end-stage effects, for example, interrupting the sig-
naling of the products of mast cells and basophils such as the cysteinyl leukotriene
and histamine antagonists monteleukast and loratidine[69] or aim to inhibit mast cell
degranulation using local administration of disodium cromoglycate[70, 71]. Clinicians
have also explored the use of allergen desensitization by giving escalating doses of aller-
gen sublingually, orally or subcutaneously[72–74]. Desensitizing immunotherapy can
take months to years to be effective and is generally incomplete, however, treatment
usually increases the tolerated allergen dose and reduces the severity of the allergic
symptoms evoked by chance or experimental allergen exposure[74, 75]. During the
desensitization process, patients can experience mild allergic symptoms[75] and a rare
but major risk of desensitization therapy is allergic anaphylaxis[76]. To limit the risk
of anaphylaxis during immunotherapy, desensitization strategies have explored, with
some success, the use of peptide fragments of allergens, rather than whole allergens
for therapy[77]. One of the most promising therapies to date uses allergen non-specific
anti-IgE antibodies. This approach has reduced the severity and incidence of allergic
responses and allergic asthma in the clinic setting[78–81] and is also shedding light on
the processes that permit and perpetuate allergic responses once established[82–85].
While allergic responses in the lung are not a focus of this thesis, allergic asthma also
affects a number of New Zealanders, and thus its management deserves a brief men-
tion. To manage allergic asthma, inhaled glucocorticosteroids and when necessary,
leukotriene modifiers and β2 adrenergic agonists are the most commonly prescribed
preventative therapies, and β2 adrenergic agonists are also used to reverse acute
asthma attacks[81]. These, however, do not reverse sensitisation, and aim to limit
the severity and frequency of allergic asthma. The major current therapies, therefore,
try to reverse sensitization or diminish the effects of the mast cell products. To date
no single treatment has had complete success and each has associated maladies and
contraindications. Understanding the steps that lead to sensitization and perpetuate
allergies is key to reducing the incidence of allergic disease.
11
1.2.7 Identification of food allergy
Not only are food allergies difficult to manage, they are difficult to distinguish from
other gastrointestinal disorders. Some diseases exist that present with similar symp-
toms to food allergies[86–89] and cases have been identified in which the response is
likely to be IgE-mediated but systemic IgE and peripheral disease manifestations are
not detected[90]. The identification of a specific causative food allergen is made even
more difficult as the majority of allergic individuals are sensitized to multiple foods
and often to multiple proteins contained in a single food[32, 33, 35, 91, 92]. This can
make it difficult to appropriately exclude the allergen without unneccessarily restrict-
ing the diet, which is especially important for infants where dietary exclusion could
significantly impact on normal development and growth[86, 93]. Thus, identifying the
presence of a food allergy, particularly in the paediatric population, requires careful
evaluation.
Standardised processes for food allergy determination are improving disease identi-
fication. IgE assays with high positive predictive values have now been established
for some major allergens in the US, including milk and egg[31]. However, allergies
to other foods still benefit from confirmation by the double-blind placebo controlled
oral food challenge test. As self/parentally-reported food allergy incidence is inflated
by several-fold[11], it is now advised that before allergen elimination is trialed, food
allergies are diagnosed based on a combination of medical history, skin-prick testing,
serum antigen-specific IgE titres and when it is not ill-advised, a double-blind placebo
controlled oral food challenge[11, 94]. Thus, simple quantitative disease readouts en-
able rapid identification of potential allergens and support the qualitative observations
used to identify a specific food allergy.
1.2.8 Hereditary risk factors for food allergy
Numerous risk factors for the development of allergic disease have been identified[19,
95]. Current reviews of risk factors[19, 95] and genes associated with allergy and
asthma[96] are available.
First, there are hereditary and genetic predispositions. Allergies, asthma and eczema
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encompass the atopic disorders[97], and are associated with polymorphisms in some
genes. Generally, the interaction of a number of genes with low penetrance are thought
to compound to increase disease risk, and these are revealed in carefully controlled,
genome-wide association studies[96]. For example, high frequencies of single nu-
cleotide polymorphisms in the Il4 or IL-4Rα genes are associated with increased risk or
severity of asthma and allergic disease[98–100]. There are also specific mutations that
can be associated with disease phenotypes. For example, loss-of-function mutations in
the filaggrin gene, which is associated with epidermal barrier defects, predisposes in-
fants to eczema, and increases risk of asthma and allergic rhinitis[19, 101, 102]. People
of certain ethnicities, like african americans, are more likely to develop allergies than
caucasian americans[19, 103]. Collectively, allergies are considered hereditable[104],
but there is significant gene-environment interaction that makes it difficult to predict
disease development and the specific type of atopic disease that will present[96].
1.2.9 Diet and the intestinal microbiota influence disease risk
A risk factor that is not limited to the allergic disease setting, relates to the intestinal
microbiota. A balanced and diverse intestinal microbial community protects from
numerous diseases. Reduced intestinal microbial diversity in infants is associated
with increased risk of allergic disease[105], and diet supplementation with selected
probiotics has been associated with reduced incidence of allergies[106, 107]; similarly,
drinking unpasteurized milk is associated with reduced skin prick test positivity in
farm children[108] and this may relate to the effect of raw milk on intestinal microbiota
composition. In terms of early-life exposure, birth by casearian section has, in some
cases, been shown to be a risk factor for allergic sensitization[109, 110]. It has been
suggested that this may be influenced by the type of microbes to which the infant
would be exposed through the birth canal (i.e., vaginal and intestinal commensals),
or without it[109–111]. Treating mice with antibiotics has been shown to alter the
diversity and composition of the resident intestinal microbiota for long periods[112],
and also to promote IgE production, basophil hyper-responsiveness and to increase
allergic airways inflammation in mice[113]. The resident microbiota is now considered
to significantly influence the intestinal immune system, and examining the changes in
13
population dynamics that are observed, and potentially influence human health and
disease will continue to be an important focus for balanced human health.
Nutrition is both affected by, and thought to affect allergic disease progression. Aside
from the obvious, that exclusion of allergens from the diet improves infant growth[114],
levels of essential dietary metabolites, like vitamin A and D are associated with al-
lergic disease risk[115–118]. Food allergies are associated with numerous subsequent
developmental problems, including rickets, failure-to-thrive and some psychosocial
maladies[114, 119–121]. More recently, the links between diet, microbiota and allergic-
type immunity has been linked: Maslowski et al.[122] demonstrated that the short-
chain fatty acids released by the break-down of dietary fibre by the intestinal micro-
biota limit allergic and enteric disease severity[122]. Thus, nutrition and commensal
microbiota are inter-related disease risk factors.
1.2.10 Environmental exposure as a risk factor for allergy
There are also environmental risk factors involved in the development of food aller-
gies. In a seminal study David Strachan showed that family position influenced the
risk of developing an allergic disease and argued that this might relate to a ’dirty’
environment[123]. Sensitization to environmental allergens has been associated with
the levels of allergens found in the home[124]. Similarly, environmental sensitization
has been proposed as a potential mechanism for sensitization to stable food allergens.
This follows evidence that demonstrates an association between eczema, asthma, and
allergic disease. Infants who develop atopic dermatitis at a young age are at increased
risk of developing asthma and some forms of allergy in later life[97]. In a series of
studies, Lack et al. examined the incidence of peanut allergies in infants in early life.
In these studies, oral ingestion of peanuts was associated with protection from disease,
whereas high household consumption in infants not fed peanuts, or exposed to peanut
products by skin application through moisturisers of eczema creams, were associated
with increased risk of peanut sensitization[125–127]. These data suggest that envi-
ronmental, rather than intestinal exposure to some stable allergens may increase the
risk of food sensitization; however, these studies are not all-encompasing. Maternal
exposure to house dust mite allergens during pregnancy is associated with increased
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cord blood IgE levels[128], which indicates that sensitization may occur in utero. The
range of potential mechanisms of sensitization have lead to the removal of the advice
that allergens should be avoided, in both the USA and the UK[19, 129].
1.2.11 Oral tolerance
The default response to ingested food proteins is oral tolerance. Oral tolerance is an
active regulatory immune process that acts to reduce subsequent immune responses to
specific antigens[130]. Feeding mice with OVA prior to sensitisation, either by gavage
or indirectly through the breastmilk prevents sensitization and the subsequent genera-
tion of allergic responses in the intestine or lung of mice[130–136]. In humans, similar
observations have been made. In an oral feeding study, Husby et al.[137] immunised
individuals subcutaneously with keyhole limpet hemocyanin (KLH), half of whom had
previously been fed numerous low doses of KLH. When individuals were subsequently
challenged with KLH, IgM, IgG and IgA antibodies and antibody-secreting cells were
detected systemically, but individuals that had ingested KLH eventually demonstrated
diminished T cell proliferative responses and reduced frequencies of delayed-type (type
IV) hypersensitivity reactions[137]. KLH can also induce IgE-mediated responses in
humans, because skin wheal-and-flare responses can be induced by intradermal KLH
injection in healthy and atopic individuals, if they are first immunised with KLH and
alum[138]. However, oral exposure in some circumstances can result in sensitization.
If mice are fed with protein in the presence of cholera toxin, this will result in IgE gen-
eration, intestinal mast cell infiltration and allergic sensitization permissive of allergic
responses[139, 140]; guinea pigs can be sensitized through oral exposure in the absence
of adjuvant[141]. In mice and humans, ingestion of proteins usually induces active
immune processes that suppress subsequent immune responses[130, 142]. Therefore,
the development of an allergy involves not only sensitisation, but a corresponding
break in oral tolerance.
Work has investigated the processes involved in oral tolerance. Treg cells (that
suppress other T cell responses) are involved in oral tolerance in rodents[131, 134,
143]. Similarly, Grindebacke et al.[144] recently demonstrated that for the first 18
months of life, Treg cells express the intestinal homing molecule α4β7[142] at in-
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creased frequencies[144], indicating that the infant immune system may be precon-
ditioned to support oral tolerance. The uptake and processing of the food proteins
is also thought to be important. Particulate antigens, like bacteria and caseins are
taken up by specialised M (microfold) cells in the follicle-associated epithelium over-
lying Peyer’s patches[130, 139, 142]. These cells take up antigen and deposit the
particulate matter, undigested, in an invagination below the M cell for uptake and
presentation by other antigen presenting cells. This processing is thought to con-
tribute to the tolerance process to intestinal bacteria[130]. Dendritic cells in, and
directly beneath, the intestinal epithelial layer can extend dendrites into the intesti-
nal lumen to sample antigens[142, 145]. Tolerance to soluble antigens involves den-
dritic cell antigen carriage[130], their migration to the mesenteric lymph nodes and
induction of Treg cells that could subsequently migrate into the intestinal lamina
propria[130, 134, 142, 143]. IL-10 producing T cells in Peyer’s patches are also impli-
cated in oral tolerance[146, 147]. There are also some other potential mechanisms of
tolerance generation. Epithelial cells in orally fed naive rats have also been shown to
produce antigen-loaded MHC-II ’tolerosomes’ that disperse systemically and inhibit
delayed-type hypersensitivity reactions[130, 142, 148]. This tolerizing capacity was
lost if it was first MHC-II-depleted[148], suggesting that the tolerosomes specifically
were required for tolerance development. Further, depletion of antigen by removing
antigen-bound MHC-II is not a sufficient explanation for the loss of activity. While
allergen is absorbed systemically following oral ingestion[149], and can induce allergic
responses in passively-sensitised skin[150], the tolerizing capacity of serum does not
relate to the amount of antigen contained in the transferred serum[151]. Therefore,
in addition to specialised antigen presenting cells that are implicated in the genera-
tion of Treg cells, systemically dispersed tolerosomes may also contribute to the oral
tolerance process.
Collectively, while much is known about the disease phenotype, the underlying phys-
iological mechanisms that cause the allergic response, and the factors that increase
disease risk are being elucidated, current treatments are inadequate. Better under-
standing of the allergic disease process is required to improve quality-of-life for allergy
sufferers. Many allergic responses require the coordinated interaction of IgE, allergen
and mast cells, so factors that promote allergic sensitization, beginning with the role
16
of the allergen itself, in the allergic process, are important.
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1.3 Allergenicity and the epidemiology of allergic disease
1.3.1 Allergy and allergenicity
Proteins that have been identified as allergens in five or more people are now classified
by the World Health Organization and International Union of Immunological Societies
Allergen Nomenclature Sub-committee. Allergens are named based on the source
species, and the order in which they were identified[152, 153]. For example, bovine
serum albumin was the sixth identified allergen sourced from the common dairy cow
Bos taurus, formerly Bos domesticus, and is referred to in the allergen nomenclature
as Bos d 6. All classified allergens are listed at http://www.allergen.org[152]. This
and similar allergen databases are proving useful in the identification of common
properties of allergens[154].
In terms of what substances evoke allergic responses, not all proteins are equal. In
2008, Radauer et al.[155] observed that when allergens, including food, environmental
and industrial allergens, are classified by structure only 2% of structural families
contained allergens[155]. An equivalent distribution of randomly selected proteins
from the same source taxa incorporated 5% of families[155]. The findings of Radauer
et al. provide evidence that some allergens share common structural features. This
was further evidenced in their analyses because specific protein families were enriched
for allergens. Prolamins, profilins and EF hand domain-containing proteins were the
most common plant allergens; tropomyosins, EF hand domain-containing proteins,
lipocalins and PR-1 proteins were the most common animal-derived allergens[155].
With similar observations made by other groups[154], the findings of Radauer et
al.[155] suggest that there is some intrinsic feature that makes a protein or food more
likely to be an allergen.
This intrinsic property is not simply proportional to the amount of protein to which an
individual is exposed. Small contaminants in highly purified proteins can provide the
major sensitizing capacity of a food protein[156]; autoadjuvant properties of allergens
can contribute to their sensitizing potential[157, 158], trace and non-protein antigens
can evoke allergic responses[91, 158]; and cooking and sterilization processes can alter
an allergen, rendering it innocuous or more hazardous[139, 159–162]. For example,
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pasteurizing purified milk proteins increases the severity of the allergic response they
induce in mice[139], but baked products containing milks are often well tolerated[162].
It is important to keep in mind that while studies like those of Radauer et al.[155]
indicate some protein structures are more likely to be found in allergens, every food
has the potential to be an allergen[10]. Similarly, it is thought that certain protein
folds or structures are more likely, rather than are the only folds that are immunogenic
and/or allergenic[163]. The term ’allergenicity’ was coined to describe the intrinsic
capacity of a substance to sensitise and trigger an allergic response. Allergenicity
conveys a sense of the ’relative allergic risk’ of a given protein or food, indicating
its likelihood of being problematic in allergy-susceptible individuals[164]. Unravelling
what gives an allergen allergenic properties has been a key question for a number of
years[104], and is likely to continue as an important question for a number of years
to come.
1.3.2 Molecular properties of allergens, with specific refer-
ence to food allergens
Numerous excellent reviews regarding the common features of allergens are available,
and these identify some general properties common to food allergens (e.g., [153, 154,
164]). First, food allergens are usually small proteins, ranging in molecular weight
from 10-70 kDa[153, 164, 165]. Bovine beta-lactoglobulin is an 18 kDa protein[56]; the
egg allergens OVA and ovomucoid are 45 and 28 kDa, respectively[156]. However, the
almond storage protein amandin (Pru du 6), is a hexameric protein with molecular
weight estimates of 200, 360 and 427 kDa[166–168], and bovine immunoglobulin (Bos
d 7) when fully assembled is 160 kDa and is ingested in milk[169]. Thus, there are
examples of large food allergens.
One often overlooked feature of food proteins in general, is that proteins generally
evolve with a purpose. Many allergens have been characterized as possessing a spe-
cific biological function, such as proteolytic activity[154]. Taking the most common
allergen structures determined by Radauer et al.[155] as examples, plant allergens were
enriched in the profilins, EF hand domain and tropomyosin families[155]. Profilins are
involved in the regulation of signal transduction and actin polymerisation, and some
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of these are food allergens[154]; polcalins are two EF hand-containing calcium-binding
proteins that can be aeroallergens[154, 170, 171]; Tropomyosins are common food al-
lergens, and are muscle proteins found in invertebrates[154]. Some food allergens are
energy storage proteins, like albumins[154] and the almond allergen amandin (Pru du
6)[166, 168]. Nonspecific lipid transfer proteins cause cross-reactive fruit allergies to
peach and apple[154, 172, 173] and were identified[155], and the lipocalin BLG binds
a number of molecules, including fatty acids, cholesterol and vitamin D2[174–177].
Whether fatty acid transport is its natural function is not established[174, 175]. How-
ever, proteins with protease and enzymatic function, calcium, ligand- or metal-binding
activity are enriched in allergens and this is also true of food allergens[154, 155].
The third property common to many food allergens is that they are often resistant
to proteolytic digestion at acidic pH[153, 178]. Proteolysis-resistant proteins are typ-
ical class 1 food allergens[153], and can trigger responses in the intestine. When
incubated in simulated gastric fluid at low pH (less than 3), ovalbumin (Gal d 2),
beta-lactoglobulin (Bos d 5) and the apple allergen Mal d 2 all remain intact for at
least sixty minutes[178–180]. It has been shown that the IgE binding capacity of BLG
can be removed if it is de-stabilised and rendered susceptible to digestion[181]. The
apple allergen Mal d 3 that is stable to proteolytic digestion causes cross-reactive fruit
allergies[154, 172, 173]. Many response-evoking food allergens are therefore resistant
to digestion.
Again, while resistance to digestion is a property of some food allergens, digestibil-
ity does not preclude a food from being an allergen. Food proteins that are di-
gested by pepsin in less than two minutes, like caseins[178], can be major allergens
in humans[91, 182, 183]. After extensive incubation of protein in digestive enzymes,
antigenic epitopes can remain intact[184]. Foods can also contain both digestible
and undigestible allergens[180, 185] and cross-reactive allergens from different food
sources can be differentially sensitive to gastric digestion[186]. Class 2 food aller-
gens are allergens that do not have sensitizing capacity, but are cross-reactive with
aeroallergens[153]; the class 2 apple allergen Mal d 1 is readily degraded by pepsin at
gastric pH[186], but can still trigger allergic responses in the upper gastrointestinal
tract, skin and face[187]. Additionally, gastric transit time and pH are not always slow
and low, and can also be compromised. For example, in newborns, the average gastric
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transit time is short (around 25 minutes[188]) and their gastric pH is generally higher
than in adults (pH 5 or more[189]). Proton pump inhibitors that prevent gastric acid
secretion and raise the stomach pH are also prescribed to some infants[114], which
could limit the opportunity for gastric enzymes to cleave ingested proteins. In terms
of the allergic response, these processes could result in ’digestible’ allergens passing
through to the small intestine intact. However, not all individuals have allergic re-
sponses; clearly, exposure to a highly allergenic, stable protein does not automatically
render an individual allergic. Understanding not only the features of the allergen that
permit allergies, but also elucidating why only some individuals become sensitized
requires further investigation.
The many exceptions to the general features of a food protein that can make it aller-
genic suggest that we do not fully comprehend what contributes to allergenicity. In
part, I think that under the appropriate inflammatory conditions, any protein could
be rendered allergenic Adjuvants are employed with the intention of increasing the
immunogenicity of antigens used to immunize and similar adjuvanticity effects could
be argued to increase allergenicity. Even in these contexts, however, I would expect
the longevity of the induced allergy-type immune response to differ between common
and uncommon allergens I think the immune system can sometimes work out when
its response is misdirected. As such, rather than discrete populations of allergens and
non-allergens, food proteins are likely to comprise those that are high-risk for allergy
and those that are of lower risk. As multiple factors contribute to the development and
maintenance of allergic sensitization (e.g., exposure frequency, exposure mass, route
of first exposure, age of first exposure, inflammatory environment surrounding first
exposure, route of second exposure), examining the ability of foods to induce allergic
immunity, as well as the host-derived and environmental factors that increase the like-
lihood of sensitization and/or an allergic response need to be explored synchronously
and considered together.
1.3.3 The epidemiology of food allergy
The allergenicity of food proteins has largely been established from epidemiological
data. Similar to the restricted set of protein families that contain most allergens, most
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food allergies can be attributed to a small number of allergens[60]. Food proteins
have different likelihoods of sensitising infants, and have different resolution rates
as children age[9, 33, 35, 190]. During infancy, milk allergies account for half of all
food allergies, occurring in 2.5% of children, while the next most frequent allergen,
egg, causes a response in 1.5% of children[9]. For milk and egg allergies, 70 to 80%
resolve by the age of sixteen[4, 33, 35]. While less frequent[9], soy allergies follow a
similar prognosis, with 70% resolving by age ten[32]. In contrast, although allergies
to peanuts, tree nuts, fish and shellfish are also less frequent in infants[9], they are
unlikely to resolve[4]. Allergies that persist into adulthood are associated with high
IgE levels[32, 34] and for milk, peanuts and eggs, allergen-specific IgE titres with
greater than 95% positive predictive value for an oral response have been determined
empirically in some clinics[31].
1.3.4 Sensitization to multiple foods
An allergy to one protein is also highly likely to co-present with allergies to other
foods[191] and this is a particular problem in milk allergic infants. While most milk
allergies resolve, one major complication for milk allergic infants that cannot be breast-
fed, is that there are few alternatives for feeding. In cow milk allergic individuals,
cross-sensitization to other milks is common[169, 191]. Greater than 90% of cow milk
allergic infants are cross-sensitized to goat milk[192], 40% of milk allergics are co-
sensitized to soy[35], and 80% of soy allergic infants are also allergic to cow milk[32].
There are also rare cases of IgE cross-reactivity to homologous human milk proteins
in cows milk-allergic infants[193–197]. Often, the best nutritional source for milk
allergic infants is an extensively hydrolysed milk-based formula or a synthetic single
amino-acid formula[114, 120]. Although they have poor palatability and different
physico-chemical composition to normal milks[93], they are considered nutritionally
complete. Further, the makeup of milks from different species is also different[169].
Food allergies, particularly milk allergies, during infancy may put infants at risk of
nutritive deficiencies[121], failure to thrive[60, 93, 120] and impact the quality of life
of allergic individuals and their families[97, 119]. Elucidating the molecular changes
that result in sensitization, particularly milk protein sensitization, may provide novel
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ways to interrupt the allergic process.
1.3.5 Atypical mechanisms of sensitisation
While epidemiological data shed some light on the ’relative allergic risk’ of a number
of proteins, defining an all-encompasing allergenicity hierarchy is not straightforward
because sensitization to specific allergens can be contextual. During the first three
years of life, most allergies that develop are to food proteins, whereas the prevalence
of environmental allergen sensitization increases after this time[97, 198]. However,
this does not preclude allergies to foods developing later in life, as they can form part
of a normal diet during infancy but become problematic after cross-sensitization to an
environmental allergen. This frequently occurs with class 2 fruit allergens, to which a
large number of people are only sensitised after allergies develop to birch pollen during
the teen years[187]. For example, exposure to Bet v 1 from birch can sensitize indi-
viduals to Mal d 1 in apple[186, 187, 199, 200]. Chronic workplace allergen exposure
can also result in adult sensitisation, for example, in woodmill workers, fish packers,
and bakers continually exposed to wheat flour[201–203]. Healthcare workers that reg-
ularly use latex gloves are similarly at increased risk of developing cross-reactive latex
allergies than the general populace[76, 204].
Recently a unique subtype of IgE-mediated allergy has also been identified. The car-
bohydrate antigen galactose-alpha-1,3-galactose induces allergic responses to meats in
adults[205]. This carbohydrate antigen is present on a number of mammalian meats,
and results in an allergic phenotype presenting three to six hours after eating meat.
This is thought to be because the meat needs to be digested to trigger mast cell de-
granulation. The symptoms of this type of allergy, contrasting with many allergies,
involve the organ systems of the intestine, skin and sometimes systemic anaphylac-
tic responses, but are not associated with allergic asthma[206]. This adult-onset
allergy has also been shown to be caused by IgE cross-reactivity with Amblyomma
americanum ticks, and to occur almost exclusively in tick-sensitized individuals[207].
Galactose-alpha-1,3-galactose also causes cross-reactions with a monoclonal antibody
(the specificity of which is epidermal growth factor receptor[208], but this is irrelevant
for the reaction) that contains the galactose-alpha-1,3-galactose sugar moeity in its
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heavy chain[209, 210]. While these findings also suggest that tolerance can be broken
in special circumstances, it is clear that the sensitising capacity and aetiology of al-
lergy is different for different proteins and foods. The mechanisms that explain these
differences, and why only some people develop allergies to allergenic substances are
only now becoming apparent.
1.3.6 Physical and immunological differences in cow and goat
milks
Whole milk is a complex mixture of protein, lactose, oligosaccharides, a range of fatty
acids, lipids, non-protein nitrogen, vitamins and minerals[211–218]. The protein com-
prises of two main fractions: The casein fraction and the whey fraction. Casein was
originally defined by its precipitation at pH=4.6 at 20 ◦C[211], whereas the whey pro-
teins remain soluble. There is significant species-to-species variation in the absolute
composition of milk (Table 2). Different to other mammals, humans consume the milk
of other species. For example, cow, goat and sheep milks are frequently included as
part of the normal infant diet in different parts of the world[219, 220]. However, the
consumption of milk from other species allows the possibility of allergy development
to other species’ milks. Allergies to cow, goat and sheep milk have all been reported,
and milk allergies are not specific to western countries[34, 219, 221].
Breast milk is considered the gold standard in infant nutrition[222]. It is also im-
portant for the physiological development and maturation of the infant immune sys-
tem (for review and discussion see[223, 224]). The main proteins in human milk are
β-casein, κ-casein, α-lactalbumin, lactoferrin, immunoglobulins, serum albumin and
secretory component[193, 225, 226]. Approximately 60% of the total protein content
of human milk comprises the more soluble whey proteins[227]. β-casein is the domi-
nant human milk protein, followed by α-lactalbumin[193]. The protein αs1-casein is
present at low-to-undetectable concentrations[193, 228]. There are also a number of
other trace proteins[229].
There are some significant differences in the composition of human and cow milks.
In contrast to human milk, 80% of the protein in cow milk is casein[169, 230]. The
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casein fraction in cow milk comprises 40 - 50% αs1 casein plus three other casein
proteins: αs2-casein, κ-casein and β-casein[169, 211]. The other 20% of cow milk
protein is the more soluble whey fraction. The predominant whey protein is BLG
(60 - 80% of whey), with lower amounts of α-lactalbumin, immunoglobulins, serum
albumin and traces of lactoferrin[169, 211, 231]. In comparison to human milk, cow
milk has additional proteins (αs2-casein and β-lactoglobulin[193, 228]); a different
whey to casein ratio; less non-protein nitrogen[223] and more concentrated protein, at
3 g/100 mL[169, 211] compared to approximately 1.6 g in colostrum, and ≈1 g /100
mL in at later times for human milk[223, 225].
For cow and goat milk, there are some differences and similarites in their composition.
Cow and goat milks have similar total protein content, similar β-lactoglobulin content,
and similar casein:whey balances[141, 169, 211, 231–235]. However, goat milk has
lower levels of αs1-casein and higher β-casein levels[232, 234–236]. Like human milk,
β-casein is the dominant protein in goat milk[233, 237]. One of the other differences
between cows and goats, is that some breeds of goat produce milk with higher total
fat content, and goat milk invariably has higher medium-chain fatty acid content than
cow milk[235, 237]. The increased medium-chain fatty acid content renders goat milk
fats more digestible by lipase activity[237]. Goat milk proteins are also more heat-
labile[238] and more digestible by human- and simulated-gastric fluids than those
of cow milk[185]. There are also differences in non-protein nitrogen content and
composition between the two milks[215]. Mineral and vitamin content can differ
between the species, but there is significant seasonal and study-to-study variation
(c.f.[217, 235, 239]). The reported differences between cow and goat milks relate
primarily to protein homology, αs1 casein content and the amount of medium-chain
fatty acids present in the milks.
When individual proteins are examined, goat and cow milk proteins are more similar
than cow and human homologues. Any given goat milk protein shares 85-95% ho-
mology with its cow milk counterpart[169]. In humans, the most conserved protein,
α-lactalbumin, shares 76-78% sequence identity and almost 90% homology with cow
α-lactalbumin[169, 193, 240], but other proteins are less homologous. Bovine and
human β-casein are 47-57% homologous[169, 196]. Human α-s1 casein shares only
partial (≈32%) sequence homology with cow α-s1 casein[241, 242]. While it is absent
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from human milk[228], BLG shares structural homology with serum retinol binding
protein[177, 243]. It is also related to other human lipocalins, the glycodelin precur-
sor protein[244], and human placental protein-14[245](44% by DELTA-BLAST; see
methods section). Allergens often share sequence similarity with host proteins[246],
and the similarities in cow and human milk proteins may contribute to the frequent
incidence of cow milk allergy in humans[246].
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Table 2: Composition and homology of human, goat and cow milk
Human Goat Cow
Protein (%) 0.8-1.25 4.3 3.2-3.6
Caseins (%) ≈40 ≈80 ≈80
Whey (%) ≈60 ≈20 ≈20
Dominant milk protein β-casein beta-casein αs1-casein
αs1-casein 0.8 g/L 0-3.5 g/L 12-15 g/L
αs2-casein Not present 3.8-3.9 g/L 3-4 g/L
β-lactoglobulin Not present 2.9-3.4 g/L 2-4 g/L
Homology (% to cow)
αs1-casein 31.9 87.9 100
αs2-casein N/A 88.3 100
β-casein 56.5 91.1 100
β-lactoglobulin N/A 94.4 100
Proportions and concentrations are compiled from [141, 169, 193, 211, 225, 227, 228,
233, 235–237]; Homology data are taken from [169].
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Evidence suggests that while goat and cow milk proteins are largely homologous, they
have distinct properties as allergens. In one study, some cow milk allergic individuals
tolerated goat milk, and in those that did not, as much as five times more goat milk
was required to cause an allergic response compared with cow milk[192]. Further, the
IgE-binding repertoire of sera from cow milk-allergic individuals generally binds to a
comparably reduced set of goat milk proteins[192, 247, 248]. In terms of its ability
to sensitize and evoke an allergic response in orally-sensitized mice, goat milk is less
allergenic than cow milk[234]. Oral feeding of goat milk to guinea pigs results in less
frequent challenge-induced anaphylaxis than cow milk[141]. Further, the allergenicity
of ruminant milk correlates closely with its αs1 casein content, both in terms of
IgE cross-reactivity in sera from cow milk allergic individuals, and in terms of its
sensitizing and allergic response-evoking capacity in experimental systems[141, 232,
234, 236, 249]. Low αs1-casein levels are more typical of goat milks and demonstrate
reduced allergenicity in mice and guinea pigs[233, 236, 249, 250]. Evaluating whether
these differences can be attributed to differences in intrinsic allergenicity, or more
predominantly to digestibility of the milk, remains to be addressed.
1.4 Predicting allergenicity
1.4.1 In silico prediction
As well as understanding the epidemiology of food allergy, predicting allergenicity and
cross-reactivity are becoming more important in the modern world. Novel proteins
are being introduced into the food chain, such as those from genetically-modified
crops, and these need to be assessed for their allergic potential. Generally, cross-
reactive allergens share more than 70% sequence homology with each other[154], so
in silico comparisons to known allergens can be used as an early step in the screening
process (e.g., [251, 252]). In fact, the second step in the World Health Organisation
decision tree for the evaluation of allergic potential, after assessing whether a protein
is derived from an allergenic source, is to examine sequence homology using protein
databases[253, 254] . However, in silico analyses are only a start point. Even if
allergenic potential is not identified in structural screens, serum screens, animal models
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and screening for pepsin resistance are recommended by the guidelines[253, 254]. If
a protein is able to sensitize animals, this is considered a significant risk factor for
it to be a sensitizing allergen in humans[253, 254]. In silico screens also have the
potential to reveal features of allergens of biological importance that may be missed
in specific bioassays[152]. Allergenicity screening is beginning to incorporate in silico
methodologies as an adjunct to biological testing (e.g.,[255]).
1.4.2 Biological evaluation of allergenicity and cross-reactivity
Examining allergenicity in biological systems utilises a variety of approaches. Classical
analyses have examined peptide recognition of sequential epitopes, and in some cases
these have identified certain B cell epitopes that correlate with allergies that persist
(e.g.,[256, 257]). Other approaches use surface plasmon resonance to examine the
affinity and/or avidity of antibody for antigen, and this has been used to analyse
IgE affinity distributions in polyclonal sera in some cases[258, 259]. Linear epitope
analysis can be informative, particularly for T cell epitope detection, because T cells
recognise short linear epitopes (generally 8-20mers); there are a significant number of
allergens for which discontinuous B cell epitopes are thought to be key[260]. This is
exemplified nicely in the study by Clement et al.[259], in which only 1 of more than
50 monoclonal antibodies recognised denatured BLG, but epitope masking was able
to identify 12 antigenic clusters on the surface of native BLG[259]. When the first
crystal structure of an IgE-bound allergen was solved, specific surface-exposed residues
identified in the screen by Clement et al.[259] were also involved in IgE-binding to
BLG[261]. Similarly, the majority of IgE binding to recombinant α-lactalbumin is
predicted to bind to a cluster of surface-exposed residues[262]. Combining structural
data with epitope analysis has been useful in the indentification of discontinuous
epitopes that would not necessarily be observed if the full structure of the protein was
not examined.
A range of novel in vitro and in vivo animal methods for testing changes in the
allergic potential of foods are being trialed. These include oral sensitisation using
allergen in the presence or cholera toxin, followed by analysis of the T cell, B cell and
allergen-induced mast cell response[263]. Measuring degranulation products of mast
29
cells, the antibody response and the impact of feeding on basophil populations has
been examined in this system to evaluate changes in the allergenicity of hydrolysates
in mice[264]. It has also been used to compare the epitope specificity of IgE generated
in mice to the epitopes involved in human IgE binding[265], and similarly to exam-
ine specific allergens contained in whole foods against which antibody responses are
directed[263]. Similar examinations have examined the proteins to which antibody
binds in guinea pigs sensitized to whole milks[232, 249]. There are numerous mouse
models that examine a range of different aspects of the allergic process. I site some
examples for further reading[136, 266–269]. In a similar attempt to clarify what makes
chemical a (type IV) contact allergen, Kimber et al.[270] examine the response in an
isolated lymph node assay[270]. In an independently derived, but similar assay, our
lab has developed a novel mouse assay of allergenicity (see next section).
Collectively, a range of methods have been, or are being applied to the evaluation of
the allergenicity of foods. These assays are also used to improve our understanding of
the properties of allergens that render them allergenic and/or cross-reactive. Further,
these models can provide information about the basic mechanisms that control the
allergic process. Employing multiple biological approaches, in addition to in silico
prediction methodologies will continue to be key for the determination of the allergenic
potential of foods.
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1.4.3 Development of a novel assay of allergenicity and Th2
function
In addition to the various tools that have been developed to examine allergenicity,
our lab has used the G4/+ reporter in an assay that measures allergenicity in di-
rect proportion with Th2 cell development. In early studies by Belkaid et al.[271],
intradermal administration with L. major promastigotes induced local inflammation
isolated to the ear[271]. Our lab examined Th2 cell development induced by dead
parasite antigens, known allergens, or bacterial products in the auricular (superfi-
cial parotid) lymph node[1, 57, 272]. In experiments using indian violet ink, our lab
determined that this is the only lymph node to which antigen administered to the
ear is drained (figure 1.2; photo and observation made by Graham Le Gros). By
combining this sensitive, single lymph node assay with an IL-4-reporter mouse[273]
IL-4-producing CD4+ T cells can be sensitively identified and counted. The inflam-
mation can be used to examine immunogenicity and GFP+CD4+ Th2 cell numbers
can be used to compare allergenicity. Numerous immunogens have been compared in
this system (figure 1.3; data generated by Mali Camberis and Melanie Prout). The
most potent Th2-polarising immunogen that has been observed in this system, so far,
is antigen derived from dead iL3 N. brasiliensis larvae (figure 1.3). Dermatophagoides
pteronyssinus house dust mite extract (HDM), also induces strong Th2 cell develop-
ment (figure 1.3). The expansion of IL-4-producing Th2 cells, as reported by GFP
expression in G4/+ mice is reproducible. In addition to the data shown (figure 1.3),
my studies have recapitulated these original findings: Immunisation with dead par-
asite antigens, caused a 200-fold increase in Th2 cell numbers, and HDM generated
four-fold fewer Th2 cells than dead N. brasiliensis larvae (figure 1.4B). In this manner,
in vivo Th2 cell development can be examined and has the potential to be applied in
the analysis of intrinsic allergenicity.
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Indian ink-containing
draining lymph node
non-draining
lymph nodes
non-draining
contralateral
lymph node
opaque
non-lymphoid
tissue
Figure 1.2: Indian violet ink drains to a single lymph node. Seven days after
intradermal injection of 600 dead iL3 N. brasiliensis larvae mixed with indian vio-
let ink, the tissue architecture around the head of a mouse was photographed. The
same picture is shown twice, and in the right-hand photo the location of the auric-
ular draining (superficial parotid[272]) and non-draining (mandibular and accessory
mandibular[272]) lymph nodes are indicated. In all other experiments, indian ink was
not included in the injection. A non-lymphoid, likely adipose, tissue deposit is also
indicated for disambiguation. The contralateral auricular lymph node can be seen
at the arrow tip just above the ensanguined area at the junction of the superficial
temporal and maxillary veins.
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Figure 1.4: Th2 response to parasite and dust mite antigens. (A) Total live cells
were examined by flow cytometry for CD4 and GFP expression in draining (DLN) and
non-draining (nDLN) lymph nodes of +/+ and G4/+ mice. (B) The total number of
GFP+CD4+ T cells induced by immunization with 600 dead iL3 N. brasiliensis larvae
(L3) or 100 µg HDM (HDM) in G4/+ mice were combined from all experiments de-
scribed in this thesis hereafter. The control (ctrl) group includes naive, PBS-injected
and non-draining nodes of G4/+ mice. Symbols show individual responses of (n=72)
N.b.-immunised, (n=27) HDM-immunised, and (n=76) control lymph nodes. Data
were analysed by One-way ANOVA with Tukey’s post-test. ****p<0.0001.
34
1.5 The immunological mechanisms of allergic disease
1.5.1 The generation of IgE
IgE is central to the allergic response, therefore, the processes that lead to IgE produc-
tion are a key process in the allergen-directed immune response. IgE class switching
is CD4+ T cell dependent[274, 275]. With some exceptions, isotype switching oc-
curs in lymph nodes concomittant with affinity maturation[276–280]. The enzyme
Activation-Induced Cytidine Deaminase is central to both processes[281]. Prior to
isotype class switching, naive B cells excise the µ and δ heavy chains and begin to
transcribe downstream heavy chain transcripts (γ,  or α)[282, 283]. This means that
naive B cells are IgM+IgD+, while isotype class-switched B cells will lose IgM and
IgD expression and express IgG, IgE or IgA. When B cells mature into plasma cells,
the class-switched B cell receptor is secreted as antibody of the class-switched isotype
(for an example see [284]).
The cues required for B cell isotype switching to IgE have been determined and IL-4
is the most critical factor. In the 1980s it was discovered that when the protein BCF-
1, now known as IL-4, was added to cultures of mitogen-activated B cells or human
peripheral blood B cells they class-switched to produce antibodies of the IgE and IgG1
isotypes (or IgE and IgG4 in humans)[285, 286]. In mouse studies, it was shown that
blocking IL-4 signaling by sequestering secreted IL-4[287] or by blocking IL-4 receptor
signaling[288], IgE production was impaired by greater than 95 percent. The advent
of IL-4 knockout mice confirmed the central role of IL-4 in IgE production[289]. In
response to infection with the rodent helminth N. brasiliensis that usually generates
high titres of IgE and IgG1, IL-4-deficient mice generated no detectable IgE and
exhibited an 80 percent defect in IgG1 production[289]. The cellular source of IL-4
that provokes IgE production is known to be the CD4+ T cell[274, 275] and CD4+
T cell expression of CD40-ligand (L) is also critical for the CD4-dependent isotype
class switch[290–292]. Thus, by producing IL-4 and expressing CD40L, CD4+ T cells
promote IgE class switching.
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1.5.2 Additional roles of IL-4
IL-4 influences not only IgE production, but also a number of other aspects of the
allergic process. IL-4 increases mast cell FceRI-expression[293] and potentiates non-
haematopoeitic cells to respond to vasoactive mediators of allergy[48, 50]. IL-4 sig-
naling is required for experimental allergic airways disease[294] and for oral allergen-
induced mastocytosis that follows the first few oral challenges of sensitized mice[295].
Clinically, IL-4 and T helper type 2(Th2)-associated cytokine mRNA trancript num-
bers are elevated in bronchoalveolar lavage lymphocytes of asthmatics and in the
jejunal tissue of food allergic individuals[90, 296] indicating that IL-4 may evoke local
tissue effects during allergic and asthmatic responses. These Th2-associated cytokines
include IL-4, and also IL-5 and IL-13. All three of these cytokines are observed at
increased levels following oral allergen challenge in sensitized mice[37, 58].
1.5.3 Mice are rendered susceptible to intestinally-triggered
allergic responses in a post-sensitization oral potentia-
tion phase
The elevation in Th2-associated cytokines is an important aspect of the intestinal
allergic process. While experimental intestinal allergic responses are IgE- and mast
cell-dependent, after sensitization, multiple oral exposures are usually required before
severe diarrhoea is observed; it is in this phase that precedes disease in which Th2
cytokines first become elevated[37]. In sensitized wild-type BALB/c mice, multiple
oral challenges are required to generate sufficient intestinal mast cell infiltration to
permit oral allergen-induced diarrhoea development[36, 37, 67]. Further, passive sen-
sitization does not permit diarrhoea without multiple previous oral challenges[67]. It
has, however, been demonstrated that once mice have been orally challenged multiple
times with OVA, passive sensitization with IgE against the trinitrophenyl (TNP) hap-
ten permits diarrhoea development upon the first feeding of TNPylated-bovine serum
albumin[67]. This suggests that both peripheral sensitization and intestinal mast cell
infiltration are required, but these are discrete and likely independent processes that
permit allergic diarrhea to be triggered by oral allergen challenge. As this local Th2-
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type inflammatory process precedes observable diarrhea, I will refer to this process as
oral potentiation.
IL-4 is key to oral potentiation, but other Th2-associated cytokines also become ele-
vated during oral potentiation. In orally-challenged mice, IL-5 levels become elevated
and increased intestinal eosinophil influx is observed[37, 58, 297]. There is no role for
eosinophils in IgE-mediated diarrhoea[37], but they are implicated in villus shortening
in oral-allergen challenged mice[42]. While beyond the scope of this thesis, eosinophils
are also involved in other IgE-associated diseases, like eosinophilic esophagitis[11]. In
terms of disease-relevant Th2 cytokines, IL-13 levels also increase in orally challenged
mice[295] and blockade of IL-13 signaling decreases disease incidence in mice without
significantly impairing mast cell infiltration[295]. This may be due in part to the
effects of IL-13 on the smooth muscle tissue itself[50, 66]. The CD4+ T cell-derived
cytokine, IL-9, is also implicated in the expansion of intestinal mast cells[57]. IL-4,
IL-5 and IL-13 can all be produced by CD4+ T cells, so in addition to their role in
IgE generation, there are a number of additional allergic processes that are associated
with CD4+ T cell activity, including the oral potentiation that permits triggering of
intestinal anaphylaxis.
1.5.4 CD4+ T cells are implicated in oral potentiation
Studies in three similar systems implicate intestinally-localised CD4+ T cells in the
oral potentiation process[37, 57, 58, 298]. Prior to diarrhoea onset, sequential intra-
gastric OVA challenges induces proliferation of- and α4β7 expression on- OVA-specific
CD4+ T cells[38], IL-4 production by intestinal CD4+ T cells[57, 58], and intestinal
transcription of CCL20[299]. Additionally, adoptive transfer of in vitro restimulated
OVA-specific CD4+ T cells from diarrhetic mice transfers disease susceptibility to
naive mice[38]. As outlined previously, this oral potentiation period is also associated
with increases in intestinal mastocytosis. The involvement of the IL-4/-13 STAT-6
signaling pathway in experimental food allergy is unequivocal[37, 57, 58, 295], how-
ever the distinct effects of CD4-derived IL-4 on IgE production and tissue-specific
mast cell activity remain unknown. There is also evidence that after sensitization,
CD4+ T cell recirculation is not required for disease to develop[299]. This indicates
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that either peripheral processes (like IgE generation), or intestinally-localised CD4+
T cells are sufficient for oral potentiation. It has also been demonstrated that after
oral potentiation, disease ensues when IL-4 is neutralised[295]. The processes involved
in oral potentiation and those that maintain disease susceptibility may therefore be
mediated by distinct cytokines and different cell types. In a similar vein, cells other
than CD4+ T cells, namely basophils, eosinophils, iNK T cells, mast cells and B
cells have been shown to produce IL-4, and could therefore contribute to the oral
potentiation process[300–305]. The correlation between Th2 cell infiltration and IL-4
production implicate CD4+ Th2 cells in the allergic process, but whether they are
required, or simply sufficient, for the induction of intestinal anaphylaxis in mice re-
quires clarification. The involvement of CD4+ T cells in disease maintenance is also
unclear: addressing the role of CD4+ T cells in the maintenance of disease is required.
Close inspection of the role of CD4+ T cells in the post-sensitization phase of food
allergy may establish unknown subtleties of the allergic process that facilitate better
long-term disease alleviation.
1.5.5 Cytokine requirements for intestinal mastocytosis
Mast cells are key effector cells in IgE-mediated allergies. However, there is evidence
that allergic responses that are induced by challenge in different tissues are mediated
by different effector molecules. For some responses, passive sensitization through
the transfer of IgE-containing serum is sufficient to permit immediate, local, type I
hypersensitivity reactions. For example, injection of purified antigen-specific IgE, or
antigen-specific IgE-containing serum into the ears of mice is sufficient to permit acute
mast cell-dependent type I responses in the ears of mice[43, 306]. Passive sensitization
can also permit systemic anaphylaxis in mice[41, 48]. Passive sensitization is possible
in humans, too. Intradermal injection of reaginic serum to non-sensitized humans, fol-
lowed by oral allergen ingestion, induces wheal-and-flare reactions in the skin without
intestinal disease manifestations[150]. In mice, passive sensitization alone does not
permit severe intestinal allergic responses without the oral potentiation phase[67].
Therefore, while IgE alone is sufficient to permit cutaneous and systemic disease,
additional cues are required to promote intestinal mast-cell dependent allergic ana-
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phylaxis.
There are a number of mast cell-active cytokines, and three of these are critically
involved in inflammatory mast cell responses in mice. It is known that stem cell fac-
tor (SCF) is required for the presence of mast cells in the intestine at baseline[307].
Mutations in the gene encoding cKit render mice mast cell-deficient, in intestinal,
peritoneal, and cutaneous tissues[43, 307, 308]. In contrast, while mast cells and
their activity can be observed in mice deficient in IL-3, IL-4, or IL-9[50, 57, 309,
310], these three cytokines amplify intestinal mast cell infiltration caused by parasite
infection[311–313]. These are the three cytokines that are most important for inflam-
matory mast cell responses. Exogenous administration of these cytokines can also
expand intestinal mast cell populations[309, 314]. IL-3, is a particularly potent mast-
cell active cytokine, and can increase intestinal mast cell progenitor numbers in the
presence of SCF to a greater extent than IL-4 and IL-9 combined[314]. In vitro, IL-6
and IL-10 can also contribute to mast cell development[314]; however, each of IL-3,
IL-4 and IL-9, has been demonstrated to expedite parasite expulsion and are therefore
important in intestinal Th2 responses[50, 309, 311–313, 315]. Further, production of
IL-3, IL-4 and IL-9 can be attributed, at least in part, to CD4+ T cell activity[316–
318]. Roles for IL-4 and IL-9 in experimental oral allergen-induced mastocytosis and
diarrhoea have been demonstrated[57, 295] but the potential involvement of IL-3 in
the intestinal allergic process is currently unknown.
1.5.6 Intestinal mastocytosis heightens allergic disease sus-
ceptibility
Intestinal mast cells also contribute to additional aspects of the allergic disease pro-
cess. High basal mast cell activity increases gut permeability, and this renders mice
more susceptible to allergic sensitization and anaphylaxis[57, 67]. This is associated
with a corollary decrease in blood plasma volume and impaired basal intestinal bar-
rier function at baseline[57, 67]. Individuals with food allergies also have increased
intestinal permeability, or a leaky gut[319]. Long-term changes in permeability are also
observed in orally-primed wild-type mice[37, 57, 149]. It has also been demonstrated
that hypothermia and shock can be induced by oral feeding of allergen, but only if
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the allergen can cross the intestinal epithelial barrier and get into the blood[67, 68].
Correlations have also been drawn between mast cell numbers and orally-induced ana-
phylactic severity[36, 39]. Intestinal uptake of allergen is expedited by sensitization
in a mast-cell dependent manner[308, 320], and the allergic leaky gut results in a
200-fold increase in allergen levels in the blood of allergic mice fed allergen compared
to non-allergic mice[149]. Oral allergen challenge has also been shown to enhance
systemic anaphylactic responses[37] and exacerbate lung inflammation to unrelated
allergens[321]. These findings collectively suggest that intestinal mast cell activity
can exacerbate not only intestinal allergic responses, but can also permit allergen dis-
semination and amplify systemic allergic responses. Processes that increase intestinal
mast cell activity therefore have the potential to promote allergic responses, and this
may be an important aspect of the clinical allergic process.
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1.6 Th2 cells and the functional Th paradigm
While the full role of CD4+ T cells in allergic disease requires continued investigation,
impetus already exists to investigate the signals that promote their development into
Th2 polarised cells. Since 1986, IL-4 production by a CD4+ T cell has identified it as
part of the Th2 subset, and much is now known about Th2 cell development in vitro;
much still remains to be determined regarding their development in in vivo allergic
disease contexts. In order to understand the early events that induce naive CD4+ T
cells to attain Th2/IL-4-producing function the host-derived signals that lead to Th2
development have been investigated in detail.
The designation of the Th2 cell came, originally, from studies by Coffman and colleagues[322]
in which CD4+ T cells were shown to develop into two mutually exclusive subsets
based on function and their cytokine production profile. Long-term T cell clones that
produced IL-2 and IFN-g were termed Th1 clones, whereas those that produced IL-
4 (then called BCF-1), IL-5 and IL-10, were designated Th2. Th2 clones were the
only clones capable of enhancing IgE and IgG1 switching during polyclonal B cell
stimulation[322] and Th2 clones also permitted mast cell generation (both of these
responses were identified as IL-4-dependent processes[322]). Further, irrespective of
the strain of the mouse used, immunization with chicken red blood cells gave rise only
to Th1 clones; in contrast, Th2 clones exclusively were generated by fowl gamma-
globulin immunization. Thus, from the first demonstration of Th subset polarization,
the concept was inherently tied to that of protein allergenicity. While Th2 cells are
implicated in allergic disease and anti-parasite responses[38, 57, 58, 323], Th1 cells
are effector cells that are important for the control of intracellular pathogens[324].
There are now a number of proposed Th subsets, including Th9, Th17, Treg (regula-
tory) and TFH (follicular helper) cells, and multifunctional populations that do not
segregate clearly into any one particular subset[324, 325], however, Th2 cells remain
an important allergy-associated cell. The involvement of Th17 cells in some allergic
processes have been gaining interest[158], and in terms of the oral potentiation pro-
cess, IL-9 derived from Th9 cells may also play an important role[57, 326]. However,
the central role of IL-4 in the allergic process means that IL-4-producing Th2 cells
remain the focus of this discussion.
41
If Th2 cells promote allergy, and allergenic immunizations promote their develop-
ment, the question arises, what are the immunological changes triggered by an im-
munization that promote the differentiation of a CD4+ T cell toward any specific,
and particularly a Th2 pathway? Commitment to a given Th subset is determined
by lineage-specifying gene activation, and silencing of lineage-inappropriate cytokine
genes[324, 327]. The master regulator of Th2 commitment, GATA-3[328] acts in
conjuction with STAT-6 for the full elicitation of Th2 development and function in
vivo[329–331], and simultaneously silences Th1 commitment[332]. T-bet is the master
Th1 specifying transcription factor[333], and acts in collaboration with STAT-1[334].
Th17 cells are under the control of the master transcription factor RORγt[335], and
are cross-antagonised by Foxp3 which specifies Treg development[336]. TFH cells,
which are specialized B helper cells[275, 337, 338], are now known to develop under
control of BCL-6[339–341]. In allergic disease IL-4, IL-5 and IL-13 producing Th2
cells are the most important Th subset and understanding the events that initiate
and enhance their development are key current investigations.
1.6.1 The early and late events specifying Th2 polarization
in experimental systems
The correlation between Th2 cells and allergic disease is clear, however, the events
that permit their development remain incompletely defined. In addition to the role
of the allergen in the induction of the allergic process, significant effort has gone into
investigating the host-derived proteins that permit the acquisition of polarised Th
function. Some work has been done in vivo, but the majority of understanding comes
from in vitro studies.
In vitro studies have been important in elucidating the factors that promote Th2
cell development. Early studies identified IL-2 and IL-4 as important factors for in
vitro Th2 cell differentiation[342–344]. Studies have now established that early IL-4
transcription is triggered by TCR ligation, CD4 co-receptor stimulation and IL-2R-
signaling, and only later is IL-4R signaling required for continued Th2 development[345–
349]. When naive CD4+ T cells are stimulated by plate-bound anti-CD3/CD28 or
antigen presenting cells loaded with cognate antigen, increases in IL-4 mRNA can be
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detected as early as one hour after stimulation, but in the absence of IL-4R signal-
ing this is not maintained, and Th2 cell development thereafter is impaired[347–349].
Similarly, studies using an IL-4-linked conditional toxic gene construct identified that
naive CD4+ T cells will die upon initial stimulation, but if they are first polarized to
the Th1 subset they will not die[327, 350]. This indicated that the IL-4 gene is tran-
siently expressed by naive T cells, but an important part of differentiation is silencing
of alternate lineage cytokines thereafter[327, 347, 350]. These studies identified that
Th2 development and IL-4 expression in vitro begins in an IL-4-independent manner,
and this is followed by a period in which IL-4 specifies Th2 lineage commitment[347].
The importance of this IL-4-independent phase of in vitro Th2 cell development is
only beginning to be appreciated, but has lead to a number of investigations into the
Th2-initiating processes. More recently, tissue-derived cytokines have been demon-
strated to promote Th2 cell development by modulating dendritic cell function in
vitro[351]. In addition to the cytokine milieu and involvement of IL-4 in Th2 develop-
ment, TCR affinity also influences Th polarization[349] and increased cellular stress
is associated with Th2 polarization[352].
The conditions that lead to Th2 cell development in vivo are more complex. There is
evidence that demonstrates Th2 immunity is amplified by the innate-type cytokines
IL-25, IL-33 and TSLP[353–356], but these cytokines are not required for the de-
velopment or function of CD4+ Th2 cells[357–359]. The role of IL-4 in Th2 devel-
opment in vivo shares similarities with the in vitro data but is less clearly under-
stood and far less rigorously validated. While IL-4 can maintain the population of
cells transcribing IL-4 in vivo[360–362], IL-4 signaling is not required for early Th2
generation[1, 360, 362, 363]. Studies over the last 15 years have investigated the role
of IL-4 in Th2 development in vivo and determined that the early generation of Th2
cells is equivalent in IL-4Ra-/- and WT mice[362]; memory Th2 numbers are similar
in doubly IL-4 and STAT-6 deficient mice[1]; IL-4 mRNA accumulation is equivalent
in early immune responses[360]; and naive IL-4Ra deficient CD4+ T cells that have
received TCR ligation will produce IL-4 on ex vivo TCR stimulation[363]. However,
when IL-4Ra deficient mice are injected in the hind footpad with OVA plus alum
adjuvant, draining lymph node IL-4 transcription is induced, but transcript levels
decay relative to wild-type mice concomitant with lymph node atrophy as the im-
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mune response progresses[360, 361]. Thus, IL-4 can influence the amount of IL-4
transcribed in an isolated lymph node in vivo, at least in an adjuvant based immu-
nization regimen. Further, when IL-4 signaling is interrupted in mice responding to
helminth infection, full Th2 effector function is diminished, as bronchoalveolar lavage
(BAL) eosinophilia, which is a normal attribute of the anti-helminth response, and
IgE switching are lost[1, 289], ex vivo T cell IL-4 production is curtailed[363], and
the maintenance of Th2 cell and B cell populations is impaired[362]. It is becom-
ing apparent that IL-4 is not required for Th2 development in vivo, but ascertaining
the influence, rather than dependence, of IL-4 on Th2 cell development in primary
Th2 contexts is becoming an increasingly important direction of current allergy re-
search.
As such, studies investigating the role of IL-4 in allergen-induced Th2 development
require further investigation. The in vivo studies that demonstrate a potential role for
IL-4/STAT-6 signaling in Th2 development have examined mRNA transcript levels[1,
360, 361] and more recently an mRNA-tagged IL-4 reporter[362] either in response
to live parasite infection[1, 362] or following adjuvant-based immunization[360, 361].
Other studies of allergenicity in an adjuvant-free context have had to rely on the B
cell response as the primary readout of Th2 development[268]. Understanding the
involvement of IL-4 in in vivo Th2 development as a function of allergenicity is an
important, but unexplored area. In particular, close dissection of the role of IL-4
in Th2 development, and the relationship between Th2 cells and the other identified
in vivo IL-4-producing cell, the TFH cell, induced in an adjuvant-free allergic con-
text may provide new insight into the aetiology and initiation of the allergic disease
process.
1.6.2 Are there multiple populations of IL-4-producing CD4+
T cells?
In 2009, Reinhardt et al.[275] along with two other groups[362, 364], provided evi-
dence that lymph node IL-4 derives predominantly from CD4+CXCR5+PD-1-hi TFH
cells located in follicular regions of lymph nodes. These works followed the identi-
fication of TFH cells that have transcribed IL-4 mRNA during T-dependent B cell
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responses[337]. Subsequently it was shown that the molecule GL-7, which is expressed
on activated T cells[365] and germinal centre B cells[338], demarcates germinal centre
TFH that contain particularly high levels of IL-4 mRNA[366]. IL-4 producing Th2
cells that do not have the TFH phenotype or produce the hallmark TFH cytokine, IL-
21, can also be found in the tissues[275, 317]. It is possible that these tissue-localised
Th2 cells have come from the TFH cell pool[367], however, evidence is accumulating
that lymph node versus tissue effector fate can be dictated early during lymph-node
T cell activation[368, 369]. Additional data shows that IL-4 production by TFH is
not strictly limited to Th2 immunisation, because IL-4 production by TFH cells is
observed not only in response to Th2 stimuli such as live N. brasiliensis, H. poly-
gyrus bacheri, L. major and S. mansoni infection[275, 362, 364], but also following
lymocytic choriomeningitis virus (LCMV) infection[366] and in lymph node- but not
lung-localised CD4+ T cells responding to experimental influenza virus infection[370].
Thus, while IL-4 production is typically associated with Th2 immunity and allergy,
understanding the function and eventual fate of the developing IL-4-producing CD4+
T cell may have implications for the potential disease phenotype of a given immuni-
sation strategy.
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1.6.3 Measuring IL-4 production using IL-4 reporter mice
One of the difficulties in monitoring Th2 development and IL-4 production in vivo is
the short half-life of IL-4[371]. To facilitate better detection of IL-4 production, four
different IL-4 reporter constructs have been reported in the literature[273, 372–374],
and the use of three of these is still commonplace. The three widely used reporters are
the 4get, the KN2 and the G4 reporter constructs (Figure 1.5). Each differs slightly
in the way it has been inserted into the IL4 gene and they provide complementary,
but context specific, information about the regulation of IL-4 production.
First, the 4get construct is an IL-4 mRNA tagged enhanced green fluorescent protein
(GFP) construct that adds the sequence for GFP protein with an internal ribosomal
entry site (IRES) construct to the 3’ region of the gene encoding IL-4[372]. Thus, the
4get construct remains IL-4 sufficient, has the 5’ untranscribed region (UTR) intact
and at least 5 kb of the 3’ UTR of the IL-4 gene remaining as part of the replaced
gene segment[372]. The 4get construct remains IL-4 sufficient because the eGFP gene
is placed directly downstream of the full-length IL-4 sequence. However, it has been
shown that GFP expression in 4get cells does not demarcate cells actively producing
IL-4, but rather identifies cells with the potential to produce IL-4[373], such that
GFP+ 4get cells are considered ’Th2 competent’ cells[275]. The 4get construct is
generally used in conjunction with the IL-4 knockin human CD2 (hCD2) construct,
abbreviated to ’KN2’[373].
The KN2 reporter replaces the first two exons, plus the intronic region between exons
1 and 2, of the murine IL-4 gene with the gene encoding hCD2 without disrupt-
ing other IL-4 promoter/enhancer regions (see supplementary data of[373]). The
murine CD4 enhancer is included in the construct to amplify the hCD2 signal to de-
tectable levels[373, 375]. KN2/KN2 mice, homozygous for the KN2 allele, are IL-4
deficient[373]. However, when KN2 cells are provided with Th2 stimulation, cells will
express hCD2 on the surface, and this can be detected by flow cytometry[352, 373].
The advantage of the KN2 reporter is that in in vitro KN2/+ heterozygote Th2
cultures up to 80 percent of IL-4-producing cells express hCD2[373]. Further, Th2
immunizations that induce IL-4 production in vivo also induce hCD2 expression, and
the longer half-life of hCD2 makes it simpler to detect IL-4 producing cells than using
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conventional methods[373]. However, not all hCD2+ cells express IL-4, so while the
KN2 construct is a useful tool for studying IL-4 synthesis in vivo, there remain some
nuances of this reporter construct that will need clarification in the future.
The G4 construct inserts the gene encoding (enhanced) GFP into the IL-4 gene,
replacing exon 1 and 178 nucleotides of the first intronic region of IL4 [273]. The posi-
tion of the insertion renders the G4 allele IL-4 null, like the KN2 construct, such that
G4/G4 homozygous mice lack IL-4-dependent features of Th2 immune responses[1].
The reporter mouse developed by Littman and colleagues[374] was similar to the KN2
reporter, but is no longer used.
The methods used to generate the knock-ins of all three reporters were similar. The
Littman group originally designed the hCD2 construct for insertion into the CD4
gene[375], but by altering the target site they were able to insert the construct into
the IL-4 gene but with low detection levels in Th2 cells[374], so they included the
murine CD4 enhancer sequence with the hCD2 knockin, such that higher levels of
hCD2 were observed in conditions under which IL-4 would normally be expressed[374].
The hCD2 protein was modified to render it non-functional when expressed, and is
therefore considered to operate solely as a ’reporter’[375]. The construct also included
a neomycin resistance cassette which was used to identify successfully incorporated
transgenes. The KN2 construct used the same reporter construct, but with an addi-
tional lox-cre site included to remove the neomycin resistance cassette after positive
selection. The G4 construct also contained a lox-cre neomycin resistance cassette but
does not include the CD4 enhancer site. Mohrs et al. used transient cre recombinase
electroporation[373], and Hu-Li et al. crossed reporter mice to C57BL/6-cre mice
in the F1[273] to remove the neomycin resistance cassette. The stem cells used for
electroporation for the constructs were from strain 129, strain 129/SvJ, and E14 em-
bryonic stem cells for the G4, KN2 and Littman constructs, respectively. All three
were transferred to C57BL/6 blastocysts to yield chimeric mice, and then outbred for
ten generations. Lastly, the G4 construct additionally contains the herpes simplex
virus thymidine kinase gene 5’ of the reporter, which allowed gancyclovir sensitivity
screening assays to be used in the selection process. Both the G4 and KN2 reporters
therefore were introduced in slightly different manners, and disrupt the IL-4 gene at
different sites.
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4get
KN2
Native Il4
G4
exon: 1 2 3 4
sequence
removed
eGFP gene
KN2 gene
IRES-eGFP gene
poly-A tail
Figure 1.5: Insertion sites of 4get, KN2 and G4 reporter constructs. (A)
Wildtype Il4, (B) Addition of the eGFP gene with an internal ribosomal entry site
was inserted upstream of the polyadenylation site of the full-length IL-4 cDNA for the
4get construct. (C) The KN2 construct replaces exon 1, intron 1 and exon 2 of the
murine Il4 gene. (D) The G4 construct replaces exon 1 and the first 178 nucleotides
of intron 1 of the Il4 gene. IL-4 protein is not produced from either the KN2 or the
G4 allele. Data are modifed from [273, 372, 373, 375].
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1.6.4 The regulation of IL-4 production
Epigenetic changes influence cytokine gene accessibility
The development of the polarised IL-4-producing Th2 cell phenotype is now estab-
lished to involve many regulatory processes. With increasing proliferative cycles, Th2
cells become more likely to produce IL-4 and loose their capacity to produce IFN-
γ[347, 376]. During this process, the chromatin structure of the Th1 genes becomes
less accessible, and that around the Th2 locus becomes more accessible[347, 377]. This
process involves changes to the chromatin structure that are the result of epigenetic
modification.
Epigenetic modification is important in Th2 cell development. This is exemplified
clearly in an early study by Bird et al.[378]. In this work, STAT-6-deficient CD4+
T cells cultured in IL-4 did not subsequently produce IL-4; however, if the cellular
methylation/acetylation apparatus were interrupted, 16% of STAT-6-deficient CD4+
T cells produced IL-4 upon restimulation[378]. Numerous studies have confirmed the
importance of changes in gene access and chromatin modification to the development
of the Th2 phenotype[377, 379–384]. Regulation of gene access is now recognised as
an important part of Th2 regulation (For review, see[324, 385]).
Probabilistic processes in biology
In addition to epigenetic regulation, some biological processes occur through stochas-
tic, or probabilistic mechanisms. The immune system is no exception. T cells acti-
vated under Th2-polarising conditions become increasingly likely to produce IL-4 with
increased proliferative cycles[376] and are progressively more likely to inactivate Th1
genes with sequential divisions[347]. However, synchronously stimulated T cells do
not divide synchronously: probabilistic regulation influences their rate of division and
dictates the eventual Th cell phenotype that arises[376]. Probabilistic mechanisms
have also been shown to underlie B cell population expansion, by balancing prolifer-
ation, isotype class-switching and death[386]. In this manner, ’chance’ processes can
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affect the eventual biological response.
Probabilistic gene expression
Probabilistic regulation can account for the expression of some genes. Probabilis-
tic regulation was proposed, based on the observation that in response to a given
stimulus, many cells will produce a large amount of a gene product, and others will
remain inactive[387]. A good example of this is seen in cells retrovirally transfected
to express Lacz, rather than produce retrovirus: At baseline, very few cells will ex-
press β-galactosidase, reflecting Lacz activity, but those that do, exhibit significant
activity[387]. The proportion of cells that exhibit activity increases when the ’signal
strength’, or exogenous stimuli that promote transcription increases. This is argued
to be an attribute of an error-prone process, the success of which was increased by the
multiplicative success of activation of enhancers[387]. In cases like this, the amount
of a gene product produced by a clonal cell population will be controlled in an on/off
manner, with cells producing either a lot, or no, product (figure 1.6B). This contrasts
with the conventional, deterministic view, in which the ’signal strength’ influences the
transcriptional activity or amount of a gene product from each cell (figure 1.6A). In
this manner, stochastic processes can regulate gene expression.
Probabilistic regulation of IL-4 gene expression
Probabilistic regulation of the Th2 locus has been proposed based on numerous studies
identifying monoallelic expression of IL-4. When Th2 cells are activated in vitro, or
expanded from clones, in a substantial proportion of cells, only one IL-4 allele will
be detected. In the G4 reporter system, when in vitro-generated G4/+ Th cells
are stimulated with antigen-loaded APCs in the presence of IL-4, approximately 7%
will produce IL-4, approximately 7% will express GFP and less than 1% of cells will
produce both IL-4 and GFP[1, 273, 388]. In other studies, IL-4 mRNA from only one
allele was detected in approximately half of cloned Th2 cells[389]. It has also been
observed that differences in IL-4 production between different strains of mice relates
to the frequency of CD4+ T cells that produce IL-4, rather than regulation based on
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the amount produced by each cell[390]. These observations have lead to the proposal
of probabilistic monoallelic regulation as an advanageous means by which to regulate
IL-4 production[381].
However, some equivocality exists in the predominant expression profile and defini-
tive determination of whether cytokine genes, including IL-4, are regulated at the
single allele level[352, 373, 391]. While induced by simular stimuli as IL-4 protein
and the G4 allele, the KN2 reporter operates differently to the G4 construct in one
key aspect - Where G4 GFP expression occurs mutually exculsive with IL-4 protein
in 80-90% of in vitro Th2 cells[1, 273, 388], hCD2 expression occurs in 80% of IL-4
producing KN2/4get Th2 cells in vitro[373]. Further, where approximately equiva-
lent proportions of GFP and IL-4-producing cells have been observed soon after TCR
restimulation of G4/+ cells[1, 273] and also at times when IL-4 mRNA levels are at
their peak[388], in the KN2/4get system a greater proportion of Th2 cells express
hCD2 than IL-4, such that 60% of hCD2+ cells do not produce IL-4 protein[373].
More recent studies have, however, shown a less complete dominance of hCD2 over
IL-4 expression in KN2/+ cultures[392]. Together, these data indicate that our un-
derstanding of the regulation of IL-4 production is incomplete and requires further
clarification, both in vitro and in vivo.
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1.7 Themes of this thesis
The primary goal of this thesis was to clarify the key factors involved in the allergic
process. This resulted in targeted investigations into the development and function
of IL-4-producing CD4+ Th2 cells in allergic Th2 immune response models. Three
questions pertaining to Th2 cell function and development were examined during this
work, and relate, first to the controversial role of IL-4 in Th2 cell development in
vivo; second, to their involvement in tissue-specific intestinal allergies; and third, to
the way allergens initiate Th2 cell development and can be compared allergenically.
After a short investigation characterising a novel reporter mouse used in our in vivo
studies, these concepts form the focuses of chapters 4-6. The relevant background,
and an overview of the concepts tested in each section are introduced at the beginning
of each chapter.
The over-arching aims of this thesis are:
1) To clarify whether IL-4 alleles are regulated in an allele-specific, probabilistic
monoallelic process in vitro;
2) To determine the role of IL-4 in in vivo allergen-induced primary Th2 cell devel-
opment;
3) To examine the influence of IL-4 heterozygosity on Th2-dependent allergic immu-
nity;
4) To clarify the role of CD4+ T cells in the oral potentiation of allergic disease;
5) To determine whether there is an immunological basis to the differential allergenic-
ity of cow and goat milk components.
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Chapter 2
Methods
2.1 Special reagents and miscellaneous procedures
2.1.1 Allergens
House dust mite (HDM) was purchased from Greer laboratories (Lenoir, NC, USA).
Albumin from chicken egg white (OVA) was purchased from Sigma (St Louis, MO,
USA). Bovine serum albumin (BSA) was purchased from Sigma. iL3 Nippostrongylus
brasiliensis larvae were cultured in house according to established protocols[393] and
were killed by three freeze-thaw cycles at −80 ◦C. The whole casein fraction from cow
and goat milks were prepared as described[394] and were provided by Ali Hodgkinson,
AgResearch, Ruakura. Briefly, milk from a Hamilton dairy goat farm was heated to
45 ◦C and centrifuged at 1650 g for 30 minutes and then had the fat removed. The
milk was reheated to 45 ◦C, the pH was adjusted to 4.2 using 2 M HCl, stirred for 30
minutes and centrifuged at 1650 g for 15 minutes to recover the precipitated caseins.
These were resuspended four times in 10 times the original milk volume and stirred
for 60 minutes before recentrifugation at 1650 g for 15 minutes. After the washes, the
casein was freeze-dried, vacuum packed and stored at 4 ◦C until further use. Upon
use, the caseins were dissolved in Dulbecco’s phosphate buffered saline (PBS; Invit-
rogen, Auckland, New Zealand) at 37 ◦C for 60 minutes and then sonicated to further
solubilise them. The final LPS concentrations were in the range 150-300 EU/mg for
each. αs1 casein was purified from milk from the same source by high pressure liq-
uid chromatography. Bovine β-lactoglobulin and caprine β-lactoglobulin were also
provided by Ali Hodgkinson, and were purified by Trichloroacetic acid (TCA) precip-
itation.
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2.1.2 Mice
Mice were aged 6-12 weeks at the start of experiments. BALB/c mice were from two
sources. Early experiments in BALB/c mice used mice originally sourced from the
Wellington School of Medicine maintained at the Biomedical Research Unit (BRU).
The BALB/c breeding colony was replaced with BALB/c-ByJ mice sourced from The
Jackson Laboratory (Bar Harbor, ME) in 2011 and these were used in later exper-
iments. KN2 mice[373] were donated by Richard Locksley (University of California
at San Francisco, CA). G4 mice[273] were donated by William Paul (National Insti-
tutes of Health, Bethesda, MD). IL-3-/- mice have been described[309, 395, 396] and
were donated by Booki Min (The Cleveland Clinic Foundation Biological Resources
Unit, Cleveland, OH). Mice with an IL-9 transgene under the control of the intestinal
rat fatty acid binding protein promoter (iFABPp-IL-9)[57] were a gift from Klaus
Matthaei (John Curtin School of Medical Research, Australian National University,
Canberra, Australia). All strains were backcrossed to a BALB/c background prior to
arrival at the BRU, except iFABPp-IL-9 mice which were generated using BALB/c
blastocysts[57]. KN2/KN2 and G4/G4 homozygotes were crossed to BALB/c-ByJ
mice to generate KN2/+ and G4/+ mice, respectively. KN2/G4 mice were the F1
progeny of a KN2/KN2 by G4/G4 cross. To generate iFABPp-IL-9-IL-3-/- mice, IL-
3-/- mice were first crossed with an iFABPp-IL-9 homozygote. F1 mice were crossed
to IL-3-/- and F2 pups that had no detectable IL-3 gene and carried the transgene
were used as iFABPp-IL-9-IL-3-/- parental mice. These F2 mice interbred with IL-
3-/- mice were used as the source of iFABPp-IL-9-IL-3-/- and IL-3-/- sib-matched
controls in the F3. P1 iFABPp-IL-9 mice were used as iFABPp-IL-9-IL-3+/+ mice
in these experiments. Experimental mice were maintained in a 14/10 hour light-dark
cycle at the BRU at the Malaghan Institute of Medical Research, Victoria University
of Wellington. Mice were euthanised by either cervical dislocation or carbon diox-
ide asphyxiation. Mice were used in accordance with the permissions of the Victoria
University of Wellington Animal Ethics Committee.
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2.1.3 Genotyping
Tail tips or ear clips of mice were lysed in 75 µL lysis buffer (25 mM sodium hy-
droxide, 0.2 mM Ethylenediaminetetraacetic acid (EDTA; Invitrogen) in deionised
H2O for 60-120 minutes at 95
◦C. Lysis was stopped by addition of 75 µL 40 mM
Tris-HCl. Debris was removed with a quickspin in a benchtop centrifuge and ge-
nomic (g)DNA was quantified by nanodrop (A260/280) and stored at 4 ◦C until be-
ing run through the polymerase chain reaction (PCR). Primers against wild-type
Il9 and the iFABPp-IL-9 transgene were purchased from Sigma and were as fol-
lows: iFABP (forward) construct: GTGGACAGGACCGAATCTCTGC. Il9 gene
(forward): CAGGTTTGAGGGAAGCTGGTCC; 3’ IL9 reverse primer: GCCTTTG-
CATCTCTGTCTTCTGG. PCR amplification was performed using the iTaqTMDNA
polymerase pre-mix kit (BioRad, Hercules, CA, USA) . A master reaction mix con-
sisting of 1x Magnesium-free master mix buffered with 2 mM MgCl2, 400 nM iFABP
(forward), 70 nM Il9 gene (forward), 400 nM Il9 reverse primer, 200 µM dNTPs, 0.2
µL iTaqTMDNA polymerase to which 300 ng template DNA were added to a total
volume of 25 µL. Primer aliquots were stored as 100 µM stocks and pre-diluted such
that 0.5 µL would give the appropriate concentration (20 µM, 3.5 µM and 20 µM
respectively). The PCR cycle was as follows: Stage 1: 94 ◦C 3 minutes; Stage 2: 40x
94 ◦C 20 s 64 ◦C 20 s, 72 ◦C 20 s; Stage 3: 72 ◦C 3 minutes followed by an infinite hold
at 4 ◦C. Amplified products were run on a gel made from 1-1.5% agarose (Invitrogen)
and the presence of the iFABPp-IL-9 transgene was detected as an approximately 400
bp product. PCR success was evaluated by the presence of a 200 bp WT band.
The same lysis conditions were used for the Il3 gene. Primers (Sigma) against the
gene encoding murine IL-3 amplified a were as follows: Forward primer: 5’GAACCT-
GAACTCAAAACTGAT3’ Reverse primer: 5’CTGAAGATTGGACTTGATAAC.
A 1x master mix was made to give a final reaction volume of 20 µL containing 500 nM
of the forward and reverse primer and 0.2 µL iTaqTM. 200-500 ng DNA were added to
each tube and the amplification cycle was as follows: Stage 1: 94 ◦C 2 minutes; Stage
2: 94.0 ◦C 20 s, 56.1 ◦C 10 s, 72.0 ◦C 30 s; stage 3: 72 ◦C 5 minutes followed by an
infinite hold at 4 ◦C. The reaction was predicted to yield an 1131 bp fragment and IL-
3-/- mice were identified as those in which the wild-type IL-3 band was not detected.
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The success of the PCR in IL-3-/- mice was further confirmed by the presence of the
wild-type IL-9 gene. In the F2, IL-3+/- and IL-3-/- mice were born in approximate
Mendelian ratios.
2.1.4 Protein quantification
Protein was quantified by nanodrop or using the Bicinchoninic acid BCATMprotein
assay kit (Thermoscientific, Rockford, IL, USA) according to the manufacturers rec-
ommendations with the following modifications. Samples, standards and reagents
were added in 30 µL volumes. After 30 minutes incubation at 37 ◦C plates were
removed from the incubator and read at 562 nm on a Versamax plate reader.
2.1.5 Trypan blue exclusion test
Samples were diluted 1:1 with 0.4% trypan blue (Invitrogen). Between 30 and 200 cells
were counted and these were back-calculated to the total volume for numbers.
2.1.6 Prediction of sequence homology using DELTA BLAST
The sequence for cow β-lactoglobulin was taken from Alexander et al.[397]. A protein-
protein DELTA-BLAST search[398] was performed using the http : //blast.ncbi.nlm.nih.gov/
search engine and search species were Homo sapiens (taxid:9606), Mus musculus
(taxid:10090) and Bos taurus (taxid:9913). Similar homologies to those reported
by Restani et al.[169] were observed for αs1 and αs2 caseins (not shown). The query
sequence for BLG was ALTCGAQALIVTQTMKGLDIQKVAGTWYSLAMAASDIS-
LLDAQSAPLRVY VEELKPTPEGDLEILLQKWENDECAQKKIIAEKTKIPAVFKI-
DALNENKVLV LDTDYKKYLLVCMENSAEPEQSLVCQCLVRTPEVDDEALEKFD-
KALKALPMHIRLSFNPTQLEEQCHI. The glycodelin[244] and human placental pre-
cursor protein-14[245] proteins, both of which have been previously identified as β-
lactoglobulin-related proteins[244, 245], each returned 44% homology.
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2.1.7 Statistical analysis and graphics
Data were graphed and analysed in Graphpad Prism 5.0. Statistical analyses used
are stated in figure legends and p<0.05 was considered as significant. When multiple
individual group comparisons yielded similar significance values (i.e., were commonly
<0.05, <0.01 etc.), the significance value is indicated for all connected lines. In
comparisons between two similarly-sized groups, Student’s t-test was used. Analyses
examining a single parameter of three or more groups were compared with One-way
ANOVA with Tukey’s post-test. For experiments examining two or more groups, Two-
way ANOVA with Bonferroni’s post-test were used. Repeated measures tests were
used in cases in which the same biological sample was compared. Figures showing
data combined from multiple experiments were first normalised such that baseline
values were similar across combined experiments. Unless otherwise stated, symbols
represent individual mice and error bars represent mean ± the standard error of the
mean (SEM).
pTh2 assays were designed to detect 2-3-fold differences with 80% power (1-β; β=0.2)
at α=0.05 in experiments using one or more experiments including groups of 5-10
mice. The calculation employed was:
n=(Z2α+Zβ)x(Z2α+Zβ)x((SD1)x(SD1)+(sd2)x(sd2))/(ED);
Where, ’n’ is the number of mice required per group, ’ED’ is the expected difference
(µ1-µ2), ’SD1’ is the empirical SD for the responding immunogen, and ’sd2’ is the
sd of the group for comparison. For experimental groups, ’sd2’ was approximated
as half the expected µ2. Empirical values attained using mice (n=298) immunised
intradermally with 600 dead iL3 N. brasiliensis larvae give µ=226379±133931 Th2
cells; (n=27) HDM-immunised G4/+ nodes µ=87021±39275; control lymph nodes
(n=43) µ=2018±1444. To fit with historical data and reduce the occurrence of type-1
errors, pTh2 data were not log-transformed prior to analysis. An example derivation
for HDM power is shown:
To detect an x -fold difference to an allergen response on a similar scale to HDM
immunization in 80/100 experiments (β=0.2):
(x=1.2, n=71.8);
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(x=2, n=8.4);
(x=3, n=4.1);
(x=4, n=3.1);
(x=5, n=2.6);
(x=10, n=2.0) mice/group.
Figures were prepared in Adobe R©Illustrator R©version 5.1.
2.2 Cell culture
During preparation, cells were handled in Iscove’s modified Dulbecco’s medium + Glu-
tamax (IMDM; Invitrogen). Base culture medium consisted of 5% or 10% foetal calf
serum (Sigma), 100 U/mL Penicillin/100 µg/mL Streptomycin (Invitrogen), 55 µM
β-mercaptoethanol (Invitrogen), in IMDM (cIMDM). Standard incubation conditions
of 37 ◦C humidified in 5% CO2 in air were used.
2.2.1 Hybridoma culture
GK1.5 (process similar for other antibodies made in house) anti-CD4 monoclonal anti-
body was prepared in house from the culturesupernatant of the GK1.5 hybridoma[399].
The GK1.5 hybridoma was grown by culture in 10% cIMDM and antibody was isolated
from the supernatant by fast pressure liquid chromatography using Hitrap protein G
affinity columns (GE Healthcare) used according to the manufacturer’s instructions.
After isolation into neutralising buffer, antibody was dialysed for 2-4 hours in 2L
PBS using 10000 molecular weight cut-off (MWCO) cassettes (Pierce). The PBS was
changed and antibody was dialysed overnight. The next day, dialysed protein was
extracted from the cassette and concentration was determined by nanodrop absorp-
tion at 280 nm. Antibody was concentrated to 2.5 mg/mL in 10000 MWCO or 30000
MWCO vivaspin microtubes (GE Healthcare). Heavy and light chain expression was
confirmed by sodium dodecyl sulfate gel electrophoresis, and in some cases, in vivo
depleting capacity was assessed. Mice received 0.5 mg (200 µL) antibody i.p. with
each injection according to standard protocols[400], and in maintenance experiments,
antibody was readministered every four days. On days of challenge plus monitoring
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for peripheral CD4+ T cell content, monitoring was done prior to gavage and prior
to GK1.5 administration. Mock-depleted mice received 0.5 mg polyclonal Rat IgG
purified from naive rat sera purified in house by Hitrap protein G affinity or was
purchased from Sigma.
2.2.2 Bone marrow cell culture for IL-3- and TSLP-elicited
basophils
Bone marrow cells were isolated as described in mouse manipulations. Bone marrow
cells were seeded at 1x106/mL in 24-well plates. Cells were cultured in the presence
of 10 ng/mL IL-3 (Peprotech, Rocky Hill, NJ, USA), 1 µg/mL TSLP (R&D Systems,
Minneapolis, MN, USA), 10 ng/mL IL-3 plus 1 µg/mL TSLP, or an equivalent volume
of 1% BSA/PBS as medium alone controls. After three days, half of the medium
was removed without disrupting the cells and replaced with fresh medium containing
10 ng IL-3, 1 µg TSLP, 10 ng IL-3 plus 1 µg TSLP or an equivalent amount of
1% BSA/PBS as seeded. On day five, non-adherent cells were harvested, counted
by trypan blue exclusion, and analysed by flow cytometry. By day five, adherent
cells in IL-3-containing cultures had reached confluence and the medium had changed
colour. TSLP containing cultures were predominantly non-adherent, however, some
sparse adherent cells were observed extending pseudopods; these were also observed
occassionally in medium-only cultures. FceRI+cKit- cells comprised approximately
0.8% of bone marrow cells on day 0, and at seeding of G4/+ cultures, 60% of these
cells were GFP+.
2.2.3 Th cell polarization
Twenty-four-well plates (BD) were coated overnight at 4 ◦C, or for 2 hours at 37 ◦C
with anti-CD3 in PBS (2C11, 1 µg/mL, 300 µL/well; in house). On the day of
the assay, plates were washed twice with 500 µL IMDM and 1x106 splenocytes from
naive mice of the specified genotype were added to each well in a 1 mL culture volume.
Cultures were left untouched for three days, at which point wells were resuspended and
half of the cells were removed and discarded and 500 µL of 2x conditioning medium was
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again added to wells. On day 4, 500 µL was removed without resuspension and cells
were fed as on day 3. For restimulation assays, cells were removed from wells on day 5,
washed twice in IMDM and replated in wells containing 100 U/mL IL-2 and anti-IL-4
(11B11, 10 µg/mL; prepared in house) as the final culture conditions. During the rest
period, half of the medium was replaced every day and if the medium reached pH7.0
or less in any culture, determined by a change in phenol red colouring, the contents of
the wells were split in two. Separate wells were maintained for individual mice from
the start of culture throughout the process, such that data points represent biological
replicates unless explicitly stated. For initial conditioning, Th0 medium contained 100
U/mL IL-2, 10 µg/mL anti-IL-4 and 10 µg/mL anti-IFN-γ (AN.18; prepared in house).
Th1 medium contained 100 U/mL recombinant (r)human IL-2, 10 ng/mL rIL-12p40
and 10 µg/mL anti-IL-4. Th2 medium contained 100 U/mL IL-2 and 1000 U/mL
chinese hamseter ovary (CHO)-mIL-4 (IL-4 activity was compared by ELISA using
standards originally calibrated using the CT.4S cell line as described[342]. One unit
is equivalent to approximately 0.5 pg IL-4/mL[342]). During primary stimulation, all
cultures contained 20 µL/mL anti-CD28 (37.51; grown and titrated in house without
purification) that was not replaced during subsequent feeds.
2.2.4 In vitro restimulation of Th cells
After conditioning, Th cells were transferred to wells coated with anti-CD3 at 10
µg/mL as per vanPanhuys et al.[1]. Restimulation medium included 100 U/mL IL-2
and 20 µL/mL anti-CD28. In experiments examining IL-4 protein production, anti-
IL-4 was also included in the restimulation medium. For the detection of intracellular
cytokines, 4 µL GolgistopTMcontaining monensin (BD) was combined with 16 µL
IMDM and 20 µL was added to each well two hours before the cells were harvested.
In experiments that simultaneously examined cytokine production, parallel cultures
to which monensin was not added were used.
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2.2.5 IgG1 spot assay
MAIPSWU10 0.45 µm hydrophobic Immobilon P memprane 96-well ELISpot filter
plates (Millipore, Billerica, MA) were pre-soaked for 90 seconds with 50 µL 70%
ethanol. After removing the ethanol, plates were washed five times with 200 µL
PBS and incubated overnight at 4 ◦C with 10 µg/mL of the coating antigen. The
following day plates were washed five times with 200 µL PBS and were left at room
temperature with 10% cIMDM to block unbound sites on the plate. After processing,
spleen and/or bone marrow cells were resuspended in 10% cIMDM, and were serially
diluted and transferred to spot assay plates. Plates were given a soft spin (50 g for
60 s) and overlaid with a further 50 µL assay medium and incubated for 4 hours at
37 ◦C. After incubation, plates were washed five times with 200 µL PBS and then
incubated with 0.91 µg/mL biotinylated rat anti-mouse IgG1 (A85-1; BD) overnight
at 4 ◦C. Plates were washed a further four times with PBS and incubated with 1/1000
SPX for 1 hour at room temperature in the dark and detected with the 3-amino-9-
ethylcarbazole AEC Chromogen staining kit (Sigma) resuspended in deionized water
according to the manufacturers instructions and 40 µL was added to each well. Forty-
five minutes later, plates were washed with tap water and put at 37 ◦C in air until
dry. Spots formed a red precipitate and were enumerated by eye and validated using
images acquired on an ELIspot reader. Concentrations at which densities were to
numerous to count were not included in quantitations; otherwise all dilutions were
included in frequency calculations.
2.3 Mouse manipulations
2.3.1 Primary Th2 (pTh2) assay
After anaesthesia with 200 µL anaesthetic solution (100 mg/Kg ketamine, 3 mg/Kg
Xylazine), mice were intradermally injected in the outer ear pinna (generally the left
ear) with 30 µL of immunogen in PBS. The draining auricular lymph node was later
excised and examined for live cells by trypan blue exclusion and for proportional GFP
expression in CD4+ T cells by flow cytometry. Generally, analyses were performed
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seven days after innoculation. When data were compiled from multiple experiments
the proportion of GFP+ cells or hCD2+ cells were normalised to 0.04<x<0.05% of
CD4+ T cells in wild-type (+/+) mice immunized with either dead iL3 N. brasiliensis
larvae or HDM. In cow and goat milk comparisons, casein samples had low solubility in
PBS, therefore three separate injections were required and administered in the centre
of the pinna, then on then in two additional injections perpendicular to the centre of
the pinna. Controls also received 3 x 30 µL injections in these experiments. In pTh2
assays that also examined B cell responses, the total number of IgG1+IgD-B220+
cells was determined by multiplying the proportion of live cells that were IgG1+IgD-
B220+, as determined by flow cytometry, by the total number of live cells found in
lymph nodes.
2.3.2 Oral allergen-induced experimental anaphylaxis (diar-
rhoea) model
A model of oral allergen induced diarrhoea was employed as established[37]. Mice
were sensitized intraperitoneally (ip) twice, two weeks apart with 50 µg ovalbumin
(OVA; Sigma) + 1 mg Alu-gel-S (Serva Electrophoresis GmbH, Heidelberg, Germany)
in 200 µL using a 1 mL tuberculin syringe (BD) and 25-gauge needle (BD). Thrice-
primed mice received an additional ip injection on day minus 14. From day 28, mice
were fasted for four hours prior to gavage and subsequently challenged intragastrically
three times a week with 50 mg OVA (200 mg/mL) in PBS. Mice were monitored for
diarrhoea development 60 minutes later. For serum analyses, mice were bled two
hours after challenge. Mice were bled by the submandibular route using a 4 mm
lancet (Ables scientific, Welshpool, Western Australia) or were pre-heated under a
heat lamp followed by lateral tail vein bleeding using a #10 carbon steel surgical
blade (Swann-Morton, Sheffield, England). When applicable, CD4+ T cells were
depleted with ip injections of 0.5 mg GK1.5 on days 25, 26 and 27, or the three
days following challenge ten. Mock-depleted mice received polyclonal IgG purified
from Hooded Lister rat serum. For long-term depletions, booster injections were
administered every four days.
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2.3.3 Active systemic anaphylaxis
Mice were warmed with a heatlamp for 3 minutes and then received 100 µg OVA in
PBS intravenously through a 29-gauge needle (BD). Intravenous challenges were done
two or three days after mice received their final gavage challenge. Temperatures were
monitored using a RET-3 rectal temperature probe attached to a digital thermometer
(Coherent Scientific, Hilton, South Australia).
2.3.4 Packed Cell Volume (PCV)
Haematocrit was taken directly from a tail nick and was most pronounced 45-60
minutes after challenge. 75 mm heparinized capillary tubes (Drummond scientific,
Broomall, PA) were used to take haematocrit and were plugged with plasticine. Tubes
were spun at 8000 rpm for 5 minutes on a benchtop centrifuge. PCV was assessed
using a sliding scale and represents proportion of the total volume that were red blood
cells.
2.3.5 Serum isolation
Blood was left to clot overnight at 4 ◦C. Blood was spun for 3 minutes at 4 degrees
(RCFmax=1523), serum removed and frozen at −20 ◦C until analysed by ELISA.
2.3.6 Tissue isolation
After euthanasia, mice were rinsed with 70% ethanol. Depending on the requirements,
the spleen, mesenteric and auricular lymph nodes were isolated by blunt dissection
with forceps. Bone marrow was removed as outlined below. Colons and caecae were
excised afterwards and the jejunal tissue was removed by cutting away the mesen-
teries. The first 1.5 cm of the intestine proximal to the stomach was deemed the
duodenum. The next 1-1.5 cm of jejunal tissue was used for histological sections,
and for cell isolation the next 5 cm section of jejunum was used. Jejunal tissue for
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cell analyses were flushed with 5 mL Ca2+ and Mg2+-free Hanks’ Balanced Salt Solu-
tion (HBSS; Invitrogen) using an 18-gauge needle (BD) and were stored in Ca2+ and
Mg2+ free HBSS on ice. All other tissues were stored in IMDM on ice until subsequent
processing.
2.3.7 Processing of jejunal tissue
After vigorous shaking with forceps to dislodge mucus and remaining gut content,
Peyer’s patches were excised and put on ice. Jejunal sections were transferred to
6-well plates (BD) containing 5 mL stripping buffer (5 mM EDTA), 25 mM HEPES
(Sigma), 10% FCS in Ca2+ and Mg2+ free HBSS) pre-heated to 37 ◦C. Tissues were
incubated in air at 37 ◦C with shaking (100 rpm) for five minutes. Tissues were
vigorously shaken with forceps to remove stripped epithelial cells. The process was
repeated two more times for a total of 15 minutes stripping. Tissues were rinsed in 5
mL 4 ◦C Ca2+ and Mg2+ free HBSS and placed on tissue paper to remove moisture.
Jejunal tissue was chopped into pieces small enough to pass through a 1 mL pipette
tip and incubated with shaking for 30 minutes in 5 mL 2.4 mg/mL collagenase A from
Clostridium histolyticum (Roche Diagnostics Gmbh, Mannheim, Germany) in IMDM.
The solution was subsequently passed through a 21-gauge needle (BD) with pressure
on the bottom of the plate and incubated for a further 15 minutes at 37 ◦C with
shaking. Debris was removed by passing through two layers of cotton gauze (Sefar
Filter Specialists Ltd., Te Papapa, Auckland, NZ) and rinsed with 10 mL cIMDM or
flow buffer and then through a 70 µm cell strainer (BD). Cells were then processed as
per standard flow cytometric procedures, but all isolated cells were stained for flow
cytometry.
2.3.8 Bone marrow preparation
The left femur was used for bone marrow isolation. The leg was washed with 70%
ethanol and the surrounding muscle was removed. The tibia was disconnected by
dislocating the knee and then using forceps, the bone was removed by cutting under
the hip socket. Bones were cleaned and stored in IMDM on ice until processing. To
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process bones, both ends were cut and a 22-gauge needle (BD) was inserted into the
bone tip. Five mL IMDM was flushed through the bone to isolate marrow, which was
spun down and resuspended in red blood cell lysis buffer (Sigma) for 2 minutes at
room temperature. Lysis was stopped by addition of 13 mL 5% cIMDM. Cells were
again spun and then resuspended in 10% cIMDM for the spot assay, 5% cIMDM for
mast cell culture, and were subsequently transferred to flow buffer (2% FCS, 0.01%
w/v Sodium Azide (Sigma) in dPBS) for staining.
2.3.9 Splenocytes
After excision from the mouse, spleens were placed on a 70 µm cell strainer and dis-
sociated with pressure against the strainer using the rubber end of a 1 mL tuberculin
syringe (BD) and rinsed with IMDM. Cells were spun down and resuspended in 2
mL red blood cell lysis buffer for 2 minutes at room temperature. The reaction was
quenched with 13 mL 5% cIMDM or flow buffer and then tubes were spun down for
4 minutes at 1400 rpm (419 x g). Spleen cells were then resuspended in 10 mL buffer
for counting. Cells were respun and resuspended for future use.
2.3.10 Lymph node cells
Mesenteric, auricular lymph nodes and Peyer’s patch cells were liberated by crushing
lymph nodes through a 70 µm cell strainer with the rubber end of a 1 mL tuberculin
syringe (BD) and rinsed with flow buffer for flow cytometry. Cells were spun and
resuspended in 4 mL buffer for counting. Red blood cells were ignored during counting
and were identified as small, dense, spherical cells with a darker hue than lymphocytes.
For flow staining, cells were transferred through 70 µm gauze and stained for flow
cytometry.
2.3.11 Jejunal mast cell quantification
Jejunal tissue sections were removed from mice and put in 10% formalin (4% w/v;
Sigma) and stored at 4 ◦C until embedded in paraffin. Tissues were processed into 4
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µm sections using standard histological techniques by Jane Anderson of the Wellington
School of Medicine. Slides were stained with chloroacetate esterase (CAE) stain and
lightly counterstained with hematoxylin as described[37, 57]. Mast cells were identified
as CAE positive cells, which were easily identified as bright red cells as previously
described[37, 57]. Four randomly selected high power fields (550 µm/field; 400 x
magnification using 0.22 mm Field Number 10x ocular and 40x objective lens) were
examined from each mouse.
2.4 Flow cytometry
2.4.1 Flow Cytometry reagents
A full list of the flow cytometry reagents is included in the appendices. The fol-
lowing viability dyes were used: 4,6-diaminidino-2-phenylindole (DAPI; Molecular
Probes); 7-Amino Actinomycin D (7-AAD; BD Pharmingen). For intracellular stain-
ing, Live/Dead R© fixable blue (Invitrogen) was used in place of DAPI.
Antibodies against the following molecules, and secondary reagents were purchased
from BD Pharmingen, unless otherwise specified (clone): B220-V450 (RA3-6B2);
B220-PE-Texas Red R©(Ra3-6B2); CD3-AF488 (500A2; Invitrogen Molecular Probes);
CD4-APC (RM4.5); CD4-APC-H7 (GK1.5); CD4-FITC (GK1.5; Prepared in house);
CD4-PE (GK1.5); CD4-Percp (RM4.5); CD4-Qdot605 R© (RM4.5; Invitrogen Molec-
ular Probes); CD8a-AF700(536.7; Biolegend); CD8a-PE/Cy7 (53-6.7); CD19-APC-
H7 (ID3); CD44-PE (IM7); CD45-Pacific blueTM (30F11; Biolegend); CD62L-Biotin
(MEL-14); CD62L-Pacific blue (MEL-14; Biolegend); CD117(cKit)-APC (2B8); FceRI-
PE (Mar-1; eBioscience); FcgRII/III-FITC (2.4G2); human CD2-APC (RPA2.10);
Ia/Ie-PE/Cy7 (M51114.15.2; Biolegend); IL-3-PE (MP2-8F8); IL-4-APC (11B11); IL-
4-PE (11B11); IL-5-PE (TRFK5); IL-10-PE (JES5-16E3); IL-13-PE (eBio13A; eBio-
science); IgD-PE (11-26c.2a); IgE-biotin (R35-118); IgG1-biotin (A85-1); Pan NK-
PE/Cy7 (DX5; eBioscience); Streptavidin-APC; Streptavidin-FITC; Streptavidin-PE;
Streptavidin-PE-TexasRed R©.
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2.4.2 Surface staining
After tryan blue exclusion, 1.25x106 cells were transferred to 5 mL flow-compatible
tubes through 70 µm gauze. Flow buffer containing 50 µL anti-CD16/32 antibody
(24G2) made in house was added to each tube for five minutes which was then incu-
bated with 50 µL containing the primary antibody mix. Samples were incubated for
30 minutes at 4 ◦C and then washed with 4 mL flow buffer (2% FCS, 0.01% sodium
azide in PBS) and resuspended for flow. For secondary antibody incubation, cells were
instead resuspended in 100 µL containing optimally diluted secondary reagent.
2.4.3 Intracellular staining
Cells were harvested and transferred to flow-compatible tubes containing 3 mL 4 ◦C
PBS. Tubes were spun and resuspended in 1 mL PBS for counting. Cells were respun
and incubated with 1 mL 1/1000 Live/dead fixable blue in PBS for 30 minutes at 4 ◦C
in the dark. Cells were washed with 3 mL flow buffer and were subjected to normal
surface staining methods. After staining, cells were fixed and permeabilized using the
Fix & Perm R© cell permeabilization kit (Invitrogen) according to the manufacturers
instructions with the following modifications. Cells were fixed for 15 minutes using
’Reagent A’ at room temperature, followed by quenching with 4 mL room temperature
flow buffer. Samples were split in two at this stage and spun down at 1400 rpm for
4 minutes at room temperature. Intracellular stains for analysis and in some cases,
isotype controls, were added diluted to 100 µL volumes of reagent B. After spinning
down the cells, Intracellular stains or isotypes were added to samples and incubated
for 20 minutes at room temperature. The staining was stopped by addition of flow
buffer and samples were spun down then resuspended for flow cytometry.
2.4.4 Flow cytometers
A table of cytometers, lasers and filters used to detect specific fluorophores is included
in the appendices.
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Samples were analysed on an LSR-II special order product (BD) equipped with the
following lasers. Fluorophores were detected as specified. Numbers indicate filter
and the letter denotes the position of the detector in the flow cube. Ultraviolet
laser (355 nm): DAPI 450/50B, Live/Dead fixable blue 450/50B. Violet laser (405
nm): Brilliant Violet 421 450/50F, Pacific Blue 450/50F, Horizon V450 450/50F,
Qdot-605 605/40C. Blue laser (488 nm): PerCp 705/70A, GFP B515/20B, FITC
B515/20B, Alexafluor488 B515/20B, Side Scatter 488/10C. Green laser (532 nm): PE-
Cy7 780/60A, 7-AAD 660/40C, PE-Texas Red R© 610/20D, PE G575/26E. Red laser
(633/640 nm): APC-Cy7 780/60A, APC-H7 780/60A, Alexafluor-700 710/50B, APC
670/14C. In some experiments a BD FACSCalibur was used. For these experiments
7-AAD was used as the live/dead stain in place of DAPI. The configuration for these
experiments was as follows: Blue laser (488 nm): One of FITC, Alexafluor-488 or
GFP on the 530/30 FL1; PE 585/42 FL2; 7-AAD 670LP FL3; APC 661/16 FL4.
Sorting was done on a FACSDiva equipped witha Blue (488 nm) laser with a 530/30
FL1 filter; 585/42 FL2 filter and an FL3 670LP filter. Red laser (633 nm): 661/16
FL4, 780/60 FL5. UV laser (355 nm) FL6 450/50, FL8 620LP. Sorting used DAPI in
FL6 PE from FL2, and APC in FL4.
2.5 ELISAs
2.5.1 Antigen-specific IgG1, IgG2a and polyclonal Ig ELISA
Ninety-six well Immunosorp Maxi plates (Nunc) were coated overnight with 100
µL/well, 10 µg/mL HDM (Greer laboratories), OVA, bovine or caprine BLG in
pH=9.6 0.1 M carbonate buffer. The next day, plates were washed with 0.05% Tween-
20 (Sigma) in PBS (pH=7.4) on an automated plate washer (Skatron) and blocked
for one hour with 200 µL/well 10% FCS/PBS (blocking buffer). Blocking buffer was
removed and replaced with 100 µL sera diluted in blocking buffer and incubated for
two hours at room temperature in the dark. Wells were washed then incubated for 60
minutes with 100 µL/well of 91 ng/mL biotinylated anti-mouse IgG1 (A85-1; BD) or
91 ng/mL biotinylated anti-mouse IgG2a (R19-15; BD) or 33.3 µg/mL biotinylated
polyclonal goat anti-mouse Igs (cat #553999; BD) diluted in blocking buffer, followed
70
by a wash and incubation with streptavidin-conjugated horse radish peroxidase (GE
Healthcare, Auckland, New Zealand) for 60 minutes. After a final wash step, 100
µL TMB substrate (BD Pharmingen) was added and 5-20 minutes later the reaction
was stopped with 50 µL 0.5 M sulphuric acid. The absorbance was read at 450 nm
on a Versamax plate reader. Serum titres were calculated in Graphpad’s Prism 5.0
and were defined as the EC50 O.D. of serum dilution curves, constrained to plateau
at 0.0, and a shared group maxima based on the average highest O.D. value in the
series. EC50s were calculated for each mouse and their reciprocal value is shown as
the titre.
2.5.2 IgE
For total and OVA-specific IgE, plates were coated overnight with 100 µL/well 0.5
µg/mL anti-mouse IgE (6HD5; in house). Plates were washed with 0.05% Tween
20 in PBS (pH=7.4) and then incubated with 10% foetal calf serum (FCS) in PBS.
Plates were washed and samples and standards were incubated for two hours at room
temperature in the dark. In some experiments plates were instead left overnight at
4 ◦C. Plates were washed and then incubated with 100 µL/well 3 µg/mL biotinylated
Rat anti-mouse IgE (R1E4; in house; total IgE) or 100 µL 20 µg/mL biotinylated
ovalbumin for 90 minutes at room temperature in the dark. Plates were subsequently
washed and incubated with 100 µL streptavidin horse radish peroxidase for 60 minutes.
After a final wash step, 100 µL TMB substrate was added and 10-20 minutes later
the reaction was stopped with 50 µL 0.5 M sulphuric acid. The absorbance was read
at 450 nm on a Versamax plate reader.
2.5.3 Murine mast cell protease-1 (mMCP-1).
mMCP-1 was analysed according to the manufacturers instructions. Initially kits were
purchased from Moredun Scientic (Midlothian, Scotland) but became unavailable in
2011. mMCP-1 kits were subsequently purchased from eBioscience (San Diego, Ca)
and again used according to the manufacturers instructions. Similar absolute values
in the range of 10-40 ng/mL for naive mice and 5000-10000-fold increases in mice with
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active diarrhoea were attained using both kits.
2.5.4 Total IgG1 and Total IgG2a
Total IgG1 and IgG2a reagents were purchased (Bethyl Laboratories, Montgomery,
Texas) and analysed according to the manufacturers instructions with some modifi-
cations to the recommended buffers. Plates were coated overnight with 100 µL of a
1/100 dilution of antibody in pH=9.6 0.1 M carbonate buffer. The next day plates
were washed with 0.05% Tween 20 in PBS (pH=7.4) using an automated plate washer
and then incubated with 10% foetal calf serum (FCS) in PBS. Plates were washed
and samples and standards were incubated for two hours at room temperature in
the dark. Plates were washed and then incubated with 100 µL/well horse radish
peroxidase-conjugated goat anti-mouse IgG1 or IgG2a diluted as recommended. Af-
ter a final wash step, 100 µL TMB substrate was added and 10-20 minutes later the
reaction was stopped with 50 µL 0.5 M sulphuric acid. The absorbance was read at
450 nm on a Versamax plate reader.
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Chapter 3
Does the in vitro IL-4 allelic
expression profile reflect functional
segregation of IL-4-producing Th2
cell subsets?
3.1 Introduction
3.1.1 Monoallelic regulation of the IL-4 gene
Studies over the past fifteen years have aimed to establish the molecular events that
generate stable IL-4-producing CD4+ T cells. During these studies, the observation
was made that many cells produce IL-4 from a single allele (between 52 and 85%)[273,
374, 389]. To explain the observations, in 2005, Guo, Hu-Li and Paul argued for
potential advantage of a probabilistic regulation mechanism, opperating at the single
allele-level for the IL-4 gene[401]. However, these investigations have been undertaken
exclusively in an in vitro context, and will benefit from elaboration in vivo.
In order to evaluate IL-4 production in vivo, IL-4 reporter systems have been devel-
oped. In our lab, we have recently combined two of these, the KN2 reporter[373] and
the G4 reporter[273]. This combined reporter has the potential to record expression
of each IL-4 allele individually, through the expression of two distinct reporters. In
this chapter, we sought to characterise the behaviour of the KN2/G4 reporter in vitro
to clarify its potential utility for in vivo investigations into the role of IL-4 in Th2
immunity. In this chapter, we used established in vitro culture methods, and IL-4 re-
porter systems to determine the allelic expression profile of IL-4 in vitro. We further
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test whether conditions that lead to IL-4-producing Th2 cell development in vitro also
induce reporter expression in KN2/G4 cells.
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3.2 Aims
The experiments in this chapter were designed to evaluate the allelic expression profile
of IL-4 in KN2/G4 cells in vitro.
Our specific aims were:
1) To test whether hCD2 and GFP are expressed in conditions known to promote
IL-4 production;
2) To assess if IL-4 is produced from one or both alleles in KN2/G4 mice;
3) To evaluate whether IL-4 alleles are regulated independently in KN2/G4 reporter
mice.
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3.3 Results
3.3.1 Examining IL-4 reporter expression during primary cul-
ture
Our first experiments were designed to establish whether conditions that promote IL-
4 protein production also result in hCD2 and GFP expression in KN2/G4 cells. IL-4
promotes IL-4-producing Th2 cell development in vitro[342], so we began by culturing
CD4+ T splenocytes on anti-CD3-coated plates in titrated doses of IL-4. Three days
after seeding we used flow cytometry to examine the expression of hCD2 and GFP in
KN2/G4 reporter cultures. KN2/G4 cells are IL-4-deficient, so in these experiments,
the only potential source of IL-4 is exogenous.
When KN2/G4 cells were seeded in wells without any IL-4, expression of hCD2 and
GFP were low (Figure 3.1A and C). CD4+ T cell numbers were similar at all concen-
trations of IL-4 (Figure 3.1B), but the number of cells expressing hCD2 and/or GFP
increased in an IL-4 dose-dependent manner above 10 U/mL (Figure 3.1C). Therefore,
IL-4 promoted reporter expression by KN2/G4 CD4+ T cells.
Our next step was to evaluate the relative expression of each allele. When we examined
the allelic expression of IL-4, we observed that the majority of reporter was expressed
from a single allele at all IL-4 concentrations assessed (Figure 3.2E). However, while
monoallelism predominated, we also observed disparity between the absolute expres-
sion of hCD2 and GFP, because hCD2 was expressed on up to 60% of CD4+ T
cells, whereas GFP was detected in a maximum of 30% of KN2/G4 cells (Figure
3.2G). While having different absolute frequencies does not preclude monoallelic reg-
ulation, to conform to an independent probabilistic regulatory mechanism, acquisition
of biallelism would need to be a function of the likelihood of the expression of each
individual allele. Based on this premise, independent probabilistic regulation would
result in Pbiallelic=(%hCD2
+*%GFP+)*100, where %hCD2+ is the total percent of
CD4+ T cells expressing hCD2 (Q1 + Q2, depicted in figure 3.2C) and %GFP+
is the total percent of CD4+ T cells expressing GFP (Q2 + Q3, depicted in figure
3.2D). By comparing the actual proportion of cells that were biallelic (Q2, depicted
in figure 3.2C), to the predicted proportion based on the expression of the individual
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reporters, we observed that at IL-4 concentrations above 25 U/mL, biallelism was
observed more frequently than would be expected if the two alleles were expressed
entirely independently (Figure 3.2F). Therefore, while monoallelic expression of IL-4
predominated the response, biallelic expression was more frequent than was expected
for independently-expressed alleles. Therefore, in the presence of 25 or more IL-4
U/mL, the expression of one reporter was associated with an increased likelihood of
co-expressing the alternate reporter allele during primary stimulation.
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Figure 3.1: KN2/G4 cells cultured in IL-4 express IL-4 reporters. Splenocytes
from KN2/G4 mice were stimulated on anti-CD3 coated plates for three days in the
presence of 100 U/mL IL-2, anti-CD28 and titrating amounts of IL-4. (A) shows
representative plots of cells cultured in the presence of 0 or 1000 units (U) of IL-4
and identifies quadrants 1-3 (Q1-3) used to define reporter-expressing cells. (B) The
total number of live CD4+ cells and (C) proportion that were GFP+ and/or hCD2+
(Q1+Q2+Q3), were determined by trypan blue exclusion and flow cytometry. Data
points show mean±SEM of (n=3) individually cultured spleens from one of three
similar experiments. Data were compared using one-way ANOVA with Bonferroni’s
post-test for increases above wells that did not contain IL-4; *p<0.05, ***p<0.001.
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Figure 3.2: Culture in IL-4 increases biallelic IL-4 production above pre-
dicted levels. Cells were stimulated as in figure 3.1 for three days. The red boxes
show the quadrants used to identify the total proportion of CD4+ T cells express-
ing (A) either hCD2 or GFP (monoallelic) (B) both hCD2 and GFP (biallelic), (C)
hCD2, or (D) GFP. The same plot is shown in (A-D) and was generated in a culture
containing 50 U/mL IL-4. (E) The total proportion of Th2 cells expressing IL-4 from
one (monoallelic as in (A)) or both (biallelic as in (B)) alleles were compared; Data
points were compared by two-way repeated measures ANOVA with Bonferroni’s post-
test and all data points were significant to p<0.0001. (F) The proportion of CD4+
T cells expressing both hCD2 and GFP observed experimentally (black circles; as in
(B)), or predicted by Pbiallelic=(%hCD2
+
total*%GFP
+
total)
∗100 (white circles, predicted),
were compared. (G) The total proportion of CD4+ T cells expressing hCD2 (black;
as in (C)) or GFP (white; as in (D)) were determined by flow cytometry. Data points
show mean+SEM of (n=3) individually cultured spleens from one of three similar ex-
periments. Across experiments, both female and male mice were used and mice born
to G4/G4 and KN2/KN2 mothers were assessed with similar differential expression
profiles and biallelism responses irrespective of mouse gender or paternity. (F,G) Data
were compared by Two-way repeated measures ANOVA with Bonferroni’s post-test;
*p<0.05, ***p<0.001, ****p<0.0001 at the same dose of IL-4.
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3.3.2 Examining IL-4 production in differentiated Th2 cells
We observed that primary culture in the presence of more than 25 U/mL IL-4 resulted
in an increased proportion of cells expressing hCD2 and GFP biallelically (Figure
3.2F) and were interested to determine if this biasing was maintained in imprinted
Th2 cells. Th2 cells can remain stably polarised to the Th2 subset after the removal
of IL-4 and TCR stimuli for at least 3-7 days[1, 343, 388]. Therefore, in the next set
of experiments, our aim was to determine the allelic expression profile of rested Th2
cells upon reactivation.
In this experiment, KN2/G4 and +/+ cells were stimulated with anti-CD3/anti-CD28
in the presence of anti-IL-4 or 1000 U IL-4 for five days, and then transferred to un-
coated culture wells containing anti-IL-4 and 100 U/mL IL-2. Three to four days
later, cells were restimulated on anti-CD3-coated plates in the presence of anti-CD28
and IL-2 for 5-6 hours. While the frequency of reporter positive cells under Th0
conditions was low and these assays may have limited statistical reliability, when we
examined the proportion of cells that expressed both hCD2 and GFP prior to restim-
ulation, less than 10% of reporter+ cells expressed both alleles, under both anti-IL-4
and plus IL-4 culture conditions (Figure 3.3A and 3.3C). When cells were restimu-
lated, we observed proportional increases in hCD2 and GFP expressing cells from cells
cultured under both anti-IL-4 and plus IL-4 culture conditions (c.f. figure 3.3A and
3.3B). In cells cultured with anti-IL-4, while biallelic expression was four-fold higher
than prior to stimulation, the ratio of mono:biallelic expression was unaltered (Figure
3.3C). In contrast, in IL-4-conditioned cells we observed a more pronounced 100-fold
increase in biallelic expression, and an altered mono:biallelic expression ratio (Figure
3.3C). While the low frequencies of biallelic cells under anti-IL-4 culture conditions
may be statistically limiting and will require follow-up validation, these data indicate
that enrichment in biallelic expression was observed in restimulated IL-4-conditioned
cells.
In an additional effort to examine the allelic expression profile of Th2-conditioned
cells, we asked whether monoallelic expression predominated only in KN2/G4 cul-
tures. Therefore, we examined the frequency differential of single or dual IL-4 allele
expression in KN2/+ and G4/+ cultures (Figure 3.4). In these experiments, spleno-
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cytes were activated in the presence of IL-4 for five days, subsequently rested for 5-6
days in the presence of anti-IL-4 and restimulated in the presence of anti-IL-4. Mo-
nensin was added two hours prior to harvest at each timepoint. At each timepoint,
cultures were normalised such that hCD2 and GFP proportions were less than 0.1%
in +/+ cultures, and the IL-4+ pouplation was less than 0.1% in KN2/G4 cultures.
This is why the gates in the figures differ at the two timepoints.
When we examined expression of hCD2 and GFP after three hours, the majority
of Th2 cells expressed a single IL-4 allele in KN2/G4, KN2/+ and G4/+ cultures
(Figure 3.4A-F). By six hours, the proportion of Th2 cells that were biallelic had
increased in all three strains (Figure 3.4D-F). The biallelic population in KN2/G4
cultures plateaued at its maxima (Figure 3.4D); in KN2/+ and G4/+ cultures, IL-4
production was not maintained and resulted in a diminution of the biallelic population
concomitant with the loss of IL-4 (Figure 3.4E and 3.4F). We compared the observed
frequency of biallelism to the expected frequency as calculated previously (Figure
3.2F). In all three strains, statistically significantly for the KN2/+ and G4/+ strains
at the six hour timepoint (peak of the response), the proportion of cells detected
as biallelic was greater than predicted (Figure 3.4G-I). These studies indicate that
while IL-4 production derived predominantly from a single allele, biallelism was more
frequent than predicted. This was a feature of both primary and secondary Th2 cell
stimulation.
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Figure 3.3: Culture in IL-4 potentiates cells to produce IL-4 biallelically
upon secondary stimulation. After culture on anti-CD3-coated plates for five
days in the presence of 100 U/mL IL-2, anti-CD28 and (Th0) anti-IL-4 or (Th2)
1000 U/mL IL-4, spleen cells were rested for three to four days in uncoated plates
containing 100 U/mL IL-2 and then restimulated with anti-CD3 in the presence of
anti-CD28 and 100 U/mL IL-2. (A) Cells were examined prior to or (B) 6 hours after
restimulation. (C) The proportion of cells that expressed both hCD2 and GFP were
compared in cells prior to (pre) and after (re) restimulation. Bars show mean±SEM
of single spleens cultured in triplicate from one of two similar experiments. Data were
analysed by Two-way ANOVA with Bonferroni’s post-test; **p<0.01.
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Figure 3.4: Biallelic IL-4 production exceeds predicted frequencies in res-
timulated KN2/+ and G4/+ cells. Splenocytes culture in the presence of 1000
U/mL IL-4 as in Figure 3.3 were rested for five days. Cells were then left unstim-
ulated or restimulated on anti-CD3 in the presence of 100 U/mL IL-2, anti-CD28
and anti-IL-4 and examined for hCD2, GFP and IL-4 production. Unstimulated cells
were cultured with monensin for 2 hours and then stained, and all other cultures had
monensin added for the last two hours of culture. (A) KN2/G4 (B) G4/+ and (C)
KN2/+ cells were examined for GFP, hCD2 and intracellular IL-4 without stimulation
(0 hours) or after 3 hours (3 hours). The proportion of Th2 cells that were biallelic
in (D) KN2/G4, (E) G4/+ and (F) KN2/+ cultures was determined. The predicted
(determined as in Figure 3.2) and observed frequencies of CD4+ T cells that were
biallelic were compared in (G) KN2/G4, (H) G4/+ and (I) KN2/+ cultures. Data
show mean±SEM of (n=2-3) individually cultured spleens from one of three similar
experiments. (G-I) Data were compared using Two-way repeated measures ANOVA
with Bonferroni’s post-test; *p<0.05, ****P<0.0001.
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3.3.3 Testing for interactions between IL-4, KN2 and G4
In our studies, hCD2 expression was more frequent than GFP expression, and up to
75% of GFP+ cells co-expressed hCD2 (Figure 3.1A). Therefore, we were interested
to determine if hCD2 was out-competing the G4 allele for transcription factors, re-
sulting in a skewed hCD2:GFP ratio as we had observed (Figure 3.2G). If increases in
the expression from one allele were an impediment to the expression of the other, we
predicted that IL-4 production by G4/+ and KN2/+ cultures would differ; similarly,
GFP expression in KN2/G4 cultures would be different from G4/+ cultures, and like-
wise for hCD2 expression in KN2/G4 and KN2/+ cultures. We used Th2 conditioned
spleen cells rested for 5-6 days, and then restimulated in the presence of anti-IL-4 to
compare hCD2, GFP and IL-4 production (by intracellular cytokine staining) in the
three different strains of mice. Monensin was added for the final two hours of culture.
We also included wild-type (+/+) mice in the experiments.
When we restimulated the cells, the proportion of cells producing IL-4 was similar in
KN2/+ and G4/+ cultures, and 50-65 percent of +/+ cultures (Figure 3.5A). Up to
30% of +/+ cultures produced IL-4, whereas the two heterozygous cultures peaked at
≈20%. We also observed similar expression of hCD2 in KN2/G4 and KN2/+ cultures,
and similar expression of GFP in KN2/G4 and G4/+ cultures (Figure 3.5B and C).
These relationships were maintained at all timepoints examined after restimulation.
The kinetics of IL-4 production varied between experiments, but in all cases, intracel-
lular IL-4 expression was maximal between 6 and 12 hours, as shown (Figure 3.5A).
Proportional hCD2 and GFP expression were maintained for much longer periods
than intracellular IL-4, such that the proportion of cells expressing hCD2 or GFP
plateaued and were maintained out to 24 hours, and this occurred similarly in IL-
4-sufficient and IL-4-deficient heterozygotes (Figure 3.5B and C). Thus, we conclude
that while the absolute levels of hCD2 and GFP expression were different, this was
not a result of transcription factor competition between the constructs. Therefore,
while GFP and hCD2 expression were not independent events in IL-4-conditioned
cells, neither were they cross-antagonistic.
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3.3.4 Comparison of IL-4 production in homozygous and het-
erozygous reporter strains
Previous investigations examining the allelic expression profile of IL-2 in vitro com-
pared IL-2+/+ and IL-2+/- cultures, and observed a 50-65% differential between
the wild-type and heterozygous cultures[402]. Our observation of a 50-65% differ-
ential between +/+ and the two heterozygous strains (Figure 3.5A) lead us to ask
if, despite being expressed to different absolute maxima, similar differentials may
be observed between reporter heterozygotes and homozygotes. In the next experi-
ments, we cultured cells in the presence of IL-4 or anti-IL-4, and examined hCD2
and GFP expression three days later. In these experiments, we used spleen cells from
+/+, KN2/+, KN2/KN2, KN2/G4, G4/+ and G4/G4 mice. Quadrants for hCD2
and GFP were positioned to below 0.1% in +/+ cultures. Representative plots from
which data were generated are shown in figure 3.6 and figure 3.7.
We began by examining hCD2 and GFP expression in cells cultured in anti-IL-4. After
three days of primary culture in medium containing anti-IL-4, we observed that the
proportion of KN2/G4 CD4+ T cells that expressed hCD2 was 50-65% the frequency
of KN2/KN2 cultures (Figure 3.8A). Similarly, when we examined GFP expression, we
observed a similar proportional reduction in KN2/G4 cells compared to G4/G4 cells
(Figure 3.8B). G4/+ and KN2/+ cultures demonstrated similar reductions, although
these differences were not stastically significant. We conclude that similar relative
decreases in hCD2 and GFP expression in heterozygous versus homozygous reporters
occurred in the absence of IL-4 signalling.
When we examined hCD2 and GFP expression in our IL-4-containing cultures, the
relationship was different. GFP expression in KN2/G4 cells remained close to the
predicted range differential (50-65% of G4/G4 mice; figure 3.8D), but the addition of
IL-4 induced almost equivalent frequencies of hCD2+ cells in KN2/G4 and KN2/KN2
cultures (Figure 3.8C). KN2/+ cultures expressed hCD2 at 80% the level of KN2/KN2
cultures and G4/+ cultures expressed GFP at ≈70% of G4/G4 cultures (Figure 3.8C
and 3.8D). These data may indicate that the KN2 allele is more responsive to IL-4
than the G4 construct, but this will require more investigation at a molecular level.
Our studies from these experiments indicate that the behaviour of the KN2 and the
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G4 allele were similar under anti-IL-4 conditions, but may differ following culture in
the presence of IL-4.
Collectively our experiments suggest that monoallelic expression of IL-4 predomi-
nates in KN2/G4 cultures. Our data also indicate that hCD2 and GFP reflect the
production of IL-4 in vitro. We identify that the KN2 and G4 alleles are not cross-
antagonistic, and in the absence of IL-4, behave similarly to the wild-type IL-4 gene.
Additionally, we observed biallelism more frequently than was predicted, which may
indicate that biallelic IL-4 expression is a unique feature of a specialised population
of Th2 cells.
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Figure 3.5: IL-4 production is equivalent in heterozygous reporter cells.
Cells were treated as in Figure 3.4 and restimulated on anti-CD3-coated plates in
medium containing anti-IL-4, anti-CD28 and 100 U/mL IL-2. Time zero wells were
transferred to uncoated wells in the same medium and all wells had monensin added
2 hours before harvest, including the unstimulated (time zero) culture. Cells were
stained intracelluarly and analysed by flow cytometry to determine live CD4+ T
cell (A) IL-4 production, (B) hCD2 expression or (C) GFP expression after the stated
times. Data points represent mean ±SEM of (n=3) individually cultured spleens from
one of three similar experiments. Data were analysed by Two-way repeated measures
ANOVA with Bonferroni’s post-test. Different lowercase letters indicate statistically
significant differences comparing groups at the same time points; p<0.05.
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Figure 3.6: Reporter expression by homozygous and heterozygous reporter
cells cultured in anti-IL-4. Cells from mice of the indicated genotype were cultured
on anti-CD3-coated plates in medium containing 10 µg/mL anti-IL-4, anti-CD28 and
100 U/mL IL-2 for three days and examined for reporter expression by flow cytometry.
Plots are shown from one experiment used to generate data in Figure 3.8.
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Figure 3.7: Reporter expression by homozygous and heterozygous reporter
cells cultured in IL-4. Cells from mice of the indicated genotype were cultured on
anti-CD3-coated plates in medium containing 1000 U/mL IL-4, anti-CD28 and 100
U/mL IL-2 for three days and examined for reporter expression by flow cytometry.
Plots are shown from one experiment used to generate data in Figure 3.8.
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Figure 3.8: hCD2 and GFP behave similarly in the absence of IL-4 sig-
nalling. Total splenocytes received three days of primary anti-CD3/anti-CD28 stim-
ulation in medium containing 10 µg/mL anti-IL-4, or medium containing 1000 U/mL
IL-4 as indicated. CD4+ T cells were examined for hCD2 (black bars) or GFP (white
bars) as gated in Figure 3.2C and 3.2D. Data were normalised relative to expression
in KN2/KN2 homozygotes (A, C) or G4/G4 homozygotes (B, D). Data represent
mean+SEM of (n=7) anti-IL-4 and (n=8) plus IL-4 individual spleen replicates com-
bined from three (anti-IL-4) or four (plus IL-4) experiments. In each experiment
anti-IL-4 cultured homozygote reporter expression was between 2 and 10%, and IL-4
cultured homozygote reporter expression was 30 to 90% of total CD4+ T cells. The
area between 50 and 65% is shaded in grey to reflect the predicted difference based
on the difference in IL-4 production in restimulated IL-4-conditioned cells shown in
figure 3.5. Data were analysed by Kruskall-Wallis with Dunn’s post-test. *p<0.05,
**p<0.01, ***p<0.001.
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3.4 Discussion
The manner in which IL-4 production is regulated is an important focus of allergic
disease biology. Over the past 15 years considerable advances in understanding have
been made regarding the mechanisms that control its expression, conditions under
which it is upregulated, and the epigenetic changes that stably maintain access to the
Th2 locus to permit its production. One of the observations, now made by numerous
groups, is that many IL-4-producing cells transcribe only one of their two IL-4 alleles.
We have added to these studies and monitored allelic IL-4 production in primary
and secondary in vitro culture settings in two reporter systems. We found that in
KN2/G4 cells, most reporter-expressing cells expressed only one of the two reporter
constructs. We observed that biallelism was more frequent, as a proportion of the Th2
cell population, in cells cultured in the presence of IL-4 than in its absence, and was
also more frequent than we predicted for a gene with two independently regulated
alleles. We further observed that, compared to wild-type, or reporter homozygote
cultures, heterozygous cultures produced only 50-65% as much IL-4. Taken together,
these studies support the concept that monoallelic IL4 gene expression is a frequent
feature of Th2 cells.
3.4.1 Probabilistic monoallelic regulation of IL-4
Monoallelic IL-4 production has been observed numerous times in the literature. It
was first reported by Bix and Locksley[389]. These authors demonstrated that ap-
proximately 50% of Th2 clones had transcripts that were detectable from only one
of two alleles; this was a stable, heritable phenotype and could be transcribed from
either allele[389]. These were followed by studies from the same group demonstrat-
ing that the proportion of CD4+ T cells producing IL-4, rather than the amount
of IL-4 produced per cell resulted in biased IL-4 production by BALB/c compared
with C57BL/6 CD4+ T cells[390]. Subsequently, studies in two separate reporter
mice demonstrated that IL-4 was expressed predominantly monoallelically. Rivie`re
et al.[374] used a precursor reporter to the KN2 system, and observed, for the most
part, two distinct populations of hCD2-expressing or IL-4-producing cells[374]. How-
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ever, they also demonstrated that the strength of TCR mediated signalling could
increase the proportion of cells that were biallelic, under both anti-IL-4 and plus IL-4
conditions[374]. These early findings indicated that the strength of stimulus, in this
case TCR stimulation, could enhance biallelic expression of IL-4. Hu-Li et al.[273]
added to these works and investigated the longeivity of monoallelic expression. By
cloning individual T cells, they found that irrespective of the mono- or bi-allelic status
of a given cell, when passaged multiple times, the allelic expression profile of a popu-
lation of daughter progeny would recapitulate the original profile[273]. These findings
indicated that while there was clone-to-clone variation in the likelihood of expressing
one, other or both alleles, for a given outgrown clone, the probability of expression
was a predictable event.
The clearest illustration of monoallelic IL-4 production came from subsequent work by
Guo, Hu-Li & Paul[381]. Guo et al.[381] used RNA fluorescence in situ hybridisation
to analyse IL-4 expression on a per-allele basis[381]. In these studies, 538 cells express-
ing IL-4 were examined, and only 15.4% of these cells were expressing IL-4 from both
alleles[381]. When cells expressing only one of the two IL-4 alleles were examined,
there was a strong change in histone acetylation at an IL-4 enhancer, but only on
the favoured allele[381]. There is an overwhelming body of literature that establishes
the potential for monoallelic expression of IL-4 in vitro, and strong arguments that
attribute this to a probabilistic regulatory process[273, 381, 388–390, 403].
Advantages of allele-specific IL-4 production
The next point to consider is why such a process would evolve. Generally, natural
selection results in the accumulation of beneficial traits. IL-4 can have major dele-
terious effects if it is produced inappropriately[404, 405]; control of IL-4 production
through probabilistic regulation has been argued as a potentially advantageous regula-
tory mechanism[381, 390, 401]. In this respect, probabilistic rather than deterministic
regulation could provide tighter control of IL-4-dependent events; the example of B
cell IgE class-switch recombination and macrophage type 2 activation were proposed
by Guo et al., because controlling the number of IL-4-producing cells, rather than the
amount produced by an individual cell, would make it easier to balance the strength-
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of-stimulus with an appropriate strength of outcome ([381, 401]; reproduced in figure
3.9). In light of recent data indicating that in vivo, IL-4 can induce STAT-6 phospho-
rylation in all non-Th2 cells in an inflamed lymph node[334], one additional context
in which probabilistic regulation could be conceivably advantageous is in limiting the
frequency with which IL-4-exposed T cells begin to produce IL-4. The germinal centre
of the lymph node contains high frequencies of IL-4-producing TFH cells[275, 362],
which means germinal centre TFH cells are likely to be surrounded by IL-4 producing
cells in high frequency. Plausibly, a probabilistic regulatory mechanism could prevent
exponential amplification of IL-4 production through a positive feedback loop acting
on the IL-4 producing cells in close proximity to each other. This does, however,
require that IL-4 influences Th2 cell development in vivo, which is currently a contro-
versial topic. However, there are potential advantages in regulating IL-4 production
in a probabilistic process that can result in the expression of protein from only a single
allele.
In this context, the question arises, why do we see biallelic cells? In our studies we
saw that there was variability in the expression profile of each allele because some
cells in the KN2/G4 system expressed only one allele, but a reasonable proportion
expressed both alleles (Figure 3.6 and 3.8). As IL-4 expression is thought to result from
probabilistic regulation in which access to each allele is conferred independently[401]
it is reasonable to infer that biallelic cells arose from two independently regulated,
but not mutually exclusive, individually expressed alleles. In part, biallelic expression
supports the concept of a probabilistic monoallelic regulation mechanism. One of
the attributes of probabilistic regulation is that it can result in a bimodal expression
pattern[387, 388]: Genes are either expressed or they are not. For hCD2 and GFP
we observed reasonably bimodal populations (Figure 3.6 and 3.8). In earlier work,
bimodal expression of IL-4 was observed[388] and in some of our experiments we
observed sufficient separation of the IL-4+ and IL-4- populations to suggest that
IL-4, too, was expressed in a similar manner. Thus the presence of the biallelic
population does not preclude a probabilistic regulatory mechanism that acts at the
allele-specific level from operating for IL-4. However, we also observed that biallelic
IL-4 expression occurred at higher-than-expected frequencies (Figures 3.2 and 3.4),
which may indicate that biallelic expression reflects a small predisposition among the
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Th2 cell population to express both IL-4 containing chromosomes simultaneously and
this point deserves some specific discussion, as follows.
Is there evidence of functional subtypes of Th2 cells based on
their allelic expression profile?
It is important to consider potential reasons that underlie the higher-than-expected
occurrence of biallelic IL-4-producing cells. In our studies, we observed that biallelism
was increased by exposure to IL-4; previous studies have demonstrated that biallelic
IL-4 expression can be increased if the level of TCR stimulation is increased[374].
It may be that once signal strength reaches a certain threshold, biallelism becomes
more likely, which could explain the data and relate our findings to those of Rivie`re et
al.[374]. This may provide the cells with a particular niche, and provides the exciting
possibilty that biallelic cells are a specific functional subset of Th2 cells. An alternative
explanation relates to the differentiation of the Th2 population. As a population, Th2
cells that have divided more than four times produce on average more IL-4[347, 376].
Biallelism may be enriched in cells at a certain stage of development, or in cells
that have proliferated a set number of times. This could be addressed by examining
biallelism in cells labelled with proliferation dyes at the start of the experiment. STAT-
6-deficient cells have also been shown to develop IL-4-producing capacity and this is
associated with eventual accumulation of increased levels of GATA-3[348]. Examining
GATA-3 levels in KN2/G4 cells may be a simple means to identify a signal that is
associated with biallelic expression. It may also relate to pre-exisiting Th2 cells that
were present in our culture at the start. Our experiments used whole spleen cells from
naive mice, but cells with mixed surface phenotypes were present in these cultures; it
is possible that the higher-than-expected biallelic frequency is due to a small number
of in vivo-generated pre-existing Th2 cells in which IL-4 production is regulated in a
different manner to the bulk cultured population. Using sorted naive populations in
future experiments could be used to address this appropriately. Further, in this light,
investigation of the biallelic potential of Th2 cells in vivo may identify novel aspects
of Th2 cell development that are important for allergic responses and protection from
parasites.
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Reporter independence
The independent regulation of each reporter observed in our in vitro experiments (fig-
ure 3.5) suggests that cross-antagonism of reporters is unlikely to occur. When we
examined KN2/+ and G4/+ cultures, we observed that these cells produced equiv-
alent amounts of IL-4 (Figure 3.5). These findings indicate that G4 and KN2 were
equally permissive of IL-4 production. Further, the behaviour of each reporter, rela-
tive to homozygotes was similar under anti-IL-4 conditions (Figure 3.8). Comparing
the absolute frequencies of hCD2 or GFP+ Th2 cells in KN2/G4, KN2/KN2 and
G4/G4 mice may allow us to gain a preliminary view of the influence of a single allele
on IL-4 production in vivo. The disparity in absolute expression, however, requires
further discussion.
The insertion sites of the KN2 and G4 reporter constructs were similar, but not iden-
tical. The KN2 reporter allele replaces the first two exons, and the intronic region
between the two genes. Similarly, the G4 allele replaces the first intron and 178 base
pairs of the subsequent intronic region of the gene[273]. Differences in these knock-
in sites may inadvertently influence the success of their transcription. Second, the
KN2 reporter included a CD4 enhancer cassette, which was inserted to amplify its
expression and improve detection[373–375]. This may improve the likelihood of KN2
transcription without interfering with the counterpart allele. Examining similarly
sized mRNA (cDNA) products for KN2 and G4 may allow us to determine whether
there are differences in the amount of transcription, that could contribute to the differ-
ential reporter expression. Similarly, examining mRNA stability with the actinomycin
D stability assay[406] may allow us to compare the two constructs and see if they are
equivalently stable, which could also influence their absolute expression. These or
similar investigations will be informative in future studies to explain the differences
in absolute expression of the two constructs.
Collectively, our investigations have established the behaviour of the KN2/G4 reporter
system in vitro. These data provide evidence of the utility of the mouse for in vivo
studies of Th2 immunity. Our studies indicate that the majority of IL-4 is derived
from a single allele in vitro, and provide some novel directions for future work. Fu-
ture experiments will be required to determine how IL-4 expression is regulated in
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vivo.
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3.5 Summary
We find that the majority of IL-4-producing cells in vitro express only a single IL-4
allele. Biallelic IL-4 production was more frequent in IL-4-conditioned cells. Higher-
than-expected frequencies of cells producing IL-4 biallelically than is predicted for
independently regulated alleles were observed. Expression from one IL-4 allele does
not influence expression from the counterpart allele; these events are independent
events, but are induced by the same stimuli.
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Chapter 4
Evaluating the contribution of IL-4
to Th2 cell development and
function in vivo
4.1 Introduction
4.1.1 Establishing how genetic lesions in IL-4 affect allergic
Th2 cell development and function in vivo
The development of IL-4-producing CD4+ Th2 cells is a critical aspect of the aller-
gic process. One of the key factors that promotes Th2 cell development in vitro is
exposure to IL-4. Studies have investigated the role of IL-4 in in vitro Th2 cell de-
velopment in great depth, however, there is limited information addressing whether,
and to what extent, IL-4 is required for in vivo Th2 cell development. Understanding
the cascade of events that leads to the development of an allergen-responsive Th2 cell
in vivo may identify new ways to subvert the allergic process before it can manifest
as disease.
There is evidence that IL-4 is not required for in vivo Th2 cell development. Prior to
the advent of IL-4 reporter mice, it was shown that if anti-IL-4 antibody was injected
before a primary N. brasiliensis infection, IgE production was impaired by greater
than 99%[288]. However, if IL-4 production was not blocked during a secondary infec-
tion of these same mice, IgE was produced faster and with greater magnitude than was
observed during a primary infection[288]. As IgE production induced by secondary N.
brasiliensis infection is CD4+ T cell dependent[407] and IL-4 dependent[289], these
early findings suggested that Th2 cells can develop without IL-4 signaling.
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Previous studies in our lab investigated the role of IL-4 signaling in in vivo Th2 cell
development more directly[1]. These studies employed an IL-4 reporter mouse, in
which the gene encoding GFP is inserted under the control of the IL-4 promoter[273].
This is useful because IL-4 has a very short half-life and cannot be detected directly
ex vivo. In this manner, IL-4-producing CD4+ T cells, which are typically classified
as ’Th2 cells’[324, 325], can be identified directly ex vivo[1]. In the work done by our
group, G4/+ mice, which remain IL-4-sufficient through the ’+’ allele, were compared
to IL-4-deficient G4/G4 double reporter mice, or to G4/+ mice deficient in STAT-
6 signalling. This was done because STAT-6 is key for IL-4Rα signalling[329–331],
and is known to be important for optimal Th2 cell development in vitro[329]. The
observations are outlined briefly below.
In response to live parasite infection, IgE generation and bronchoalveolar eosinophil
influx were absolutely dependent on IL-4 and STAT-6, but no requirement for IL-4 or
STAT-6 in the generation of Th2 cells in vivo was identified. In G4/+ and G4/G4-
STAT-6-/- mice, Th2 cells developed with similar kinetics; the induction of IL-5 and
IL-13 mRNA in Th2 cells was similar in IL-4 deficient and sufficient mice; and memory
Th2 cell expansion was similar in IL-4 sufficient and deficient mice[1]. These, and other
findings, provide evidence that Th2 cells can develop in the absence of IL-4. A small
number of other studies have assessed the role of IL-4 in Th2 cell development in vivo,
however, none have examined the role of IL-4 in Th2 cell development to allergen in
an adjuvant free context[1, 360–363, 408]. Additionally, a limited number of studies
have attempted to modulate the level of IL-4. Instead, they generally examine Th2
cell function in IL-4-deficient mice. Therefore, we were interested to closely evaluate
the involvement of IL-4 in allergen-induced Th2 cell development and function in
vivo.
In addition to the G4 reporter, an additional system that has been used to record
Th2 cells by marking IL-4 producing cells, is the KN2 reporter mouse[373]. In this
reporter, the gene encoding a non-functional version of the human CD2 gene replaces
IL-4 but remains under the control of the IL-4 promoter[373]. In this reporter mouse,
Th2 cells have also been observed to develop in vivo in the absence of IL-4[275]. In the
studies described in this chapter, we have used both reporters, and additionally crossed
homozygous KN2/KN2 and G4/G4 mice to generate KN2/G4 reporter mice. These
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KN2/G4 mice are IL-4 deficient, and can be used to examine Th2 cells expressing a
single allele of IL-4. In the previous chapter we characterised the behaviour of the
KN2/G4 mouse in vitro. In this chapter, we employ IL-4 reporter systems, including
the KN2/G4 mouse, to ascertain how IL-4 contributes to Th2 cell development, and
subsequently, Th2 cell function.
4.2 Aims
Our specific aims were:
1) To test whether IL-4 contributes to primary Th2 cell generation following adjuvant-
free allergen immunization;
2) To determine how the lack of one IL-4 allele affects allergen-specific Th2 cell-
dependent responses.
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4.3 Results
4.3.1 Testing whether IL-4 is required for in vivo Th2 cell
development
The study by van Panhuys et al.[1] and other studies[275, 360] indicate that in vivo
Th2 cell development does not require IL-4. Our first aim was to confirm these
previous findings. We immunised G4/+ and G4/G4 mice with 600 dead iL3 N.
brasiliensis larvae. Seven days after intradermal immunization, we observed similar
proportional shifts, and similar 1000-fold increases in the numbers of Th2 cells in
immunized G4/+ and G4/G4 lymph nodes (Figure 4.1B and C). Therefore Th2 cells
indeed developed in the absence of IL-4 and to similar levels in G4/+ and G4/G4 mice.
These data recapitulate previous findings[1] and indicate that there is no absolute
requirement for IL-4 in Th2 cell development in vivo.
In this experiment, we observed that similar numbers of Th2 cells developed in G4/G4
mice and G4/+ mice (Figure 4.1C). G4/G4 mice have two reporter alleles, but G4/+
mice have only one. If IL-4 does not contribute to Th2 cell generation, Th2 cell
numbers should have been more frequent in G4/G4 mice compared to G4/+ mice.
Therefore, it is possible that there is a partial effect of IL-4 on Th2 cell development.
Further, this experiment may have been underpowered to reveal a difference. However,
it is not possible to distinguish between IL-4-dependent monoallelic IL-4 production
and IL-4-independent biallelic production by comparing these mice. Therefore, an
alternate system was required to distinguish between these two mechanisms.
In our in vitro studies, we determined that each allele in a KN2/G4 mouse was
activated independently. The two alleles were induced by the same stimulus, but
neither inhibited the level of expression from the counterpart IL-4 allele (Figure 3.5A-
C). Therefore, the KN2/G4 mouse provides an IL-4-deficient, single-allele reporter
mouse, which would allow us to distinguish between IL-4-dependent and -independent
Th2 cell development.
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Figure 4.1: Th2 cells develop in the absence of IL-4 in vivo. G4/G4 or G4/+
mice (n=5/group) were injected intradermally with 600 dead iL3 N. brasiliensis larvae
or 30 µL PBS. Seven days later draining lymph nodes were excised and live cells
were examined for GFP expression by flow cytometry. (A) Flow plots show CD4
and GFP expression in live-gated cells from PBS- or dead N. brasiliensis-immunized
G4/G4 mice. (B) The proportion of CD4+ T cells expressing GFP was evaluated
by flow cytometry. (C) Total GFP+CD4+ numbers were calculated by multiplying
the proportion of live cells that were GFP+CD4+ by the total live cell count, as
determined by trypan blue exclusion. Data points represent individual mice, and
lines represent group mean±SEM, from one of four similar experiments. Data were
compared using One-Way ANOVA with Tukey’s post-test; ***p<0.001.
4.3.2 Evaluating the influence of IL-4 on primary, adjuvant-
free in vivo Th2 cell development
To use the KN2/G4 reporter in our investigations, we next examined the Th2 response
of single-allele reporter mice, that were either IL-4-sufficient or IL-4-deficient. In these
studies, we used GFP+CD4+ T cell numbers to identify Th2 cells when comparing
G4/+ and KN2/G4 mice; we used hCD2+CD4+ T cell numbers to identify Th2 cells
when comparing KN2/+ and G4/+ mice.
We immunised G4/+, KN2/G4 and G4/G4 mice with 100 µg HDM and examined the
development of Th2 cells 3, 7 and 10 days later. We also examined Th2 cell numbers
in naive mice on day 0. Prior to injection on day 0, we observed similar, low level,
baseline numbers of Th2 cells in G4/+, KN2/G4 and G4/G4 strains (Figure 4.2B
and 4.2C). Three days after intradermal injection of 100 ug HDM, we observed that
the proportion and number of GFP+CD4+ T cells in G4/+ and KN2/G4 mice was
similar, and approximately 50-60 percent of that observed in G4/G4 mice (Figure 4.2B
and 4.2C). When we examined the response seven and ten days after immunization,
the proportion and number of GFP+CD4+ cells in G4/+ mice was higher than in
KN2/G4 mice (Figure 4.2B). Therefore, in the presence of IL-4, Th2 cell development
and/or survival was increased. We also noted that the proportional difference in Th2
cell numbers between G4/G4 and KN2/G4 mice was maintained on day seven, and the
same trend held for day ten (Figure 4.2B and 4.2C). Further, while there was some
variability at early timepoints, it may be important to note that the GFP median
fluorescence intensity generally correlated with the relative proportion of GFP+ cells
observed. In all cases, on day 10 the median fluorescence intensity of GFP in the
KN2/G4 cells trended toward being lower than those from the respective G4/+ mice
(Appendix Figure 8.3).
We next examined the response of KN2/+, KN2/G4 and KN2/KN2 mice. Similar,
almost identical observations were made in the KN2 reporter system. We observed
that KN2/+ lymph nodes contained more hCD2+CD4+ T cells than KN2/G4 nodes
on day ten (Figure 4.3B and 4.3C), and the average numbers of hCD2+CD4+ T cells
detected in KN2/G4 lymph nodes were lower than numbers detected in KN2/KN2
nodes at all timepoints. We found that these differences were statistically significant
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on days three and seven (Figure 4.3B and 4.3C). The median fluorescence intensity
of hCD2 also trended toward being lower on KN2/G4 cells in all day 10 experiments
(Appendix Figure 8.3). Therefore, in both the G4 and KN2 reporter settings, IL-4
sufficiency increased the number of detectable Th2 cells induced by HDM after day
three.
We considered it important to clarify the role of IL-4 in the Th2 response to parasite
antigens. We intradermally immunised G4/+, KN2/G4 and KN2/+ mice with 600
iL3 N. brasiliensis larvae and examined the draining lymph node response 7 days
later. When we compared hCD2 expression in KN2/G4 and KN2/+ mice, hCD2+
cells were more frequent in KN2/+ lymph nodes (Figure 4.4D and 4.4E, middle pan-
els). We observed that GFP+ cells were more frequent in G4/+ than KN2/G4 mice
(Figure 4.4D and 4.4E, left panels). When we determined the total number of Th2
cells expressing one, other, or both IL-4 reporter alleles, both the proportion and
number of Th2 cells present in KN2/G4 lymph nodes was lower than in G4/+ or
KN2/+ heterozygotes (Figure 4.4D and 4.4E, far right panels). Therefore, Th2 cell
development was increased in the presence of IL-4 when parasite antigens were used
as the immunogen. Further, when we examined the allelic expression profile of IL-4
in KN2/G4 mice, we observed that approximately 25 percent of Th2 cells expressed
both hCD2 and GFP (Figure 4.4A). Therefore, Th2 cells in KN2/G4 mice were able
to simultaneously express both IL-4 reporter alleles.
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Figure 4.2: IL-4-independent and dependent phases of Th2 development
revealed in IL-4 reporter mice. Mice were intradermally immunized with 100 ug
HDM and examined for CD4 and GFP expression by flow cytometry 3, 7 or 10 days
later. (A) Shows representative plots of total live cell CD4 and GFP expression from
mice of each indicated strain. (B) The proportion of CD4+ T cells expressing GFP
and (C) total number of GFP+CD4+ T cells in draining lymph nodes were compared.
Data points represent individual mice, and lines represent group mean±SEM; for
Day 3 and 10, of n=11-25 mice combined from 3-5 experiments; for Day seven n=9-
10 mice combined from two experiments, with the exception of G4/G4 mice (n=3,
one experiment). Data were normalised such that the GFP+ population was <0.05
percent of total CD4+ T cells in +/+ mice at each timepoint. Data were compared
using One-way ANOVA with Tukey’s post-test; *p<0.05, ** p<0.01, ***p<0.001.
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Figure 4.3: IL-4-independent and dependent phases of Th2 development
confirmed in alternate reporter mice. Mice were intradermally immunized with
100 ug HDM and examined for CD4 and hCD2 expression 3, 7 or 10 days later. (A)
Shows representative plots of total live cell CD4 and hCD2 expression from mice of
each indicated strain. (B) The proportion of CD4+ T cells expressing hCD2 and (C)
total number of hCD2+CD4+ T cells in draining lymph nodes were compared. Data
points represent individual mice, and lines represent group mean±SEM; n=9-15 mice
combined from 2 to 3 experiments at each timepoint. Data were normalised such
that the hCD2+ population was <0.05 percent of total CD4+ T cells in +/+ mice at
each timepoint. Data were compared using One-way ANOVA with Tukey’s post-test;
*p<0.05, ** p<0.01, ***p<0.001.
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Figure 4.4: IL-4 enhances Th2 response to parasite allergens. Six hundred
dead iL3 N. brasiliensis larvae were injected into the dermal ear flap of mice of the
indicated genotype and 6 days later hCD2 and GFP expression in live CD4+ T cells
was examined by flow cytometry. (A) For each genotype, the proportion of cells in
each quadrant was used to generate proportions and numbers shown in (D) and (E).
(B) Total and (C) CD4+ T cell numbers isolated from draining lymph nodes of mice
of the indicated genotype were quantified. (D) The proportion and (E) number of
CD4+ cells expressing GFP (left), hCD2 (middle) and GFP and/or hCD2 (right) was
assessed. Data points represent individual mice and lines represent group mean±SEM,
n=3-5 mice from one of two similar experiments. Data were compared using One-Way
ANOVA with Tukey’s post-test; *p<0.05, **p,0.01, ***p<0.001.
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4.3.3 Establishing the role of STAT-6 in primary, adjuvant-
free in vivo Th2 cell development
STAT-6 is important for IL-4R signaling[329–331, 347]. As a final means by which to
test the influence of IL-4 on Th2 cell development, we compared Th2 cell development
in G4/+ and G4/+-STAT-6-/- mice. Based on the impairment we observed in our
comparisons of KN2/G4 mice and IL-4 sufficient heterozygotes, we predicted that
Th2 cells would be less frequent in G4/+-STAT-6-/- than in G4/+ lymph nodes.
In this experiment, we immunised G4/+ and G4/+-STAT-6-/- mice intradermally
with 100 µg HDM and examined Th2 cell development in the draining lymph node 7
days later. When we compared Th2 cell development in G4/+ and G4/+-STAT-6-/-
mice, we observed similar numbers of CD4+ T cells (Figure 4.5A), but Th2 cells were
less frequent in the G4/+-STAT-6-/- mice (Figure 4.5B and 4.5C). Naive G4/+ and
G4/+-STAT-6-/- lymph nodes contained similar numbers of CD4+ T cells and Th2
cells (Figure 4.5D-F). Therefore, Th2 cell development in response to primary HDM
immunization was impaired in the absence of STAT-6 signaling.
Taken together, these data suggest that IL-4 signaling was not required for early
Th2 cell development, but IL-4 signaling through STAT-6 amplified in vivo Th2 cell
development. IL-4, therefore, contributed to Th2 cell generation over and above the
ability of antigens to initiate Th2 cell development. Furthermore, the proportional
reduction in hCD2-expressing Th2 cells in KN2/G4 mice compared to KN2/KN2
mice, in GFP-expressing Th2 cells in KN2/G4 mice versus G4/G4 mice and the
observation that approximately 75 percent of cells expressed only one of the two
reporters in KN2/G4 mice, also suggests that biallelic IL-4 expression in vivo occurs,
but is rare.
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Figure 4.5: IL-4-dependent Th2 response requires STAT-6. Mice of the spec-
ified genotype were injected intradermally with 100 ug HDM and seven days later
assessed for (A) Total CD4+ T cell generation, (B) GFP expression by CD4+ T
cells and (C) the total number of Th2 cells generated. In a separate experiment
naive mice of the specified genotype were euthanised and the number of (D) CD4+
T cells, (E) proportion of CD4+ T cells that expressed GFP and (F) total number
of CD4+GFP+ T cells were examined. Data points represent individual mice and
lines represent group mean±SEM. Data in (A-C) and (D-F) are from separate single
experiments. Data were compared using Student’s t-test; ****p≤0.0001.
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4.3.4 Examining the influence of IL-4 on Th2-dependent im-
mune responses
Investigating the function of Th2 cells in B cell switch re-
sponses in vivo.
We observed reduced Th2 cell generation in IL-4-deficient mice relative to IL-4-
heterozygous mice. To more fully understand the effect of IL-4 on Th2 cell devel-
opment, we were next interested to determine whether genetic deletion of one IL-4
allele, in IL-4-heterozygous mice, affected Th2 cell development relative to wild-type
mice. However, with no current access to an IL-4 reporter mouse with two intact IL-4
alleles (IL-4+/+), we cannot directly examine Th2 cell development directly using
our reporter systems. Rather, we sought to investigate the influence that the loss
of one IL-4 allele provides to the Th2 response by examining known IL-4-dependent
responses in allergic disease contexts. The B cell class-switch response to IgG1 is an
IL-4 dependent process[289], and intestinal anaphylaxis is an IL-4-dependent model of
egg allergy[295]; therefore, we next sought to determine if IL-4-heterozygosity impairs
either of these two processes. The experiments in this section of the chapter investi-
gated how the absence of one IL-4 allele affects Th2 cell function. These experiments
also sought to clarify the phenotype and function of Th2 cells in the pTh2 assay.
Assessing the phenotype of Th2 CD4+ T cells induced by
intradermal immunization
Th2 cells have been shown to function in different capacities in lymph nodes and
tissues[275, 317]. TFH cells support IgG1 antibody class-switch recombination[275],
however TFH function has not yet been evaluated in the pTh2 assay. We began this
set of investigations by examining whether pTh2 cells had the same phenotype as the
B cell-helper TFH cell. We examined Th2 cells for expression of molecules associ-
ated with TFH cell function (CXCR5, PD-1 and ICOS[337, 338, 368, 409–411]) and
for activation molecules previously observed on N. brasiliensis induced mediastinal
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lymph node Th2 cells (CD44, CD62L, and CD69)[1]. Our objective was to determine
whether auricular lymph node Th2 cells were likely to support B cell class-switch
responses.
Initially, we immunized G4/+ mice with HDM and examined expression of the early
T cell activation molecule, CD69, three days later. In a separate group of mice, we
examined CD44 and CD62L expression seven days after HDM immunization. Lastly,
we determined levels of molecules expressed by TFH cells, CXCR5, PD-1 and ICOS
seven days after injection of 600 dead iL3 N. brasiliensis larvae. As established
previously [1], Th2 cells upregulated CD44, decreased expression of CD62L and had
variable, but generally elevated CD69 expression (Figure 4.6A and 4.6B). Consistent
with previous reports[275, 362, 364], we observed that PD-1 and ICOS were expressed
by almost all Th2 cells, and the Median fluorescence intensity of CXCR5 on the total
Th2 cell population was increased over total CD4+ T cells (Figure 4.6C).
We next examined the development of TFH cells. In this experiment, mice were
immunized intradermally with 600 iL3 N. brasiliensis larvae. Mock-challenged con-
trols received 30 µL PBS. Fourteen days later, we examined draining lymph node
CD4+B220- T cells for the expression of CXCR5 and PD-1. When we examined
wild-type mice after intradermal immunization, we observed TFH cell development
in immunized, but not mock-immunized lymph nodes (Figure 4.7A and B). We also
observed that TFH cells developed in G4/+ mice (Figure 4.7A and 4.7B) and were
substantially enriched for IL-4 producing Th2 cells (Figure 4.7C). In all experiments,
between 10 and 60 percent of GFP-expressing Th2 cells in G4/+ mice induced by
intradermal immunization expressed PD-1 and CXCR5 and fell in the TFH cell gate
([275, 337]; Figure 4.7D). While the difference between TFH frequency between G4/+
and +/+ mice was not statistically significant (by Mann-Whitney U-test) this trend
was reproducible in multiple experiments. This may relate to the role of IL-4 in the
expansion or maintenance of the Th2 population (covered earlier in this chapter and
alluded to in [362]), or could also be a result of a decrease in IL-4-dependent B cell
responses that contribute to TFH cell selection, as B cells have been shown to support
TFH cell expansion in some studies[364]. Irrespective of the influence of IL-4 on the
TFH population expansion, these results demonstrate that a substantial proportion
of Th2 cells were TFH cells.
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Figure 4.6: Th2 cells exhibit an activated TFH cell phenotype. Following
intradermal challenge of G4/+ mice (n=5-6), GFP+CD4+ T cells (solid black lines)
and GFP- CD4+ T cells (grey histograms) were examined for surface phenotype.
Isotype staining on GFP+CD4+ T cells for CXCR5 is represented by the dashed
black line. Molecules associated with (A) early T cell activation, (B) effector T
cell activation, and (C) TFH cells were examined. A single representative plot is
shown from (A) one of two experiments done three days after HDM injection, (B)
one experiment seven days after HDM injection and (C) three or more experiments
seven days after dead iL3 N. brasiliensis larvae injection. Each experiment included
5-6 G4/+ mice.
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Figure 4.7: IL-4 production is common in TFH cells. Mice were intradermally
challenged with 600 dead iL3 N. brasiliensis larvae (Nb) or PBS and assessed for
TFH cell development. (A) Representative plots of CXCR5 and PD-1 expression
in live CD4+B220- cells. (B) Shows the proportion of CD4+ cells that fell in the
canonical TFH cell gate. (C) Shows the proportion of CD4+ T cells and TFH cells
that expressed GFP. (D) Shows representative CXCR5 and PD-1 expression in GFP+
and GFP- CD4+ T cells. Data shown are from one of three similar experiments. Data
were compared using Student’s t-test; *p<0.05, ****p<0.0001.
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Investigating biallelism as a specific feature of Th2 TFH cells
Reinhardt et al.[275] took advantage of reporter mice with one KN2 allele and the
IL-4-sufficient GFP-tagged 4get mRNA reporter on the other, and observed that
hCD2+4get+ cells were enriched in the TFH population. In the KN2/4get mouse,
transcriptional access to the IL-4 gene is reported by 4get expression and IL-4 pro-
duction occurs predominantly in 4get+ cells co-expressing hCD2[352, 373]. As the
B cell switch-inducing Th2 TFH cells were recorded as hCD2+/4get+ TFH cells,
this also means that the doublet population expressed, at least at the transcriptional
level, both alleles of IL-4 simultaneously. This led us to consider the possibility that
biallelism is a unique property of TFH cells, and the small population of cells we
observed expressing both IL-4 alleles in KN2/G4 mice (Figure 4.4) were exclusively
TFH cells.
To evaluate whether biallelic cells were specifically TFH cells, we intradermally immu-
nized KN2/G4 and +/+ mice with 100 µg HDM extract. Ten days later we examined
the expression of CXCR5 and PD-1 in draining lymph node CD4+ T cells. When
we examined TFH cell development in KN2/G4 mice, we found that all Th2 cell
populations (hCD2+GFP-, hCD2+GFP+ and hCD2-GFP+) contained TFH (Fig-
ure 4.8B). Further, we also observed that hCD2 expression, rather than biallelism
was the strongest predictor of TFH cell status (Figure 4.8B). Therefore, TFH cells
were not exclusively biallelic. The difference in TFH frequency in hCD2+ and GFP+
cells may also indicate that the G4 and KN2 reporters demarcate T cells with sep-
arate functions, at different stages of development, or with different fates. Future
experiments will be required to determine the relevance of the differential population
frequencies.
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Figure 4.8: IL-4 can derive from one or both alleles in TFH cells. (A) Lymph
nodes from mice of the indicated genotype were examined for CXCR5+PD-1hi TFH
cells after immunization with 600 dead iL3 N. brasiliensis larvae. (B) Ten days after
immunization with 100 ug HDM, CD4+ T cells from KN2/G4 mice expressing neither
hCD2 nor GFP (hCD2-GFP-), only GFP (hCD2-GFP+), only hCD2 (hCD2+GFP-)
or both hCD2 and GFP (hCD2+GFP+) were assessed for the proportion of cells in
that quadrant that fell in the CXCR5+PD-1Hi TFH gate. A representative plot is
shown on the left, and coordinates were set to <0.05 percent in each quadrant in
CD4+ T cells in similarly immunized +/+ mice. Bars in the graph shown in (B)
represent mean±SEM of n=12 mice combined from three experiments.
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The GL-7+ germinal centre TFH population includes a signif-
icant number of IL-4-producing cells
We reasoned that if the pTh2 response initiated IL-4-dependent B cell responses,
we would observe germinal centre formation in immunized lymph nodes. GL-7 is
expressed by both germinal centre B cells[338] and germinal centre TFH cells that
contain high levels of IL-4 mRNA[366]. We next used GL-7 expression to determine
if GC B and Th2 TFH cells are present in draining auricular lymph nodes.
In these experiments, we intradermally immunized G4/+ and +/+ mice with 100 µg
HDM antigen. Seven days later, we harvested draining lymph nodes, and non-draining
contralateral lymph nodes and examined GL-7 expression on B cells and CD4+ TFH
cells. We found that the proportion of GL-7-expressing B cells in the lymph node was
increased in draining lymph nodes (Figure 4.9B). Therefore, GL-7-expressing B cells
developed in response to immunization. Similarly, GL-7 expression by CD4+ T cells
was predominantly by PD-1-expressing cells (Figure 4.9C), and we observed that a
large proportion of TFH cells expressed GL-7 (Figure 4.9D and 4.9E). We observed
only minor differences in the proportion of GL-7+ and GL-7- TFH cells that expressed
GFP (Figure 4.9F). This suggests that GL-7- TFH have also been induced to produce
IL-4. These findings indicate that auricular pTh2 cells have the potential to support
IL-4-dependent B cell isotype class-switching.
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Figure 4.9: IL-4 is produced by GL-7+ (germinal centre) TFH cells. (A)
Seven days after intradermal immunization with 100 µg HDM, B cells were stained
with an IgM isotype (left) or anti-GL-7 antibody (right) to assess germinal centre
B cell development. The gates shown on the plots define GL-7+ and GL-7- cells
analyzed in (B) and (E-G). (B) The proportion of live B220+ cells expressing GL-
7 was compared in non-draining contralateral (nDLN) and draining (DLN) lymph
nodes. (C) CD4+ T cells were examined for PD-1 and GL-7 expression by flow
cytometry. (D) GL-7 expression was examined in TFH cells (black line; gated as
shown in Figure 4.8) and compared to isotype stained TFH (grey histogram). (E)
The proportion of CD4+ T cells and TFH cells expressing GL-7 was examined. (F)
Representative flow plots of GFP expression in GL-7- and GL-7+ TFH cells(left), (G)
in which the proportion of cells expressing GFP (percent in Q2) were compared. Data
points represent individual mice; bars and lines represent group mean±SEM. Data
are shown from one (n=3-5 mice) of four similar experiments, two using HDM and
two using dead iL3 N. brasiliensis larvae as the immunogen. Data were compared
using Student’s t-test; ***p<0.001, ****p<0.0001.
Intradermal immunization induces IgG1 isotype class switch-
ing
Germinal centre Th2 TFH cells developed in mice immunized with HDM in the ab-
sence of exogenous adjuvant. Our next objective was to examine whether IgG1 isotype
class-switching could be observed without adjuvant.
In these experiments, we intradermally immunized +/+ mice with either 100 µg HDM
antigen or 600 dead iL3 N. brasiliensis larvae. Sixteen days later, we examined IgG1
and IgD expression on B220+ B cells in draining and contralateral non-draining lymph
nodes. We observed a distinct population of IgG1+IgD-B220+ cells in draining, but
not non-draining lymph nodes of both immunized groups (Figure 4.10A - C). When we
compared the HDM and parasite antigens, we observed that twice as many IgG1+IgD-
B220+ cells developed in response to the parasite antigens (Figure 4.10C). Overall,
these data suggest that parasite antigens and HDM both induce IgG1 class switching
in the absence of exogenous adjuvant.
In a separate experiment, we examined the kinetics of IgG1+IgD-B220+ cell develop-
ment. After performing optimisation experiments with a new batch of HDM antigen
(data not shown), in draining lymph nodes of mice immunized with 200 µg HDM, the
number of IgG1+IgD-B220+ cells increased with time and became significantly ele-
vated on day 16 (Figure 4.10D). These data indicate that IgG1+IgD- B cells develop
with the kinetics expected of an affinity matured, CD4+ T cell-dependent germinal
centre response.
We were also interested to determine if we could observe systemic antibody production
following intradermal immunization. In parallel with the assays described (Figure
4.10), we bled mice and froze serum samples prior to, seven and sixteen days after
intradermal immunization. We then tested for HDM-specific IgG1 antibody in HDM-
and parasite antigen-immunized mice. We detected HDM-specific IgG1 in day 16
sera, but not in day 0 or 7 sera (Figure 4.11A). We did not detect HDM-specific
IgG1 in sera from dead iL3 N. brasiliensis-immunized mice (Figure 4.11B). These
data suggest that the intradermally-induced auricular lymph node IgG1 response is
antigen-specific.
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Figure 4.10: TFH cell function is reported by IgG1+ B cell development. (A)
Sixteen days after intradermal immunization with 100 ug HDM live auricular lymph
node B220+ cells were examined for IgD and IgG1 expression by flow cytometry in
draining (DLN) and non-draining (nDLN) lymph nodes. The proportion (B) and total
number (C) of B220+ cells that stained for surface IgG1 and not IgD was compared in
mice immunized with 100 ug HDM (black bars) or 600 dead iL3 N. brasiliensis larvae
(white bars) (n=3/group). (D) The kinetic generation of IgG1+IgD-B220+ cells was
measured in mice immunized with 200 ug HDM antigen in a separate experiment.
Data shown in (A-C) are from one of three similar experiments. The data shown
in (D) was performed and analysed in a single experiment. Data were compared by
One-Way ANOVA with Tukey’s post-test; **p<0.01, ****p<0.0001.
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Figure 4.11: IgG1 class-switch B cell response is antigen-specific. (A) Prior to
(crosses) and seven (circles) and sixteen (squares) days after intradermal injection of
100 ug HDM, mouse serum was analysed by ELISA for HDM-specific IgG1. (B) Six-
teen days after intradermal challenge with 100 ug HDM (white squares) or 600 dead
iL3 N. brasiliensis larvae (black squares), mouse serum was analysed by ELISA for
HDM-specific IgG1. Data points show mean±SEM of groups of (n=3) mice from one
of three similar experiments. Data were analysed using (A) Two-way repeated mea-
sures ANOVA with Bonferroni’s post-test versus day 0 and day 7 sera, or (B) Two-way
ANOVA with Bonferroni’s post-test versus L3 Nb; *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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4.3.5 The influence of a single IL-4 allele on primary, adjuvant-
free IgG1-class switch recombination
Parasite-induced IgG1 class-switching is reduced by approximately 80 percent in IL-4
deficient mice[289] and also requires STAT-6[330], however, signals other than IL-
4[274, 287, 288], specifically CD40:CD40 ligand (L) interaction[291, 292, 412–414],
contribute to isotype class-switching[274, 415]. Further, specific types of immuniza-
tion induce STAT-6- and IL-4-independent IgG1 production[274, 329], and in special
circumstances, even IgE can be generated in the absence of IL-4 or CD4+ T cell
help[416–418]. Therefore, it was possible that we were observing IL-4-independent
IgG1 class-switching in the auricular lymph node. We next designed experiments to
assess the involvement of IL-4 in the B cell IgG1 class-switch response. To do this we
used mice deficient in STAT-6 or IL-4 and examined the influence that the loss of a
single IL-4 allele has on the B cell class-switch response.
In these experiments, we immunized +/+, STAT-6-/-, G4/+ or G4/G4 mice with 100
µg HDM. Fourteen days later, we tested draining and non-draining lymph nodes for
IgG1+ B cells. Further, because MHC-II is upregulated on activated B cells in an
IL-4- and STAT-6-dependent manner[329, 330, 419], we also examined the expression
of MHC-II on the B cells.
As expected, STAT-6-deficient mice exhibited impaired IgG1 switching (Figure 4.12A).
Correspondingly, B cells in these draining lymph nodes of STAT-6-deficient mice did
not respond to IL-4, because expression of MHC-II was lower than observed in drain-
ing lymph nodes of IL-4-sufficient mice (Figure 4.12B). When we examined Th2 cell
development in G4/G4-STAT-6-/- mice, we observed a minor elevation in the propor-
tion of GFP+CD4+ T cells present in the draining, but not the non-draining lymph
node (Figure 4.12C). This indicates that Th2 cells developed, but were not able to
support IgG1 switching in STAT-6-deficient conditions. While the MedFI of I-A/I-E
on the B cells in the non-draining +/+ lymph node was higher than others, compar-
ison to naive lymph nodes (which were not included) would be required to determine
whether this reflects dissemination of the B cell response or not. Therefore, while
Th2 cells developed without either IL-4 or STAT-6, IgG1-switched B cell hyperplasia
induced by intradermal immunization was STAT-6 dependent.
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Figure 4.12: IgG1 class-switch B cell response requires STAT-6. Mice were
intradermally immunized with 100 ug HDM and fourteen days later draining (black
bars/symbols) and non-draining (white bars) lymph nodes were excised and analysed
by flow cytometry for IgG1 expression by B220+ cells and GFP expression by CD4+
cells. (A) The proportion of B220+ cells expressing IgG1 was examined. (B) the
expression of MHC-II (I-A/I-E) on the B220+ population was compared in mice
of different genotypes. (C) The proportion of CD4+ T cells that expressed GFP
was evaluated in the different groups. Data are shown from a single experiment
(n=3-5 mice/group) and were analysed by Two-way repeated measures ANOVA with
Bonferroni’s post-test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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While STAT-6 was required for the adjuvant-free IgG1 class-switch response, low
levels of IgG1 and IgE have been observed in IL-4- and IL-4Rα-deficient mice[418].
To examine the influence of each IL-4 allele on IgG1 class-switching, we examined
class-switching in IL-4-deficient G4/G4 and IL-4-heterozygous G4/+ mice. Fourteen
days later, we examined mice for IgG1+ B cells, the expression of MHC-II, and Th2
cell development.
We observed that Th2 cells developed in G4/G4 and G4/G4-STAT-6-/- mice (Figure
4.13C). This indicates that Th2 cells were able to develop in IL-4-deficient and IL-4
heterozygous mice. However, we observed that IgG1+IgD- B cells did not develop in
G4/G4 mice (Figure 4.13A). Additionally, we observed that MHC-II expression was
lower in G4/G4 and G4/G4-STAT-6-/- IgG1+ cells than in IL-4 sufficient G4/+ and
+/+ draining lymph node IgG1+ B cells (Figure 4.13E). Therefore while Th2 cells
developed in the absence of IL-4 (Figure 4.13) IL-4 was required for adjuvant-free B
cell IgG1 class-switch recombination. Similarly in G4/+ mice, an increase in Th2
cell number was observed in draining lymph nodes but not non-draining lymph nodes
(Figure 4.13C). When we examined the B cell response, we observed that a single IL-4-
sufficient allele was sufficient to permit B cell MHC-II upregulation (Figure 4.13B), but
was not sufficient to permit normal IgG1 induction, because these mice demonstrated
a two-fold reduction in proportional switching relative to +/+ mice (Figure 4.13A).
Thus, a 50% decrease in the number of functional IL-4-producing alleles impaired the
IL-4-dependent B cell class-switch response. Taken together, these data indicate that
the loss of a single IL-4 allele in mice impairs either Th2 cell development or TFH cell
function relative to wild-type mice.
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Figure 4.13: The IgG1 class-switch response is IL-4 allele dose-dependent.
Fourteen days after intradermal injection of 0.2 mg HDM antigen, draining (DLN)
and non-draining (nDLN) auricular lymph node B cells were examined for IgG1 and
IgD expression (A) and CD4+ cells were examined for GFP expression (C). The
expression of MHC-II (I-A/I-E) on IgG1+B220+ LN cells was compared (B). Data
are shown from one of two similar experiments (n=2-3 mice/group). (A-C) Data
were analysed by Two-way repeated measures ANOVA with Bonferroni’s post-test;
**p<0.01, ***p<0.001, ****p<0.0001.
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4.3.6 The influence of IL-4 heterozygosity on the intestinal
allergic response
As a final investigation of the effect of IL-4 heterozygosity on Th2-type allergic immune
responses, we examined the development of oral allergen-induced intestinal anaphy-
laxis in IL-4-heterozygous mice.
In these experiments, mice were intraperitoneally immunized with 50 µg OVA in the
presence of 1 mg alum adjuvant, twice, two weeks apart. Mice were then bled, and
examined for serum IgE levels. In one experiment, mice received two further fort-
nightly intraperitoneal immunizations. Following this sensitization phase, mice were
orally gavaged with 50 mg OVA, and monitored for diarrhoea development. Mice
were bled after the 9th challenge to measure haematocrit, and were bled after the
10th challenge to examine murine mast cell protease-1 (mMCP-1) and antibody titres
in the serum. In these comparisons the phenotype of G4/+ and KN2/+ mice were
essentially the same, so I will discuss these mice collectively as +/- mice. In figures
the response of mice from each genotype are shown.
When we examined IgE generation in mice immunized twice with OVA and alum,
we observed 90% less IgE in +/- mice than in wild-type +/+ mice (Figure 4.14A).
When we examined IgE levels in mice that had received a total of four fortnightly i.p.
sensitizations, and then ten oral OVA challenges, we still observed a 90% decrease
in serum IgE levels (Figure 4.15A), and also lower levels of OVA-specific IgE in +/-
compared with +/+ mice (Figure 4.15B). These data indicate that allergen-specific
IgE production is impaired in IL-4-heterozygous mice.
When we challenged mice orally with OVA, only +/+ mice exhibited diarrhoea (Figure
4.16A). Blood haematocrit was higher in diarrhoetic +/+ mice than +/- mice (Figure
4.16B). These data demonstrate that +/- mice did not develop an intestinal allergic
response. When we examined mast cell activity in these mice, we observed that
mMCP-1 titres were lower, and jejunal mast cells were less frequent in OVA challenged
+/- mice than +/+ mice (Figure 4.16C and 4.16D). While we did not examined basal
mMCP-1 levels in IL-4 +/- mice and will require confirmation, basal levels in wildtype
mice are usually approximately 20-40 ng/mL, indicating some increase in intestinal
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mast cell activity may have occurred in the orally challenged +/- mice. These data
indicate that both IL-4 alleles are required for normal oral allergen-induced mast cell
activity.
Taken together, these data suggest that both IL-4 alleles contribute to IgE develop-
ment. Mice deficient in a single IL-4 allele exhibited deficient IgE generation, impaired
intestinal mast cell activity and were protected from allergic diarrhoea. These data
suggest that both IL-4 alleles are required for normal allergen-specific Th2 immune
responses.
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Figure 4.14: IgE production is impaired in IL-4 heterozygous mice. (A) Mice
were sensitized intraperitoneally with 50 µg OVA plus 1 mg alum and 28 days later
were bled and serum was analysed for Total IgE. Data are shown from one of four
separate experiments in +/+ and G4/+ mice (n=3-5 mice). KN2/+ mice (n=5)
were analysed at this time-point once. Data were analysed by One-way ANOVA with
Tukey’s post-test; ***p<0.001.
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Figure 4.15: IgE production is impaired in hyper-primed, orally-challenged,
IL-4 heterozygous mice. Mice were sensitized intraperitoneally four times, every
two weeks with 50 µg OVA and 1 mg alum. Two weeks after the fourth i.p. prime,
mice were then orally challenged with 50 mg OVA ten times as per the standard
regimen. Sixty minutes after the final challenge, mice were bled for (A) Total IgE
and (B) OVA-specific IgE. Data points in (A) show individual mice and in (B) data
points represent mean±SEM of these same (n=3-5) mice from a single experiment.
Data were analysed by (A) One-Way ANOVA with Tukey’s post-test, or (B) Two-way
ANOVA with Bonferroni’s post-test; ***p<0.001, ****p<0.0001, +/+ versus KN2/+
or G4/+.
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Figure 4.16: IL-4 heterozygosity prevents oral-allergen induced intestinal
anaphylaxis. Mice shown in Figure 4.15 were (A) monitored for diarrhoea develop-
ment following challenges and (B) haematocrit (%PCV) 60 minutes after the ninth
challenge. (C) mMCP-1 was measured from sera taken 120 minutes after the final gav-
age challenge. (D) Intestinal mast cell infiltration at the experimental end-point. Data
are shown from a single experiment and were analysed using One-way ANOVA with
Tukey’s post-test; *p<0.05, **p<0.01. mMCP-1 data were log-transformed prior to
analysis. In two additional experiments, G4/+ mice (n=5/experiment) that received
two ip primes did not exhibit diarrhea with ten 50 mg OVA challenges.
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4.4 Discussion
The aim of this chapter was to evaluate the role of IL-4 in Th2 cell development and
function in vivo. In these studies, we employed a primary Th2 response assay to
examine the involvement of IL-4 in Th2 cell development. We subsequently examined
the phenotype of Th2 cells responding to intradermal allergen immunisation, and then
examined their ability to support IgG1 class-switch responses. We observed significant
impairments in Th2 cell development in IL-4-deficient conditions, and demonstrated
that both IL-4 alleles were required for the generation of allergen-specific IgG1, IgE
and for intestinal allergic responses. These studies illustrate the importance of IL-4
in the co-ordination of allergic Th2 immune responses.
4.4.1 The role of IL-4 in Th2 cell development
Th2 cell development was observed to occur in two phases in our experiments. We ob-
served that similar numbers of GFP+CD4+ T cells developed in G4/+ and KN2/G4
mice three days after adjuvant-free HDM immunization, but after this time G4/+
lymph nodes contained approximately 50% more GFP+CD4+ T cells than KN2/G4
lymph nodes (Figure 4.2). Thus, there was an IL-4-independent initiation phase,
followed by an IL-4-dependent amplification phase. Similar IL-4-independent and -
dependent phases were observed when we compared hCD2+CD4+ T cell development
in KN2/+ and KN2/G4 mice (Figure 4.3). We also observed a requirement for STAT-
6 in Th2 cell expansion, because GFP+CD4+ T cells were fewer in G4/+-STAT-6-/-
mice than G4/+ mice seven days after immunisation (Figure 4.5). Collectively, these
data indicated that Th2 cell development was initially IL-4-independent, but was then
amplified in the presence of IL-4. These data support the accumulating body of litera-
ture that indicates that Th2 cell development can be initiated in an IL-4-independent
manner.
Our studies examined adjuvant-free allergen-induced Th2 cell development, but sim-
ilar conclusions have been reached using adjuvant-based protein and hapten immu-
nisation regimens. Cunningham et al. examined the requirement for IL-4 signaling
using mice deficient in IL-4Rα[360]. In their studies, mice were immunised with
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haptenated fowl gamma globulin, alum and heat-killed Bordetella pertussis. To mea-
sure Th2 development, IL-4 mRNA transcript frequencies were compared in isolated
draining lymph nodes of IL-4Rα+/+ and IL-4Rα−/− mice. They observed similar in-
creases in IL-4 mRNA transcript levels and lymph node expansion in both strains
for the first three days[361]. After this time, in IL-4Rα-deficient mice, lymph nodes
atrophied and - and γ1-switch responses were diminished[361]. IL-4 mRNA tran-
scripts were, however, still detected[361]. Thus, the induction of IL-4 production
occurred normally without IL-4Rα, but IL-4-dependent B cell responses required IL-
4 signaling. Similarly, Reinhardt et al. examined Th2 cell development in response
to haptenated-bovine serum albumin adsorbed to alum[275]. They observed that
Th2 cells developed in both KN2/+ and KN2/KN2 mice, but hapten-specific IgG1
production was decreased in KN2/KN2 mice. van Panhuys et al. immunised mice
with keyhole limpet hemocyanin and alum, and then gave them an airways challenge
with keyhole limpet hemocyanin[1]. They observed that mediastinal Th2 cell num-
bers expanded similarly in G4/+, G4/G4 and G4/G4-STAT-6-/- mice, and airways
eosinophilia was unimpaired, but IgE production was ablated[1]. Our studies add to
these findings and demonstrate that adjuvant-free Th2 cell development also does not
require IL-4. Collectively these data indicate that there is no absolute requirement
for IL-4 in antigen-induced Th2 cell development, but IL-4 remains an important
molecule in Th2-mediated B cell responses.
Studies have also examined the role of IL-4 in other Th2 response models. van Pan-
huys, King, Noben-Trauth, Mohrs et al.[1, 362, 363, 420] examined the development
of the Th2 cell phenotype in parasite-infected mice. Seven days after H. polygyrus
bakeri infection, Th2 cell numbers were similar in IL-4Ra-/-4get and IL-4Ra+/+4get
reporter mice, but by day 14, IL-4Ra-/- lymph nodes contained fewer 4get+ cells and
fewer B cells than IL-4Ra+/+ counterparts[362]. Similarly, when N. brasiliensis was
used to infect G4/+ and G4/G4-STAT-6-/- mice, Th2 cells developed with similar
kinetics during primary infection, and were even observed to expand to higher abso-
lute frequencies following a secondary challenge[1]. T cells from N. brasiliensis- or
Leishmania major -infected IL-4Rα-deficient mice have been shown to produce mea-
surable amounts of IL-4 upon ex vivo restimulation[363, 420]. Th2 cell development
has also been demonstrated to be unimpaired in anti-IgD treated mice deficient in
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IL-4, IL-4Rα or STAT-6[1, 421]. Additionally, it has also been demonstrated that
dead parasite antigens induce Th2 cell development in intradermally immunised IL-4
and STAT-6 doubly deficient mice[1]. Collectively, there are numerous studies that
indicate that Th2 cell development can occur in the absence of IL-4 in vivo.
IL-4-independent and -dependent phases of Th2 cell development have been reported
not only in vivo, but also in vitro. While IL-4 enhances Th2 cell committment, naive
CD4+ T cells lack repressive epigenetic marks associated with the IL4 locus[324, 347,
377–380, 385], and contain low levels of GATA-3 that are thought to be sufficient for
the early initiation of IL-4 production[325, 422]. In vitro studies have identified that
within the first few hours of TCR ligation, IL-4 and GATA-3 mRNA transcription
are observed, even in STAT-6-deficient cells[327, 347, 348, 350]. Multiple rounds of
culture in Th0 conditions can permit 10-fold increases in IL-4 protein production
by antigen-stimulated IL-4Rα-/- lymph node cells[421]. Similarly, STAT-6-deficient
T cells can be induced to produce IL-4 and stably polarise to the Th2 subset for
a number of weeks[348]. These findings illustrate that in the absence of IL-4Rα or
STAT-6, naive CD4+ T cells can begin to develop Th2 function in vitro.
Some factors that contribute to this IL4-independent expression of Th2 genes have
been identified. Weak TCR ligation in the presence of IL-2 triggers the phosphory-
lation of STAT-5, which induces transcription of IL-4 mRNA and production of IL-
4[325, 349, 422]. GATA-3 remains important for IL-4-independent Th2 development
in vitro because in its absence STAT-5-induced IL-4 production is defective[423]. Ad-
ditionally, while STAT-6-deficient cells can become Th2 polarised, the Th2 cells that
do develop Th2 function accumulate high levels of GATA-3 mRNA[348]. Therefore,
STAT-5 promotes IL-4-independent IL-4 production in the presence of GATA-3. The
ability of low-level TCR stimulation to promote CD4+ T cell IL-4 production is also
observed in polyclonal systems, because when T cells with high-affinity for antigen
are removed from culture, IL-4 production induced by high-dose antigen stimulation
is increased[424]. Therefore, IL-2 and weak TCR stimulation induce IL-4-independent
Th2 cell development in vitro.
During primary in vitro stimulation, the IL-4-independent phase of Th2 cell develop-
ment is short. After the first 24 hours of TCR stimulation, exogenous IL-4 is required
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to increase and maintain both IL-4 mRNA and GATA-3 mRNA transcript levels in
vitro[349]. Additionally, while STAT-6-deficient cells can produce IL-4, and stably
polarise to the Th2 subset, they do not reach the levels of polarisation that can be ob-
served in STAT-6-sufficient Th2 cells[1, 348]. These in vitro studies indicate that while
IL-4 is not necessary during the initial activation phase in vitro, it remains a potent
Th2-polarising cytokine. Thus, the initial transcription of IL-4 mRNA that occurs
in vitro occurs in an IL-4-independent manner, and is followed by an IL-4-dependent
phase that amplifies in vitro Th2 polarisation.
4.4.2 Potential mechanisms that promote IL-4-independent
Th2 cell development in vivo
Understanding the initial events in IL-4-independent Th2 cell development in vivo
is only beginning to be investigated. For a long time, it was thought that IL-4 was
required for the initiation of Th2 cell development in vivo. When naive CD4+ T
cells are initially activated, they can produce minute amounts of IL-4[421]. Similarly,
NK-T cells and basophils have been shown to produce IL-4 in an IL-4- and STAT-
6-independent manner[357, 363, 421, 425]. Either of these cell populations could
have been a source of early IL-4 that promoted Th2 cell development. However,
numerous studies, including the current investigation, indicate that the initiation of
Th2 cell development in vivo cannot be attributed to IL-4 alone. Therefore, rather
than initiating Th2 cell development, these sources may instead contribute to the
expansion of Th2 cells.
A number of potential Th2-initiating pathways have been proposed. Basophils have
been implicated in the inititation of Th2 responses, both through their production
of IL-4 and by presenting low levels of antigen-MHC-II[353, 354, 426, 427]. TSLP,
IL-25 and IL-33 have also been shown to promote Th2 immunity through the devel-
opment of previously uncharacterised basophil-like and lineage-negative Th2-cytokine
producing populations[355, 428–433]. However, Th2 cells develop to normal levels in
the absence of basophils[357–359] and the tissue-derived cytokines still enhance Th2
cytokine production in the absence of CD4+ T cells[432]. Epithelial cell production of
IL-25 exacerbates allergic airways disease in mice and also promotes Th2 cell develop-
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ment in vitro; however, the effect of IL-25 specifically on Th2 cells requires IL-4[356].
Therefore, further investigations are required to determine the role of tissue-derived
cytokines and basophils in the initiation of Th2 cell development. Specialised dendritic
cell subtypes, namely those expressing FceRI or OX40L, have also been associated
with the initiation of Th2 cell development[351, 359, 434]. In in vitro studies, OX40L
also promotes CD4+ T cell IL-4 production[435, 436]. These processes may not re-
quire IL-4 to initiate Th2 cell development; this also requires further investigation.
Investigating the earliest events that promote Th2 cell development may provide novel
ways to interfere with the allergic process.
4.4.3 Potential implications on IL-4-dependent Th2 cell ex-
pansion
Understanding the manner in which IL-4 increases the number of GFP+ or hCD2+
cells may have important implications for the aetiology of allergic disease. IL-4 may
act to increase the proportion of committed Th2 cells that produce IL-4; IL-4 may in-
duce the expansion of the committed Th2 cells that developed in an IL-4-independent
manner; or IL-4 may promote polarisation of uncommitted antigen-specific Th cells
towards the Th2 phenotype.
If IL-4 increases the proportion of committed Th2 cells that produce IL-4, the com-
position of the Th2 population would not be altered. According to the probabilistic
regulation theory, the relative ’strength’ of the Th2-inducing stimulus will cause more
frequent IL-4-production by cells in a Th2 cell population[273, 401]. In this case, it
is possible that the presence of IL-4 increases the Th2-activating ’strength’ of an im-
munogen, and thus causes more committed Th2 cells to produce IL-4. Therefore, the
number of committed Th2 cells will not be altered, but our ability to detect them will
(Figure 4.17A). Thus, the composition of the antigen-specific population may not be
altered, and their polarisation toward the Th2 phenotype may not be influenced. IL-4
may simply increase the proportion of committed Th2 cells that produce IL-4.
IL-4 may alternatively have altered the expansion of the allergen-specific Th cell
population. The bulk Th2 cell population at the peak of the response could have
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developed from precommitted IL-4-independent Th2 cells (Figure 4.17B), or from
previously uncommitted Th cells that became Th2 polarised (Figure 4.17C). These
two scenarios will influence the clonal diversity of the Th2 cell population: If IL-
4 polarises uncommitted Th cells, then the Th2 cell population will become more
clonally diverse; in contrast, if IL-4 acts solely to expand pre-committed Th2 cells,
then the clonality of the Th2 cell population will not change, but the bias of the Th
population towards the Th2 phenotype will be increased. At first sight, this may seem
a redundant distinction. However, IL-4 production by CD4+ T cells has been shown
to be preferentially invoked by low-dose and weak antigen-TCR stimulation[349, 424].
If IL-4 polarises uncommitted Th cells to the Th2 subset, this provides the potential
for Th2 polarisation of Th cells with higher affinity for the insulting antigen. This, in
turn could promote IgE class-switching of the affinity-maturing B cell population and
contribute to the generation of high-affinity IgE. If instead, the pre-committed Th2
population is expanded by IL-4, identifying the manner in which IL-4-independent
Th2 cell development is initiated could identify previously unexplored avenues for
therapeutic intervention.
Basic mechanistic studies offer support to both types of Th2 population expansion.
Recent studies indicate that STAT-6 phosphorylation is observed in essentially every
non-Th2 cell in draining lymph nodes of mice infected in the foot-pad with H. poly-
gyrus bakeri [334]. IL-4Ra is downregulated on highly-activated Th2 cells[373], ren-
dering them refractory to the phosphorylation of STAT-6 caused by IL-4 produced in
a draining lymph node[334]. If IL-4 directly induces Th2 cell development, this could
indicate that the IL-4 produced by Th2 cells induces IL-4 production by previously
uncommitted cells. In the work by Perona-Wright et al.[334], when foot-pad-infected
mice subsequently received OVA-peptide-loaded dendritic cells, OVA-specific CD4+
T cells in the foot-pad draining lymph node were preferentially polarised to the Th2
subset[334]. Therefore, Th2 polarisation of uncommitted Th cells is possible, and can
induce Th2 polarisation of unrelated allergens.
While activated Th2 cells may be refractory to autocrine IL-4[334], their expansion
may occur indirectly through interaction with accessory cells. As established by
others[275, 362, 364], we observed that a large proportion of Th2 cells were TFH
cells (Figure 4.7 and 4.8). It is known that CXCR5-expressing TFH cells migrate into
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B cell follicles[337, 437], and that B cells can provide stimulatory signals to antigen-
experienced CD4+ T cells[438]. Therefore, it is plausible that committed Th2 cells,
despite being refractory to IL-4, interact with B cells, expand and continue to produce
IL-4 (Figure 4.17A). Equally, it could be argued that TFH arise from the uncommit-
ted Th population after they are exposed to IL-4. However, while TFH populations
take time to expand fully[364], the bifurcation of cells that are likely to become TFH
cells (and by proxy a reasonable proportion of Th2 cells) or non-TFH Th cells can
be identified within three days of immunisation[368]. Interaction with dendritic cells
alone is also sufficient to initiate TFH development[368, 439], and similarly to initiate
IL-4 production[408]. In the current study, we identified no requirement for IL-4 for
Th2 cell development in the first three days (Figure 4.2 and 4.3). Taken together, it
is plausible that IL-4-independent Th2 cells may be preferentially selected as the Th2
cell population prior to the involvement of IL-4 in Th2 cell expansion.
One final point we must consider is that IL-4 signalling may influence the allelic
expression of IL-4, inducing more biallelic expression. We have based our studies on
comparisons made in heterozygous G4/+, KN2/+ and KN2/G4 mice. In our in vitro
studies, we observed a disproportionate increase in biallelic IL-4 production in cells
exposed to IL-4 (figure 3.3 and 3.4). In these comparisons, KN2/+ and KN2/G4
cells cultured in IL-4 had similar frequencies of hCD2 expression as KN2/KN2 cells,
indicating that IL-4 may have influenced the allelic expression profile. While the
differential was maintained in G4/+ and G4/G4 cultures in vitro, it is possible that
IL-4 potentiated both G4/+ and KN2/+ Th2 cells to express IL-4 biallelically in
vivo. However, the concordance between the two reporter systems suggest that even
if IL-4 is ’potentiating’ biallelic expression, this ’potentiation’ of Th2 cells may be an
important component of Th2 development. Future studies will be required to clarify
the role of IL-4 in IL-4-producing Th2 cell development.
The manner in which IL-4 increases Th2 development may have important impli-
cations for allergic disease biology. If pre-committed Th2 cells expand or produce
IL-4 in response to IL-4, understanding the processes that initiate IL-4-independent
Th2 cell development may provide new prophylactic disease interventions. If IL-4 po-
larises uncommited Th cells to the Th2 phenotype, then targeting antigen-responsive
cells, rather than the Th2-polarising apparatus, may provide more therapeutic benefit.
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Further, if IL-4-independent Th2 cells are long-lived, and remain IL-4-independent,
then interfering with IL-4 signaling may limit, rather than reverse the disease phe-
notype. I think the most likely explanation is that IL-4 increases the polarisation
of uncommitted Th cells to the Th2 phenotype; however, clarifying the mechanism
that underlies IL-4-dependent Th2 cell expansion will be an important endeavour for
future studies.
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Figure 4.17: Potential mechanisms of IL-4-dependent Th2 cell expansion. (A)
IL-4 may increase the proportion of committed Th2 cells that produce IL-4 without
changing the proportion of Th2-committed cells. (B) The presence of IL-4 may result
in the preferential expansion of committed Th2 cells without altering the balance of
IL-4-producing and non-producing Th2 cells. (C) IL-4 may polarise uncommitted Th
cells towards the Th2 phenotype.
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4.4.4 A glimpse at the allelic expression of IL-4 in vivo
In addition to operating as an IL-4-deficient single-allele reporter, the KN2/G4 re-
porter mice also provided insight into the allelic expression profile of IL-4 in vivo. This
provides novel understanding of the potential phenotype of the Th2 cell. In response to
both dead iL3 N. brasiliensis and HDM immunisation, a small proportion of cells were
positive for both hCD2 and GFP (Figure 4.4 and 4.8). Previous explorations have also
identified that dual 4get/KN2+ cells develop in helminth-infected mice[275, 362] and
in response to isolated helminth antigens[364]. Similarly, GFP+CD4+ T cells isolated
from helminth-infected G4/+ cells contain elevated levels of IL-4 mRNA[1]. Thus, in
two systems, biallelic IL-4 expression has been determined at the mRNA level. Our
studies extend these findings and confirm that the Th2 cells that developed were able
to produce IL-4 biallelically. We also observed that biallelism was rare. Our observa-
tion of predominant monoallelism in vivo is in accordance with our in vitro observa-
tions, and in agreement with previous in vitro studies[273, 352, 374, 388, 401, 403].
The mice that we monitored for the development of the biallelic population were IL-
4-deficient, indicating that biallelic expression of IL-4 also did not require IL-4 to be
produced. Therefore, Th2 cells that develop in the absence of IL-4 can produce IL-4
both mono- and bi-allelically in vivo.
The allelic expression profile of IL-4 in vivo is a potentially important aspect of the
Th2 response, and we conceived that it may have demarcated functionally specialised
Th2 cells. When we tested whether biallelism specifically demarcated TFH cells, while
we observed enrichment in the biallelic population, we also observed strong enrichment
in the hCD2+ monoallelic, and to a lesser extent, the GFP+ monoallelic population
(Figure 4.8). This indicated that while both TFH development and biallelism were
rare, biallelism was not a specific attribute of Th2 TFH cells. Future investigations
will be required to determine whether there are functional differences between cells
producing IL-4 mono- or bi-allelically.
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4.4.5 Modulating IL-4 levels in Th2 immunity
Following our investigations into the role of IL-4 in Th2 cell development, we exam-
ined the influence of IL-4 heterozygosity on allergic Th2 immune responses. In these
studies, we designed experiments to evaluate how the loss of one IL-4 allele affected
IL-4-dependent immune responses.
In these experiments, we first explored the B cell-helper potential of pTh2 cells. First,
we clarified the phenotype of pTh2 cells. Our studies demonstrated that 10 to 30% of
pTh2 cells were TFH cells, and some of these had a germinal centre TFH phenotype
([366]; Figures 4.6, 4.7 and 4.9). Thus, pTh2 cells had the potential to support B
cell class-switch responses. We then confirmed that germinal centre B cells expanded
(Figure 4.9), and that IgG1 class-switching was observed in intradermally immunised
mice (Figure 4.10). This was associated with the development of systemic antigen-
specific IgG1 in mice after immunisation (Figure 4.10 and 4.11). Finally, we confirmed
that the IgG1 class-switch response was indeed STAT-6- and IL-4-dependent, as would
be expected based on established data ([1, 289, 329–331]; Figure 4.12 and 4.13). Our
studies established that the pTh2 assay is a suitable assay in which to examine IL-4-
dependent IgG1 class-switch responses.
Primary Th2 cell development and IgG1 class switch recom-
bination
While it is not directly related to our investigations into the role of IL-4, our studies
in wild-type IgG1 class-switch responses are worthy of a brief digression. In these
studies, we observed concordance between Th2 cell development and the level of
IgG1 switching induced by two different immunogens. When dead iL3 N. brasiliensis
larvae were used as the immunogen, more IgG1-switched cells were detected in the
local lymph node than when HDM was used (Figure 4.10). Similarly, more Th2
cells developed in response to dead iL3 N. brasiliensis larvae than to HDM (Figure
1.4). Taken together with the TFH phenotype established as IgG1-switch inducing
T cells[275], this suggests that class switching occurs in proportion with the number
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of Th2 cells an allergen causes to develop. Exploring this correlation with a range
of immunogens will be required to validate these findings, but this suggests that
at least two aspects of the Th2 response can be observed by primary intradermal
immunisation: Th2 cell development and IL-4-dependent class switching.
In addition to IgG1 switching, it will be advantageous in the future to examine IgE
switching in this setting. While both IgG1 and IgE require IL-4 for production, IL-21,
which is produced by TFH cells[275, 367], can have reciprocal effects on these two
isotypes[440–443]. In our studies, IgG1 titres were only elevated significantly to titres
of 1/40 or 1/80 (figure 4.11). IgE is produced at 1000-2000-fold lower concentrations
than IgG1[287], making it unlikely that we would detect systemic antigen-specific IgE
in intradermally-immunised mice. Similarly, detecting IgE class-switch recombination
is beyond the sensitivity of most current methodologies; however, newly developed
IgE-reporter technologies are shedding light on the processes that lead to IgE produc-
tion in vivo[444, 445]. These may permit the detection of the IgE-inducing capacity of
immunogens in a modified pTh2 assay. Therefore, future investigations will therefore
require examination of a larger range of allergens and will also need to determine if
IgG1 and IgE correlate with Th2 cell development, or alternatively determine if they
reflect alternate allergenic properties of immunogens.
4.4.6 IL-4 haplo-insufficiency in Th2 immunity
IL-4 heterozygous mice and IgG1 class-switch recombination
To evaluate the requirement for two intact IL-4 alleles in allergic Th2 immune re-
sponses, we examined the IgG1 class-switch response in the pTh2 assay, and sub-
sequently examined the disease phenotype of +/- mice in an oral allergen-induced
model of food allergy. When we examined IgG1 class-switching, we observed that
the loss of one IL-4 allele decreased allergen-induced IgG1 class-switching by approx-
imately 50% (Figure 4.13A). +/- mice were also shown to have a 90% impairment
in adjuvant-based IgE generation, as observed previously ([1]; Figure 4.14). +/-
mice were also protected from oral allergen-induced diarrhoea in the intestinal allergy
model (Figure 4.16). These findings indicated that both alleles of IL-4 were required
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for normal anti-allergen Th2 immune responses. IL-4 heterozygous mice are therefore
haplo-insufficient for IL-4.
Current models of antibody production indicate that the manner in which IgE is
generated differs from the other major isotypes. In vitro studies indicate that in
contrast to B cells of the IgA, IgM and IgG isotypes which can expand 5-15-fold,
IgE-producing B cells have essentially no capacity to expand once they are induced
to become an IgE-producing cell[284]. These studies are also supported by recent in
vivo studies suggesting that once B cells class-switch to IgE they rapidly differentiate
into short-lived plasma cells at a reasonably conserved ratio across a progressing N.
brasiliensis infection or following haptenated protein/alum immunization (PC:GC B
cell ratio close to 1:1)[445]. This contrasts with IgG1 class-switched B cells, which
become preferentially accumulated in the germinal centre niche (PC:GC B cell ratio
initially approximately 1:5 and later approximately 1:5000)[445]. Furthermore, as
studies of the secondary immune response using haptenated proteins or N. brasiliensis
infection reveal that IgE producing cells arise from IgE-negative memory B cells in an
IL-4 and T cell dependent manner[274, 287, 288, 306, 407], there is evidence that even
in secondary immune response contexts, IgE+ B cells have limited ability to clonally
expand.
The concept of a short-lived, poorly expanding IgE+ B cell also has implications for
the processes that select a B cell into the IgE producing plasma cell population. While
serum IgE affinity increases with time and following boost immunization[306], this is
not necessarily because the IgE-switched B cells are undergoing clonal expansion, but
could be a result of their continual loss and subsequent rederivation from IgE negative
antigen-specific B cells. Following haptenated protein immunization, there is evidence
of less affinity maturation in IgE+ plasma cells than IgG1+ plasma cells, but still a
high frequency of the IgE+ cells contain germline transcripts associated with high
antigen affinity, indicating that a substantial proportion are generated through the
extrafollicular pathway[445]. However, there are temporal increases in the number
of accumulated mutations and inferred affinity of IgE producing plasma cells[306,
445], and at later timepoints a substantial proportion of these high affinity IgE+
B cells contain sterile gamma-1 switch transcripts indicating that they have passed
through an IgG1 intermediate state[279, 306]. Thus, current models suggest that
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IgE+ B cells develop both via the extrafollicular route and during the germinal centre
reaction.
In our studies, immunization with OVA/alum generated much less IgE in G4/+ mice
than in wildtype mice (Figures 4.14 and 4.15). Further, intradermal immunization
with HDM demonstrated that IgG1 class-switching was also decreased (Figure 4.13).
Intriguingly, anti-IL-4 treatment inhibits T-dependent IgE production in both primary
and secondary immunization contexts, but does not suppress secondary immunization-
induced T-dependent IgG1 production[287]. Further, while IgE production following
anti-IgD immunization is STAT-6 and IL-4 dependent, anti-IgD induced IgG1 pro-
duction does not require STAT-6 or IL-4[287, 329, 331]. This indicates that the
production of IgE is more sensitive to defects in IL-4 than is IgG1 production. It is
possible that IL-4 is one of a number of key mediators of the IgG1 class switch, but it
is an irreplaceable mediator of the IgE class switch. Mechanistically, this could relate
to differences in the amount of IL-4 required to promote IgG1 versus IgE production.
In vitro, lower concentrations of IL-4 are required to initiate IgG1 production than
IgE production[446], which could indicate that a certain threshold level of IL-4 is
required for IgG1 and a higher threshold level is required to generate IgE in vivo.
In support of this, our id HDM immunization data, in which the magnitude of IgG1
production was approximately 100-fold lower than that induced by OVA/alum immu-
nization (antigen-specific IgG1 titres of approximately 1/1000 vs. 1/100000) showed
that draining auricular lymph node IgG1 class-switching was decreased in the G4/+
mice compared to wildtype mice. Alternatively, it is also possible that IL-4 heterozy-
gosity reveals a role for IL-4 in the initial induction of IgG1 class-switching in germinal
centre B cells, but the expansion of this population thereafter was of sufficient mag-
nitude to mask any measurable effect following protein/alum immunization. As IL-4
signaling has established roles in IgG1 affinity maturation [275], it also remains possi-
ble that even with protein/alum immunization the absence of one IL-4 allele has some
uncharacterized impact on the quality of the IgG1 response.
In contrast to the IgG1 class-switch, our data indicate that IgE production was sensi-
tive to the amount of IL-4 available at all stages, because IgE production was impaired
in G4/+ mice immunized with OVA/alum. As current models suggest that IgE class-
switched B cells have limited capacity to expand, the heterozygous cells appear to
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be unable to secrete sufficient IL-4 to induce B cells to class-switch to IgE at normal
frequencies. As previously mentioned, this may relate to the sheer amount of IL-4
available, or alternatively, could indicate that IgE switching requires highly concen-
trated synaptic production of IL-4 at the interface between cognate conjugated CD4+
T cells and B cells (i.e., at the immunological synapse). In support of this latter con-
cept, IL-4R-alpha heterozygosity impairs IgE production by approximately 90% yet
does not impinge upon IgG1 production[447]. Together with our findings, this could
indicate that B cells require either frequent or strong IL-4 receptor stimulation to
class-switch to IgE and this can only be provided by CD4+ T cells with biallelic IL-4
producing potential.
While it seems likely from current models that the class-switching to epsilon is im-
paired in the +/- mice, there are some alternate explanations to the data. Class-
switching does not guarantee a B cell will develop into an antibody producing cell[282,
283, 448]. Further, there are reported instances of IL-4-independent IgE production[416,
418] and elevated epsilon mRNA transcript frequencies in IL-4R-alpha-deficient mice[360].
While we consider it to be a less likely scenario, epsilon class-switching may occur
normally in the IL-4 +/- mice but these cells may have impaired ability to enter the
plasma cell pathway, or require high levels of IL-4 to survive. Finally, it is also possible
that both alleles of IL-4 are required to generate the precursor population from which
the IgE producing B cells derive. Again, because a substantial proportion of IgE+
B cells have passed through an IgG1 intermediate state[306] and IgG1 titres could
be generated in the IL-4 +/- mice, this seems to be unlikely, but remains a possible
source of the diminished IgE production we observe. Collectively, these findings have
implications for the manner in which an IL-4-producing CD4+ T cell can facilitate
IgE production.
Modulating IL-4 levels in other models of Th2 immunity
While the role of IL-4 has been studied many times in IL-4-deficient conditions, stud-
ies in which IL-4 levels are modified are less common. Over-expression studies indi-
cated that IL-4 results in severe auto-immune pathologies, were associated with atopic
dermatitis-like lesions, hyper-IgE production and IL-4- and CD4+ T cell dependent
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self-reactive B cell responses[404, 405]. More recently, mutations in genes that result
in over-production of IL-4 have been shown to induce similar atopic dermatitis-type
phenotypes and hyper-IgE production[449]. Regulating the amount of IL-4 produced
has key implications for the atopic/allergic process. The closest comparative study to
the current investigation comes from work done by Kopf et al., and the preceding body
of work by vanPanhuys et al. in IL-4-heterozygous mice[1, 450]. Kopf et al. examined
the effect of IL-4 heterozygosity on Leishmania major infection in mice[450]. Despite
no requirement for IL-4Rα in Th2 cell development[420], in the absence of IL-4 protein
Kopf et al. observed that footpad swelling in disease-susceptible BALB/c mice was
minimised in response to footpad inject with L. major promastigotes[450]. Similarly,
footpad swelling in +/- mice was reduced, but not ablated[450]. van Panhuys et al.,
in addition to comparing Th2 cell function in +/+ and G4/+ mice, observed 50%
less IgE in anti-IgD or N. brasiliensis-infected mice, and a 90% reduction in alum-
induced IgE production[1]. Therefore, IL-4 heterozygosity resulted in reduced disease
severity in L. major -infected mice, and decreased, but did not ablate IgE production
in IL-4-heterozgyous mice. We confirmed that IL-4-dependent Th2 responses require
both IL-4 alleles.
Determining the amount of IL-4 available locally in IL-4-heterozygous
mice
Assessing the amount of IL-4 available during local immune responses in IL-4 heterozy-
gous conditions was recently investigated based on the expression of molecules by IL-4-
exposed cells. In these studies, in vitro IL-4 concentrations above 15 pg/mL increased
IL-4Rα expression on cultured non-Th2 cells in a STAT-6-dependent manner[334].
However, when IL-4 concentrations exceeded 500 pg/mL, both STAT-6+/+ and
STAT-6-/- cells downregulated IL-4Rα expression[334]. By examining the expression
of IL-4Rα on non-Th2 cells in helminth-infected chimeric mice, they observed IL-4Rα
upregulation in STAT-6+/+ cells, but not downregulation in STAT-6-/- cells[334].
From these data, Perona-Wright et al. were able to conclude that the effective con-
centration of IL-4 in the local lymph node was equivalent to 15 to 500 pg/mL in vitro
units[334]. In our local lymph node studies in +/- mice, it may be similarly possible
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to use IL-4Rα expression to approximate the effective interstitial IL-4 concentration.
Alternatively, examining IL-4 mRNA transcript numbers, as done previously in IL-
4Rα-deficient conditions[360] may allow us to approximate the relative defect in IL-4
transcription in IL-4 haplo-insufficient conditions.
4.4.7 Mechanisms that may underlie the haplo-insufficient
phenotype of IL-4-heterozygous mice
While we observed impaired IgG1 class switching in +/- mice, at least two mechanisms
may underlie this phenotype. Polarised Th2 cell development may have been impaired
in +/- mice relative to +/+ mice. Alternatively, a single IL-4 allele may have been
sufficient to permit normal Th2 cell development, but their ability to produce IL-
4 may have been compromised. Based on the current data, we cannot distinguish
between the two.
Th2 cell development may have been compromised in +/- mice. Our studies com-
paring G4/+ and KN2/G4 mice determined that IL-4 was required for the normal
expansion of the Th2 cell population(Figure 4.2 and 4.3). However, we are unable
to compare +/- and +/+ mice in the same manner. Different aspects of the Th2
response are sensitive to differences in the concentration of IL-4 to which cells are
exposed. For example, in vitro studies show that 1000-fold lower concentrations of
IL-4 are required to induce IgG1 class-switching than that to IgE[446]. Similarly,
lower concentrations of IL-4 are required to induce MHC-II expression than IgG1
class switching of mitogen-activated B cells in vitro[288]. In our studies, we observed
MHC-II upregulation, but impaired IgG1 class-switching in HDM-immunised +/-
mice (Figure 4.13). While these in vitro experiments were very different to our in
vivo system, this indicates that IL-4 was available in +/- mice, but was at decreased
levels compared to +/+ mice. It is possible that the amount of IL-4 required for nor-
mal expansion of the Th2 cell population also requires lower IL-4 concentrations than
IgG1 switching. It may be possible to determine whether Th2 cell development is also
impaired by examining mRNA transcript levels of other Th2 cytokines, like IL-5, or
examining the development of Th2 cells using a reporter that identifies IL-4 producing
cells without interfering with the wild-type genes. Bacterial artificial chromosomes
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have been used in the past to report Th2 (IL-4) activity[383]. Similarly, using a BAC
transgenic system crossed to +/+, +/- and -/- conditions could accurately determine
how the loss of each allele affects Th2 cell development in vivo. A similar system is
being explored in our lab (Ryan Kyle, personal communication).
It is possible that IL-4 by TFH cells was impaired and Th2 cells developed normally.
Deficient IgG1 switching and IgE production could be caused by functional defects in
the TFH compartment. TFH were shown, in this and earlier studies, to be enriched
in IL-4 producing cells[275, 362, 364]. IL-4-producing cells have also been shown
in vivo to be directly conjugated to IgE class-switched and IgG1 affinity-matured B
cells[275]. Secretion of IL-4 at the immunological synapse, although not exclusively
directed towards the site of interaction[451, 452], may increase by many times the
concentration of IL-4 to which cognate B cells are exposed. Understanding how genetic
lesions in IL-4 production impact Th2 development and B cell responses could clarify
some of the most important events that lead to allergic sensitization.
4.4.8 The effect of IL-4 heterozygosity on the intestinal al-
lergic process
Allergic mastocytosis was also impaired in IL-4+/- mice. In the model we used, al-
lergic mastocytosis and diarrhoea require IL-4 signaling[295]. A number of studies
demonstrate that local intestinal elevation of IL-4 is associated with diarrhoea de-
velopment in mice[37, 38, 57, 299]. Studies also demonstrate that adoptive transfer
of Th2 cells from the mesenteric lymph nodes of mice with diarrhoea can transfer
diarrhoea to naive mice[38]. It is plausible that the loss of a single IL-4 allele re-
duced CD4+ T cell-derived IL-4 from reaching sufficient levels to promote intestinal
mastocytosis. However, Th2-associated cytokines other than IL-4 are also implicated
in the intestinal allergic response[37, 57, 295], or can enhance parasite-induced in-
testinal mast cell expansion[309, 311, 315]. Therefore, it is also possible that Th2
cell development was impaired, resulting in depressed production of other mast cell-
active cytokines. A third explanation is also possible. IgE can activate mast cells
and prolong their survival[30, 45, 453]. In our studies, we observed that alum-based
immunisation resulted in a greater than 90% reduction in systemic IgE titres, both
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prior to- and after- allergen challenge (Figure 4.14 and Figure 4.15). Therefore, it
remains possible that the apparent defect in oral-allergen induced intestinal masto-
cytosis was indirect. Thus, we cannot definitively conclude whether the lesion was
caused by impaired Th2 cell development, impaired Th2 cell function or impaired IgE
production. Clarifying the level at which the impairment in mastocytosis arises has
the potential to dissect specific functions of Th2 cells, and specific roles of IL-4 in the
full allergic process. It will be useful to further clarify the role of IL-4 in this allergic
process in future work.
While CD4+ Th2 cells are implicated in disease development, it also remains possible
that the disease was dependent on IL-4 from other cellular sources. Numerous other
cell types can produce IL-4[300–305, 363, 425] and, therefore, may contribute to the
elevation in Th2-type cytokines that permit jejunal mastocytosis. While the parsi-
monious explanations remain that either local Th2 cytokine levels were too low to
permit disease, or inadequate IgE was generated to sensitize mast cells, clarification
of the role of CD4+ T cells in the intestinal allergic process is required.
Collectively, our investigations highlight the importance of IL-4 in the allergic process.
We observed a contributory role for IL-4 in adjuvant-free Th2 cell development. We
further determined that, like mice lacking both IL-4 alleles[295], missing one allele
impaired IL-4-dependent antibody production, inhibited oral allergen-induced masto-
cytosis and ultimately prevented allergen-induced intestinal anaphylaxis. Determining
which aspect causes the largest lesion could help us understand whether targeting IgE,
targeting IL-4 or targeting allergen-reactive Th2 cells will provide a better long-term
treatment for allergic disease.
4.5 Summary
The pTh2 assay revealed that IL-4 was able to amplify Th2 cell development in a
STAT-6-dependent manner. The loss of a single allele of IL-4 impaired the B cell
class-switch response to IgG1 in IL-4 heterozygous mice immunised intradermally.
IL-4 heterozygosity also caused an impairment in adjuvant-based IgE production and
the subsequent intestinal allergic response.
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Chapter 5
Establishing an allergy-permissive
environment through allergen
exposure in the gut
5.1 Introduction
5.1.1 Assessing the role of CD4+ T cells in the post-sensitization
phase of food allergy
In 2003, Brandt et al.[37], developed an IL-4-, mast cell-, and IgE-dependent model of
oral allergen-induced intestinal anaphylaxis[37, 295]. In this system, mice are first sen-
sitized to OVA by intraperitoneal injection of OVA plus alum adjuvant, and are then
orally challenged with intragastric (i.g.) doses of OVA every second day, eventually
resulting in acute and transient diarrhoea that resolves 120 minutes after oral chal-
lenge. One of the intriguing aspects of this system is that multiple allergen challenges
are required before mice develop diarrhoea. This indicates that oral allergen challenge
of sensitized mice initiates a cascade of inflammatory events that establish the appro-
priate inflammatory milieu to permit subsequent disease triggering. Interestingly, oral
allergen challenge induces jejunal mastocytosis and increases intestinal- and systemic-
IgE production, but when jejunal Th2 cytokine levels are not elevated, disease devel-
opment is inhibited[299]. That is, there is a local inflammatory process invoked by
oral allergen challenge that precedes, but does not guarantee, the development of the
intestinal allergic response. I will refer to this process as oral potentiation, but more
accurately, it is the establishment of a Th2-associated inflammatory environment that
greatly exacerbates (and in the model employed, is required for) intestinally-evoked
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allergic responses to orally administered allergens in previously sensitized mice.
In addition to the outlined findings, further evidence implicates intestinally-localized
CD4+ T cells and Th2-type cytokines in the oral potentiation process[38, 57, 58, 295,
298, 299]. Prior to diarrhoea onset, sequential i.g. OVA challenges increase jejunal IL-
4 levels in wild-type mice[37], promotes IL-4 production by intestinal CD4+ T cells[57,
58], and triggers proliferation of- and α4β7 expression on- OVA-specific CD4+ T
cells[38]. Adoptive transfer of OVA-restimulated CD4+ T cells from mesenteric lymph
nodes of diarrhetic mice transfers disease susceptibility to naive mice[38]. CD4+ Th2
cell responses are also observed in the intestinal tissue of allergic individuals in the
clinic[90, 454]. To more closely dissect the involvement of CD4+ T cells in local
oral potentiation, we investigated how their depletion at different stages of the post-
sensitization allergic process affects disease progression.
Much is still unknown about the immune molecules that govern allergic mastocy-
tosis. This is an important issue, because the in the mouse, severity of the orally-
induced anaphylactic response correlates with the number of mast cells present in the
intestine[36]. It is known that stem cell factor (SCF) is required for the presence of
mast cells in the intestine at baseline[307], and IL-3, IL-4 and IL-9 amplify intesti-
nal mast cell infiltration caused by parasite infection[311–313]. In agreement with
this contributory role of these cytokines in the intestinal mast cell response, mice
deficient in either IL-4 or IL-9 are protected from mast cell-dependent experimen-
tal allergic diarrhoea[57, 295]. Similarly, blockade of IL-4R signaling impairs disease
development[295] and over-expression of IL-9 increases basal jejunal mastocytosis and
promotes intestinal allergic disease[57]. However, it remains to be established whether
IL-3 contributes to allergic intestinal mastocytosis and this may be a critical, previ-
ously uncharacterized component of the intestinal allergic process.
The experiments in this chapter aimed to clarify the role of CD4+ T cells and mast
cell-active cytokines in the orally-induced allergic response.
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5.2 Aims
In this section, we investigate the role of CD4+ T cells and non-classical Th2 cytokines
in the post-sensitization allergic process.
Our specific aims were:
1) To establish if CD4+ T cells are required for allergic diarrhoea;
2) To determine whether CD4+ T cells contribute to disease maintenance;
3) To elucidate whether IL-3 is involved in experimental food allergy.
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5.3 Results
5.3.1 The role of CD4+ T cells in oral potentiation
Our initial experiments focused on the role of CD4+ T cells in allergic diarrhoea.
It is established that Th2 CD4+ T cells are increased in intestinal tissues of orally-
challenged mice[57, 58] and that adoptive transfer of CD4+ T cells can render naive
mice susceptible to allergic diarrhoea[38]. While IgE and mast cells are critical medi-
ators of oral allergen-induced diarrhoea[37], numerous studies demonstrate that the
presence of IgE, and of mast cells, does not automatically render mice susceptible to
disease[57, 67, 299]. We were therefore interested to determine whether CD4+ T cells
were influencing disease susceptibility over and above their established contribution
to systemic IgE generation[275, 289, 392].
We first sensitized mice, then subsequently depleted them of CD4+ T cells with
GK1.5. Mice were then i.g. challenged with 50 mg OVA and monitored for diarrhoea
development. The sensitization, depletion and challenge regimen is shown (Figure
5.1A). We observed that sensitized, mock-depleted mice developed diarrhoea after
6-10 oral challenges, whereas sensitized-CD4-depleted mice were entirely protected
from disease (Figure 5.1B). Sixty minutes after the final i.g. challenge, mock-depleted
mice lacked colonic pellets and had voided caecae, which contrasted with the visible
pellets and normal caecal content of CD4-depleted mice (Figure 5.1G). With sequen-
tial gavages we observed increases in total- and OVA specific-IgE titres in mock-
depleted mice, which were prevented in CD4-depleted mice (Figure 5.1E and F). We
also observed approximately 100-fold less mMCP-1 and reduced jejunal mastocytosis
in CD4-depleted OVA-challenged mice (Figure 5.1C and D). This demonstrates that
oral allergen-induced jejunal mastocytosis is CD4+ T cell dependent. In a second
experiment, we showed that although CD4-depleted mice were protected from diar-
rhoea they remained susceptible to i.v.-induced systemic anaphylaxis (Figure 5.2 B
and 5.2C). This was observed both with and without oral OVA challenge (Figure
5.2 B and 5.2C). While some of the mice in the PBS-fed group succumbed to fatal
anaphylaxis, further experiments would be required to validate whether this reflects
a protective effect of oral challenge in the absence of CD4+ T cells. It was therefore
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specifically the development of an intestinal allergic response that was prevented by
depletion of CD4+ T cells. These data indicate that the development an intesti-
nal allergic response was prevented by depletion of CD4+ T cells, however, systemic
sensitization was maintained in the absence of CD4+ T cells.
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Figure 5.1: CD4+ T cell depletion prevented diarrhoea and oral potenti-
ation. Mice (n=4/group) were sensitized to OVA, depleted of CD4+ T cells with
GK1.5 or mock-depleted with Rat IgG and i.g. challenged with OVA as outlined in
(A). (B) Diarrhoea development was monitored 45-90 minutes after i.g. OVA chal-
lenge of CD4+ T cell-depleted (white boxes) and mock-depleted (black boxes) mice.
(C) Chloroacetate esterase stained cells (CAE+; mast cells) in jejunal sections col-
lected 60 minutes after the final challenge. (D) Serum mMCP-1, (E) Total IgE and
(F) OVA-specific IgE were analysed by ELISA after the stated number of i.g. OVA
challenges. Data are represented as group mean±SEM. (G) Colons and caeca of mock-
depleted (IgG) and CD4-depleted (GK1.5) mice were excised 60 minutes after the final
challenge and photographed. Data are shown from a single experiment and were com-
pared (C) using Student’s t-test or (D-F) using Two-way ANOVA with Bonferroni’s
post-test. *p<0.05, **p<0.01, ****p<0.0001. mMCP-1 data were log-transformed
prior to analysis.
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Figure 5.2: CD4+ T cell depletion did not prevent systemic anaphylaxis.
Mice (n=4/group) were sensitized and depleted of CD4+ T cells and subsequently fed
with OVA or PBS as indicated in (A). (B) OVA-fed mice (Black triangles) or PBS-
fed mice (White triangles) were monitored for diarrhoea development 45-90 minutes
following each challenge. (C) 72 hours after the final gavage, mice shown in (B), or
naive mice (plus symbols; n=2) were i.v.-administered 100 µg OVA and monitored
for rectal temperature. Data are shown from a single experiment and points show
mean±SEM of groups. x symbols denote one death in the PBS-fed CD4-depleted
group (three total).
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To determine whether short-term CD4+ T cell depletion conferred long-term pro-
tection from allergic diarrhoea, we depleted CD4+ T cells from sensitized mice and
then allowed them to replenish during the oral challenge period. We observed that
peripheral depletion lasted approximately two weeks (Figure 5.3A). During this time,
we monitored mice for diarrhoea. Initially we observed that CD4-depleted mice were
protected from allergic diarrhoea, however, diarrhoea eventually manifested in 60 per-
cent of mice (Figure 5.3B). This correlated closely in time with the re-emergence of
peripheral CD4+ T cells (c.f. Figure 5.3A and 5.3B). While we observed augmented
OVA-specific antibody production in mock-depleted mice, but changes in antibody
titres were negligible in the CD4-depleted group until they were CD4-replete (Fig-
ure 5.3C and 5.3D). Jejunal mastocytosis, serum mMCP-1 titres, and the amount of
caecal washout were reduced in CD4-replete mice compared to mock-depleted mice
(Figure 5.3E - G). Taken together, these findings indicate that CD4+ T cells play a
central role in the development of the intestinally localized allergic response.
158
BC
D
A FE
G IgG GK1.5 Unsens.
1
10
100
1000
10000
100000
1000000
m
M
CP
-1
 (n
g/
m
L)
*** ***
*
Figure 5.3: Diarrhoea development correlated with the re-emergence of
CD4+ T cells. Mice (n=5/group) were unsensitized (crosses and grey bars) or
sensitized and mock-depleted (black boxes and bars) or i.p. administered 0.5 mg
GK1.5 (white boxes and bars) then i.g. challenged with 50 mg OVA as depicted
on the x-axis of (D). (A) Live peripheral blood CD3+ cells were examined for CD4
expression by flow cytometry before and after GK1.5 administration, mock-depletion
or in unsensitized mice. CD4 depletion was significant versus both other groups at
all post-depletion timepoints to p<0.0001. Groups were monitored for (B) diarrhoea
development, (C) OVA-specific antibody production, (D) total IgE, and (E) endpoint
mMCP-1 release 90-120 minutes after challenge. The horizontal dash in (D) shows
the linearity limit of the assay. (F) Ninety minutes after the final challenge mice were
euthanized and jejunal section were stained with CAE to quantify mast cells. (G)
The picture shows caeca from two representative mock-depleted (IgG), CD4-depleted
(GK1.5) or unsensitized (Unsens.) mice after final challenge. Data are shown from
a single experiment and were compared (C,D) using Two-way ANOVA with Bonfer-
ronis post-test versus unsensitized mice; (E,F) using One-way ANOVA with Tukey’s
post-test; *p<0.05, **p<0.01, ***p<0.001. OVA-specific antibody and mMCP-1 data
were log-transformed prior to statistical analysis.
5.3.2 Segregating CD4+ T cell-dependent mastocytosis and
IgE production
Passive sensitization with IgE enhances mast cell survival, antigen responsiveness and
histamine release[30, 45, 293, 314, 453]. As well as producing effector cytokines in
the tissue[57], CD4+ T cells control memory B cell activation [288, 407] and are the
predominant source of IL-4 required for IgE class switching[275, 287, 289, 362]. It was
therefore possible that CD4+ T cell depletion prevented antibody titres from reaching
sufficient levels to permit disease, and this was the reason the treatment prevented
diarrhoea. To determine if systemic antibody production was a limiting factor in
intestinal disease development, we increased initial IgE titres by i.p. sensitizing mice
multiple times prior to CD4+ T cell depletion (Figure 5.4A). Diarrhoea developed with
similar kinetics in twice- and thrice-primed mock-depleted mice (Figure 5.4B). While it
was delayed compared to mock-depleted mice, the incidence of diarrhoea also increased
at similar rates in twice- and thrice-primed CD4-depleted mice (Figure 5.4B). mMCP-
1 production was also impaired in CD4-depleted mice (Figure 5.4C), and only mock-
depleted mice had statistically elevated jejunal mast cell numbers of PBS-fed mice
(Figure 5.4D). However, there was a clear trend indicating mastocytosis increased in
CD4-depleted mice by the end of the experiment (Figure 5.4D). In this experiment,
we observed that CD4+ T cell depletion was maintained in both twice- and thrice-
primed mice for the first five challenges (Figure 5.4E), but as they returned in thrice-
primed mice, Total IgE levels began to increase (Figure 5.4F). However, critical to our
results, after five oral challenges, CD4-depleted thrice-primed mice maintained similar
Total IgE and OVA-specific IgE levels to mock-depleted twice-primed mice, but were
protected from disease (Figure 5.4B-D). By the 5th challenge 50% of twice-primed
mock-depleted mice had developed diarrhoea (Figure 5.4B). Thus, antibody titres
were sufficiently high in CD4+ T cell-depleted mice to permit disease, but disease did
not develop, indicating that CD4+ T cells promoted jejunal mastocytosis in a manner
that was independent of their involvement in systemic antibody production.
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Figure 5.4: High-titre IgE can only confer disease susceptiblity in the pres-
ence of CD4+ T cells. Mice (n=5/group) received two (2P; circles) or three (3P;
squares) i.p. injections of OVA plus alum adjuvant as indicated in (A), were adminis-
tered GK1.5 (aCD4; white symbols) to deplete CD4+ T cells or were mock-depleted
with polyclonal Rat IgG (+CD4; black symbols) and from week six were i.g. chal-
lenged with OVA or PBS (PBS). Twice-primed mice that were fed PBS served as con-
trols (PBS; crosses). The full protocol is shown in (A). (B) Diarrhoea was monitored
after each challenge. (C) mMCP-1 was determined by ELISA. (D) CAE+ (Mast)
cells were examined in jejunal sections of mice after the last challenge. (E) Mice
were periodically bled to monitor peripheral CD4 T cell blood content. (F) Total
and (G) OVA specific-IgE were monitored during the experiment. Data are repre-
sented as group mean±SEM. Data are shown from one experiment and were analysed
(C) using Two-way ANOVA, OVA-challenged non-depleted mice versus thrice-primed
CD4-depleted mice, or (D) using One-way ANOVA with Tukey’s post-test. p<0.001.
*p<0.05, **p<0.01, ***p<0.001, ***p<0.001. Similar observations were made in
a second experiment comparing only thrice-primed GK1.5-treated mice and twice-
primed mock-depleted groups. (n=5/group).
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5.3.3 Examining the role of CD4+ T cells in disease mainte-
nance
CD4+ T cells were required for diarrhoea to be exhibited. This lead us to ask if CD4+
T cells maintained local responses after oral potentiation. Next we investigated how
CD4+ T cell depletion affected established disease. We orally challenged mice until
they presented with diarrhoea, then depleted them of CD4+ T cells (Figure 5.5).
Administration of GK1.5 depleted CD4+ T cells to <1 per 4000 peripheral blood
CD3+ T cells, whereas mock-depleted animals maintained a proportionally normal
T cell pool (Figure 5.5A). This level of depletion was maintained by GK1.5 injection
every four days and was also observed in all peripheral tissues, including the intestine
at the experimental end-point (Figure 5.5B and 5.5C). Reciprocal increases in the
CD8+ proportion were observed in all tissues (Appendices Figure 8.4). Prior to
depletion, both OVA-challenged groups had similar mMCP-1 serum titres (Figure
5.5E, left), but after CD4+ T cell depletion, challenge-induced mMCP-1 release was
decreased (Figure 5.5E, right). This correlated with fewer mast cells in jejunal tissues
of CD4-depleted mice at the experimental end-point (Figure 5.5F), and lower levels
of Total and OVA-specific IgE than mock-depleted controls following the depletion
(Figure 5.5G). Despite reduction in Th2-associated parameters, diarrhoea ensued in
the majority of CD4-depleted mice for at least seven further challenges (7/10 mice;
Figure 5.5D). We also observed that while Total and OVA-specific IgG2a titres were
unaltered (Figure 5.6A and 5.6B), CD4-depleted mice had lower Total and OVA-
specific IgG1 titres than mock-depleted mice (Figure 5.6C and 5.6D), and fewer splenic
and bone marrow OVA-IgG1 antibody secreting cells (ASCs) (Figure 5.6E and 5.6F).
Total or OVA-specific IgG2a titres were unaltered (Figure 5.6A and 5.6D). These data
suggest that while CD4+ T cells maintained underlying disease susceptibility, once
instated, the response could be triggered for long periods in their absence.
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Figure 5.5: Orally primed mice exhibited diarrhoea even in the absence of
CD4+ T cells. Mice were sensitized and orally challenged with OVA ten times, at
which point all challenged mice had developed diarrhoea. One group was then admin-
istered GK1.5 to deplete CD4+ T cells and the depletion was maintained throughout
the experiment. Sensitized mice that were fed with PBS alone served as baseline
controls. Black boxes and bars represent non-depleted mice, white boxes and bars
represent CD4-depleted mice, and grey bars and black crosses represent baseline con-
trols. The experimental regimen is outlined on the x-axis in (A). The dashed lines
in (A) and (D) represent the point at which CD4+ T cells were depleted. (A) Live
CD3+ peripheral blood cells were monitored for CD4 expression by flow cytometry.
(B) After the final i.g. feed, mice were euthanized and blood, bone marrow, spleen,
mesenteric lymph nodes (MLN), peyers patches (PP) and the jejunal lamina propria
(LPL) were examined by flow cytometry for the proportion of live CD45+CD3+ T
cells that expressed CD4. (C) The intraepithelial compartment was assessed for CD4+
T cells as in (B). (D) Diarrhoea was monitored in PBS-fed or OVA-fed mice adminis-
tered GK1.5 or Rat IgG at the dashed line. The photo shows diarrhoea in mice from
the specified groups after challenge seventeen. (E) Serum mMCP-1 was measured
following challenge ten (left; prior to depletion) and fourteen (right; after depletion).
(F) At the experimental endpoint, jejunal sections were examined for CAE+ cells.
(G) Serum Total IgE and (H) OVA-specific IgE was measured by ELISA. Data in
(B-D) are combined from two experiments (n=8 PBS-fed; n=9 Mock-depleted; n=10
CD4-depleted) mice and (A, E-H) are shown from one of the two similar experiments
with (n=4-5) mice/group, because the exact timings of the analyses were not iden-
tical. Data were compared (A, B, G, H) using Two-way ANOVA with Bonferroni’s
post-test, (C) using Kruskall-Wallis with Dunn’s post-test, or (E, F) using One-way
ANOVA with Tukey’s post-test; *p<0.05, **p<0.01,***p<0.001,****p<0.0001.
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Figure 5.6: CD4+ T cell depletion diminished the Th2-associated antibody
response. OVA-sensitized mice fed with PBS (grey bars), or administered GK1.5
(white bars) or Rat IgG (black bars) after ten oral OVA feeds (shown in Figure 5.5)
were bled at the experimental end-point. Sera were analysed for (A) Total IgG2a, (B)
OVA-specific IgG2a, (C) Total IgG1, (D) OVA-specific IgG1. (E,F) Anti-OVA-IgG1
antibody secreting cells (ASCs) were quantitated in the bone marrow or spleens. Data
represents mean±SEM of (n=3-5) mice from one of two similar experiments. Data
were analysed using One-way ANOVA with Tukey’s post-test; *p<0.05, **p<0.01,
****p<0.0001.
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5.3.4 The role of CD4+ T cells in systemic responses after
oral potentiation
Oral potentiation has been shown to increase the severity of systemic anaphylaxis
induced by i.v. allergen challenge[37]. In a final experiment using GK1.5, we examined
the development of systemic anaphylaxis in mice depleted of CD4+ T cells after oral
potentiation.
Similar to the previous experiment, mice were challenged until diarrhoea presented,
and were depleted of CD4+ T cells for the remainder of the experiment. Again,
diarrhoea ensued in the absence of CD4+ T cells (Figure 5.7A). In contrast to the
previous report[37], when mice were administered 100 µg OVA i.v. 48 hours after
oral challenge, i.p.-sensitized mice demonstrated equivalent hypothermia severity, ir-
respective of whether they were fed OVA or not (Figure 5.7B). Unexpectedly, evidence
of anaphylactic diarrhoea appeared only in mice that had been orally primed, because
10-15 minutes after i.v. challenge, only mice that had previously received oral OVA
challenges had matted fur around the anus (Figure 5.7C). This occurred in both CD4-
depleted and mock-depleted groups(Figure 5.7C), and was not observed in these mice
when temperatures were monitored prior to i.v.-challenge. Antibody levels were simi-
lar to those reported in the previous experiment (Figure 5.7D-G). These data suggest
that oral potentiation may alter the physiology of the gut, or the gut content, to
permit intestinal involvement in the i.v.-induced allergic response.
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Figure 5.7: Orally-primed mice developed i.v.-induced anaphylaxis with or
without CD4+ T cells. (A) Mice were sensitized and fed OVA (boxes) or PBS
(crosses). After ten challenges OVA-fed mice were administered three 0.5 mg doses
of GK1.5 (white boxes) or Rat IgG (black boxes), 24 hours apart, after the tenth
challenge indicated by the dashed line in (A). (B) Forty-eight hours after the final oral
challenge mice were administered 100 µg OVA i.v. and monitored for temperature
changes. Completely naive mice (plus symbols) treated with 100 µg OVA i.v. served as
unsensitized controls. (C) mice were photographed 10-25 minutes after i.v. challenge.
Bottoms were normal prior to i.v. challenge. Mice were bled 24 hours after the final
oral challenge, prior to i.v. challenge and sera were analysed by ELISA for (D) Total
IgE, (E) OVA-specific IgE, (F) OVA-specific IgG1, (G) OVA-specific IgG2a. Data
represent group mean±SEM; n=3 (naive), n=4 (PBS), or n=5 mice/group from one
experiment. Data were compared using One-way ANOVA with Tukey’s post-test;
**p<0.01.
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5.3.5 Influence of CD4+ T cells on plasma volume loss
Similar to studies of others[57], we demonstrated that diarrhoea development in orally-
primed mice correlated with an increase in blood haematocrit (Figure 5.8A). This
provides an additional method by which to assess the development of an intestinal
allergic response. In our first experiment in this chapter, mock-depleted mice devel-
oped diarrhoea and CD4-depleted mice were protected from diarrhea (Figure 5.1).
Simiarly, we observed elevated blood haematocrit in mock-depleted mice with active
diarrhoea (Figure 5.8B), but not in the CD4-depleted mice (Figure 5.8B and 5.8C),
whereas mice that had developed diarrhoea prior to their CD4-depletion showed sim-
ilar increases in their haematocrit to mock-depleted mice (figure 5.8D). While naive
mice were not analysed, the PBS-fed groups and prior-to-challenge groups indicate
that there was indeed a change in blood plasma volume associated with the diarrhea.
Therefore, mice that presented with diarrhoea lost fluid volume in both the presence
and the absence of CD4+ T cells.
Taken together, these data suggest that CD4+ T cells were required for oral allergen-
induced intestinal mastocytosis that permitted allergic diarrhoea. Once established,
however, intestinal allergy persisted for long periods in the absence of CD4+ T cells.
Further mice remained susceptible to systemic i.v.-induced anaphylaxis in the absence
of CD4+ T cells with or without prior oral potentiation.
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Figure 5.8: Haematocrit increases in intestinally anaphylactic mice with or
without CD4+ T cells. (A) OVA-sensitized mice were bled before and after the
ninth oral gavage with OVA or PBS and their haematocrit was assessed. All OVA-fed
mice had active diarrhoea at the time of bleeding. (B) Mice shown in (Figure 5.1) were
bled prior to and following the ninth i.g. challenge for haematocrit. (C) Mice depleted
of CD4+ T cells prior to being fed OVA or PBS with depletions maintained thereafter
(same mice as in Figure 5.2) were bled for haematocrit prior to and following the ninth
i.g. challenge. (D) After the thirteenth i.g. challenge, mice shown in Figure 5.7 were
bled for haematocrit. data in each (A-D) is from a single experiment (n=3-5/group).
Data were analysed using (A-C) Mann-Whitney U-test or (D) using Kruskal-wallis
with Dunn’s post-test; *p<0.05.
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5.3.6 The cytokines that influence allergic mastocytosis
In addition to supporting orally induced IgE production, CD4+ T cells promoted
mastocytosis in an additional process. In addition to IL-4 and IL-9, IL-3 is implicated
in Th2-type intestinal mast cell responses. Whether oral allergen-induce mastocytosis
is dependent on IL-3 is unknown.
As a start point, because IL-3 is associated with a Th2-type intestinal response[315],
and allergic diarrhoea is associated with a Th2 cell profile[37, 57, 58], we were inter-
ested to determine if Th2 conditioning would trigger IL-3 production from T cells. We
examined the production of IL-3 by anti-CD3 stimulated splenocytes cultured under
Th0, Th1 and Th2 conditions. When total spleen cells were added to culture medium
containing IL-4 (Th2 conditioning medium) and stimulated with anti-CD3 for three
days, splenocyte IL-3 production reached approximately 5 ng/mL, whereas under Th0
or Th1 conditions levels were lower, reaching 1 and 0.5 ng/mL respectively (Figure
5.9A). Similarly, when total splenocytes were washed and transferred to uncoated or
new anti-CD3 plates without additional IL-4, the amount of IL-3 produced in pre-
conditioned Th2 spleen cell cultures was 4-5-fold higher than under Th1 conditions
(Figure 5.9B). When parallel cultures were stained for intracellular cytokine, 10% of
CD4+ T cells from the Th2 splenocyte cultures stained positive for IL-3 after the
six hour culture period, whereas only 2% of Th1 cultured cells contained intracellu-
lar IL-3 (Figure 5.9C). Therefore, we determined that Th2 conditions promoted IL-3
production by CD4+ T cells.
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Figure 5.9: Th2 cells produced more IL-3 than Th1 cells. (A) Splenocytes were
cultured for three days on uncoated (Unstimulated) or anti-CD3 coated (Stimulated)
plates under Th0 (grey) Th1 (white) or Th2 (black) conditions and supernatants were
analysed for IL-3 by ELISA. (B) After three days stimulation on anti-CD3 under Th0
(grey) Th1 (white) or Th2 (black) conditions splenocytes cultured from individual
mice were washed, transferred to restimulation medium and replated in uncoated
(Rested) or anti-CD3-coated wells (Restimulated) for 6 hours and supernatants were
analysed for IL-3 by ELISA. (C) Side-by-side cultures of cells in (B) had monensin
added after 4 hours of culture and were stained for intracellular IL-3 two hours later.
Data are represented by mean±SEM: (A) individually cultured spleens (n=4) were
collated from two experiments; data in (B and C) individually stimulated IL-3+/+
spleens (n=7) collated from three separate experiments. In one experiment IL-3-/-
mouse spleens (n=2) were included to test antibody specificity, and in (B) one spleen
was not analysed under Th0 conditions due to a low cell yield. NA=Not assessed. For
restimulation, 500000 cells from activated wells were replated from each condition and
restimulated in medium containing IL-2 and anti-CD28. Data were analysed using
Two-way ANOVA with Bonferroni’s post-test; *p<0.05, **p<0.01, ****p<0.0001.
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IL-3 production is known to promote the development of mast cells, but also con-
tributes to basophil development from bone marrow cells. Recent evidence demon-
strates that Thymic Stromal Lymphopoeitin (TSLP) can also promote the devel-
opment of basophils from bone marrow cells[429], and TSLPR-deficient mice show
reduced disease incidence in this model[132]. This led us to investigate a potential
and unknown role for TSLP in mast cell generation. However, while we showed that
TSLP caused a significant increase in the proportion of basophils induced to produce
IL-4 (as observed previously[429]) in G4/+ mice (Figure 5.10E and 5.10F), only IL-3-
containing cultures caused mast cells to develop (Figure 5.10C and 5.10F). Mast cells
are the key effector cell in the ipig model of allergic diarrhoea[37], indicating that
while TSLP may be involved in the allergic process[132], IL-3, rather than TSLP,
promoted mast cell development from bone marrow cells.
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Figure 5.10: IL-3 but not TSLP caused mast cells to develop in vitro. Bone
marrow was isolated from (n=3) +/+ (black bars) or (n=3) G4/+ (white bars) mice
cells were cultured from each individual mouse for five days in the presence of 10
ng/mL IL-3, 1 µg/mL TSLP, both IL-3 and TSLP or medium alone. (A) Total
cells were counted by trypan blue exclusion and numbers were used to back-calculate
numbers of (B) basophils and (C) mast cells ascertained by flow cytometry. (D) The
proportion of mast cells that expressed GFP and (E) the proportion of basophils that
expressed GFP were assessed in each culture. (F) Left plots show the cKithiFceRI+
population used to define mast cells and the cKitlowFceRI+ cells that were further
examined for DX5 and GFP expression (basophils; right plots). Data are shown
from one experiment. Data were compared using Two-way ANOVA with Bonferroni’s
post-test; **p<0.01 +/+ versus G4/+.
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Allergic mastocytosis and diarrhoea were impaired in IL-3-
deficient mice.
To determine the potential involvement of IL-3 in CD4+ T cell-, IgE- and mast cell-
dependent allergic intestinal anaphylaxis, we examined the development of allergic
diarrhoea in IL-3-/- mice. When IL-3-/- mice were sensitized i.p. to OVA/Alum,
Total and OVA-specific IgE were detected in serum (Figure 5.11B and C). Similar to
wild-type mice, their Total and OVA-specific IgE levels increased following oral gavage
challenge (Figure 5.11B and C), albeit to lower absolute levels than IL-3+/+ mice. IL-
3-/- mice were protected from allergic diarrhoea (Figure 5.11A and G) and at the ex-
perimental end-point their intestines still contained numerous pellets (Figure 5.11F).
Oral OVA challenge did not increase haematocrit in IL-3-/- mice, nor in PBS-fed
IL-3+/+ mice; haematocrit in both groups remained close to 47.5%, whereas haema-
tocrit was increased to approximately 60% of blood volume in diarrhoetic OVA-fed
IL-3+/+ mice (Figure 5.11D). When we examined the mast cell response, mMCP-1
levels were lower in IL-3-/- mice (Figure 5.11E), and this correlated with fewer jejunal
mast cells in OVA-fed IL-3-/- mice than IL-3+/+ mice (Figure 5.11F). Differences in
jejunal mast cell frequencies at baseline were not statistically distinguishable, in line
with no requirement for IL-3 for basal mastocytosis as reported by other groups[309].
In preliminary examinations we also observed similar Th2 cytokine production in
spleen cell preparations from OVA-sensitized IL-3+/+ and IL-3-/- mice (Appendix
Figure 8.5A - D). Further, similar to an earlier study[455], we found that both IL-
3+/+ and IL-3-/- mice were susceptible to i.v. allergen-induced systemic anaphylaxis
(Figure 5.12B). This occurred even when IL-3-/- mice were fed with OVA (Figure
5.12B). Therefore, these data suggest that IL-3 was required for the generation of an
intestinally-localised mast cell-dependent allergic response.
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Figure 5.11: IL-3-/- mice were protected from allergic diarrhoea. (A) OVA-
sensitized IL-3-/- and IL-3+/+ mice were i.g. fed with OVA or PBS and monitored
for diarrhoea development. (B) Total IgE and (C) OVA-specific IgE were measured
by ELISA. (D) Haematocrit (%PCV) was measured 50 minutes after challenge 9 and
(E) mMCP-1 release was measured after challenge ten. (F) Jejunal sections from mice
challenged ten times were stained for CAE+ (mast) cells. Photographs were taken of
(G) colons 90 minutes after challenge ten or (H) bottoms 60 minutes after challenge
nine. Genotypes are specified at the top of the page. (A) Diarrhoea curves are shown
from one of five similar experiments each with (n=4-5) mice/group. (D) %PCV was
measured once and all other data were analysed in three of the experiments with
similar results in each case. Data are represented by mean±SEM. Data were analysed
(B,C) using Two-way ANOVA with Bonferroni’s post-test, OVA-fed IL-3-/- vs. PBS-
fed IL-3-/- mice or (D-F) using One-way ANOVA with Tukey’s post-test; *p<0.05,
**p<0.01, ***p<0.001.
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Figure 5.12: IL-3-/- mice were susceptible to i.v.-induced systemic anaphy-
laxis. (A) Wild-type and (B) IL-3-/- mice were sensitized to ovalbumin and chal-
lenged six times with PBS or OVA and then received 100 µg OVA i.v. and temperature
change was monitored. Data are represented by mean±SEM from a single indepen-
dent experiment (n=2-3 mice/group).
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5.3.7 The relative influence of IL-3 and IL-9 on allergic mas-
tocytosis
Mice carrying a single allele of the iFABPp-IL-9 transgene (Tg+/+) over-express IL-
9 locally in the jejunum[57]. This increases basal mast cell activity and predisposes
mice to allergic diarrhoea and is also associated with higher oral allergen-induced mast
cell activity compared with non-transgenic mice[57]. We next investigated whether
over-expression of IL-9 could amplify jejunal mastocytosis in the absence of IL-3.
In these experiments we compared Tg+/+ mice to IL-3-deficient mice carrying the
transgene (Tg-/-), and sib-matched non-transgenic IL-3-deficient mice (nTg-/-). nTg-
/- is used to distinguish between IL-3-/- mice and IL-3-deficient mice sib-matched to
Tg-/- mice.
When sera were analysed from naive Tg+/+ mice, Tg-/- and nTg-/- mice, mice
carrying the transgene had 4- to 5-fold higher serum mMCP-1 levels than nTg-/-
mice (Figure 5.13A). Similarly, when jejuni were sectioned and examined for CAE+
mast cells, CAE+ cells were on average, twice as frequent in naive Tg-/- mice than
naive nTg-/- mice(Figure 5.13B). CAE+ cells were present at similar levels in naive
Tg-/- mice as in naive Tg+/+ mice (Figure 5.13B). Therefore, in the absence of IL-3,
over-expression of IL-9 in the jejunum increased basal jejunal mast cell activity.
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Figure 5.13: The iFABPp-IL-9 transgene enhances basal jejunal mast cell
activity in IL-3-deficient conditions. (A) serum mMCP-1 and (B) Jejunal CAE+
cells were determined in naive mice of the specified genotype. Pictures are representa-
tive sections of CAE staining from one high power field (HPF). Lines represent mean
±SEM of (n=17 mice/group) combined from 3 separate experiments using (n=5-7
mice/group). Data were analysed using One-way ANOVA with Tukey’s post-test;
*p<0.05, **p<0.01.
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Next, we compared the development of allergic diarrhoea in Tg+/+, Tg-/- and nTg-/-
mice. After two i.p. primes with OVA, mice of all three genotypes had approximately
2 µg/mL Total IgE and OVA-specific IgE levels were similar (Figure 5.14D-F). With
multiple i.g. OVA challenges, OVA-specific IgE levels increased to similar levels in the
three OVA-fed groups (Figure 5.14D) and Total IgE levels increased to 4-6 µg/mL
in all three groups of OVA-fed mice by the experiment end-point (Figure 5.14E-G).
Similar to our previous observations in IL-3-/- mice, nTg-/- mice did not develop
diarrhoea (Figure 5.14A). Tg-/- mice also did not exhibit symptoms of diarrhoea
(Figure 5.14A). mMCP-1 levels were low in PBS-fed nTg-/- mice and did not increase
during gavage challenge (Figure 5.14B). Tg+/+ and Tg-/- mice again had elevated
baseline mMCP-1 levels compared to nTg-/- mice and these remained low in PBS fed
groups throughout the experiment (Figure 5.14B). OVA-fed mice of all genotypes had
100- to 200-fold increases in serum mMCP-1 levels compared to PBS-fed counterparts
(Figure 5.14B) and these were highest in OVA-fed Tg+/+ mice, reaching ≈50000
ng/mL following the 10th i.g. OVA challenge (Figure 5.14B). While mMCP-1 levels
in Tg-/- mice were elevated over nTg-/- mice by ten-fold after challenge 5, their
mMCP-1 levels did not reach the levels in Tg+/+ mice at any post-challenge point
(Figure 5.14B). When we examined jejunal mast cell infiltration at the experimental
end-point, jejunal mast cell density was highest in OVA-fed Tg+/+ mice (Figure
5.14C) and the number of mast cells correlated approximately with serum mMCP-1
concentration (c.f. figure 5.14B and C). When we examined mesenteric lymph node
cell expression of IFN-γ, IL-3, IL-4, IL-5 and IL-13 upon restimulation with OVA no
significant differences were observed IL-3 between Tg+/+, Tg-/- and nTg-/- cultures
except for the absence of IL-3 in IL-3 deficient mice (Appendix Figure 8.6A - E).
These data suggest that high local IL-9 levels were not sufficient compensation to
permit oral allergen-induced mastocytosis in the absence of IL-3.
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Figure 5.14: IL-3 is required for diarrhoea development in mice with high
basal mast cell activity. OVA-sensitised Tg+/+ (Squares), Tg-/- (circles), nTg-
/- (triangles) mice (n=4/group) were fed with OVA (black) or PBS (white). (A)
Diarrhoea development was monitored after oral gavage. (B) During the experiment,
mice were bled after the stated number of challenges and serum mMCP-1 levels were
determined by ELISA. (C) At the experiment end-point, jejunal sections were stained
for CAE+ cells in the indicated groups. (D) OVA-specific IgE and (E-G) Total IgE
were examined in each strain. Data are shown from a single experiment and represent
group mean±SEM. Data were compared using Two-way ANOVA with Bonferroni’s
post-test; ****p<0.0001.
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With these experiments we demonstrated that IL-3-/- mice had impaired allergen-
induced jejunal mast cell infiltration. Next we tested whether one IL-3 allele was
sufficient to permit oral allergen-induce mastocytosis, or whether both IL-3 alleles
were required. iFABPp-IL-9 mice are predisposed to oral sensitisation[57], so in this
experiment, mice were orally challenged seven days after their i.p. prime. In this
setting, when Tg+/+ mice were orally challenged with OVA, disease penetrance did
not reach 100%, precluding interpretation of the impact of IL-3-heterozygosity on
diarrhoea (Figure 5.15A). However, we were able to investigate the relative level of
oral potentiation that had occurred by examining serum mMCP-1, IgE and jejunal
mast cell infiltration. We observed that despite similar OVA-specific IgE levels at
the experiment end-point (Figure 5.15C), jejunal mastocytosis was only significantly
elevated in Tg+/+ mice, indicating that the loss of one IL-3 allele resulted in a partial
impairment in intestinal mast cell infiltration (Figure 5.15B).
Numbers of CAE+ cells were higher in Tg+/- mice compared to naive Tg+/+ mice
(shown by the dashed line in figure 5.15B), indicating that the increase in mast cells
was not due to the presence of the transgene alone (Figure 5.15B). In this modified
experimental system, Total IgE did not increase after i.g. OVA challenge (Figure
5.15D). i.g. OVA challenge caused mMCP-1 levels to increase in all groups of mice.
Following the 9th challenge mMCP-1 levels corrrelated with the number of CAE+ cells,
and not with OVA-IgE O.D. values (c.f. figure 5.15B and E, versus figure 5.15B and
C). These data indicate that the loss of one IL-3 allele caused a partial reduction in
allergen-induced intestinal mastocytosis and further suggest that the IL-9 transgene
was able to increase oral-allergen induced mast cell activity in IL-3 heterozygous
conditions.
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Figure 5.15: Lack of a single IL-3 allele causes a partial defect in allergen-
induced intestinal mastocytosis. (A) Seven days after a single i.p. sensitisation,
mice (n=5/group) were fed 50 mg OVA and monitored for diarrhoea development.
(B) At the experimental end-point, jejunal CAE+ cells were quantified in each strain.
The dashed line shows the mean number of mast cells in naive Tg+/+ mice sectioned
in this experiment. (C) Before (0) and after (9) nine oral OVA challenges sera were
analysed for OVA-specific IgE, (D) Total IgE and (E) mMCP-1 by ELISA. Data
are represented by group mean±SEM (n=5 mice/group) from a single experiment.
**p<0.01, ***p<0.001 by One-way ANOVA with Tukey’s post-test.
5.3.8 Assessing the role of IL-3 in i.v.-induced intestinal al-
lergy
In our studies with GK1.5 we observed that after a rest period, i.v. challenge of
orally primed mice resulted in diarrhea. We sought to expand on these studies by
quantifying the relative level of diarrhea by measuring the fur matting around the
anus of mice following i.v. challenge. We also examined whether IL-3 was required
for the i.v.-induced diarrhea. Mice were sensitized to OVA plus alum and then orally
challenged 10 times with OVA, at which point 75% of OVA challenged IL-3+/+ mice
had diarrhea (Figure 5.16A). Three days later, mice were i.v. challenged with 100
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µg OVA and all sensitized groups exhibited hypothermia (Figure 5.16B). However,
in contrast to the results of Figure 5.7, mice in all groups, including naive animals
exhibited some fur matting (Figure 5.16C and D). While the fur matting was most
pronounced in the orally primed IL-3+/+ mice, mock-primed wildtype mice also
exhibited significant fur matting and diarrhea (Figure 5.16C and D). The average
amount of fur matting was lower in the sensitized IL-3 deficient mice, despite at least
as severe i.v.-induced anaphylaxis (Figure 5.16B - D). Taken in conjunction with the
results of Figure 5.7, non-allergic parameters seem to contribute to diarrhea and fur
matting in this context, such as introduction of the rectal probe and the pre-heating
step. Therefore i.v.-induced fur matting may lack the sensitivity required to measure
the severity of disease, but could prove useful with further optimisation or without
the rectal probing step. With these preclusions in mind, the results of Figure 5.16 and
Figure 5.7 indicate that IL-3-dependent oral potentiation exaccerbates, rather than is
necessarily required for i.v. allergen-induced diarrhea.
Taken collectively, our findings illustrate that IL-3, in addition to the roles estab-
lished for IL-4 and IL-9[57, 295], is involved in oral allergen-induced jejunal mast cell
infiltration.
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Figure 5.16: Systemic anaphylaxis and fur matting in IL-3 sufficient and
deficient mice. (A) Mice were sensitized and orally challenged with OVA. (B) Three
days after the final oral challenge mice were i.v. challenged with 100 µg OVA. Naive
mice also received i.v. 100 µg OVA. (C) Photographs were taken 50 minutes after
i.v. challenge. (D) Zero, twenty and fifty minutes after i.v. challenge the area of fur
matting was calculated using pi*((x/2)*(y)/2)); where x and y are the horizontal and
vertical diameters of fur matting around the anus. Data are represented by group
mean±SEM (n=4 mice/group) from a single experiment. **p<0.01, ***p<0.001 by
One-way ANOVA with Tukey’s post-test. White symbols in (D) represent mice that
were not measured at earlier timepoints.
5.4 Discussion
In the model we used, multiple oral feeds with OVA are required for mice to present
with diarrhoea. Within the first three challenges, antigen-specific CD4+ T cells up-
regulate intestinal homing molecules, jejunal IL-4 mRNA levels become elevated, in-
testinal antigen-specific IgE titres rise, mMCP-1 mRNA transcripts are more frequent
and mastocytosis is observed[38, 299]. We refer to this process as oral potentiaton
and these changes are causatively or correlatively linked with the development of
disease[37]. The aim of the experiments in this chapter was to clarify the immune
processes involved in oral potentiation. Initially, we examined the contribution of
CD4+ T cells to allergen-induced mastocytosis. We then examined the role of IL-3
in the allergen-induced intestinal mast cell response.
5.4.1 The role of CD4+ T cells in oral potentiation
Our first studies were proposed based on experimental evidence implicating local
CD4+ T cells in oral potentiation. In three similar models, oral challenge of pre-
sensitized mice increases Th2-associated cytokine levels in the intestinal tissues, and
causes specific enhancement of Th2-type cytokines upon restimulation of CD4+ T
cells. This Th2 cytokine profile is observed in mice orally challenged with OVA
after: i) intraperitoneal sensitization with OVA plus alum adjuvant[37, 38, 57, 299];
ii) subcutaneous sensitization with OVA plus complete Freund’s adjuvant[58]; and
iii) oral sensitization with OVA plus cholera toxin[298]. This profile is also observed
when milk proteins or peanut allergens are used in similar models that also result
in diarrhoea, intestinal permeability and vascular leak[149, 456]. Further, in all of
these oral challenge models, mast cell and eosinophil influx follow oral challenge[37,
42, 58, 149, 456]. In all three OVA-challenge models, the allergic response is critically
dependent on IL-4/STAT-6 signalling, and in the model we have employed, has been
shown to be dependent specifically on IgE and mast cells[57, 58, 295, 298].
In our studies, we have confirmed a central role for CD4+ T cells in the development
of diarrhoea and identified two different roles for CD4+ T cells in oral potentiation.
When CD4+ T cells were depleted systemically prior to OVA feeding, oral potenti-
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ation did not occur (Figure 5.1). Allergen-induced mast cell activity was essentially
ablated in CD4-depleted mice: mMCP-1 production was 100-fold lower and jejunal
mast cell numbers averaged two per high power field, compared to approximately 35 in
mock-depleted orally challenge mice. This is similar to the number we observed in un-
challenged mice in other experiments. IgE production was also diminished relative to
non-depleted mice, as would be expected. However, this alone was not sufficient to ex-
plain the impairment in allergen-induced mast cell recruitment, because hyper-primed,
CD4-depleted mice that had IgE levels sufficient for disease exhibited delayed disease
onset (Figure 5.4). These findings lead us to conclude that intestinal mastocytosis is
a process independent of augmented IgE production. A previous report demonstrated
that treatment of mice with FTY720, a drug that causes accumulation of lymphocytes
in lymph nodes and Peyer’s patches and prevents their dissemination[457] does not
prevent oral potentiation[299]. Taken in this light, we consider the mast cell compo-
nent of disease to be controlled by intestinally-localised Th2 mast cell-inducer (Th2m)
cells, which are functionally distinct from IgE-promoting follicular T helper (TFH)
cells.
5.4.2 Distinct roles for CD4+ T cells in intestinal mastocy-
tosis and IgE generation
The requirement for CD4+ T cell function in establishing the local inflammatory
milieu in the intestine in addition to supporting IgE production is a potentially im-
portant feature of the allergic process. Current evidence suggests that IgE produc-
tion is controlled by IL-4-producing TFH cells found in lymph nodes[275] and lymph
node- and tissue-localised CD4+ T cells are differently programmed and functionally
distinct[275, 317, 368, 369]. Following helminth infection, CD4+ T cells found in the
lung produce increased levels of IL-13, and significantly less IL-21 than do CD4+
T cells in the lymph nodes[275, 317]. Further, the acquisition of TFH function, or
programming to egress from the lymph node to alternate sites are in part dictated by
T cell receptor (TCR) antigen affinity[369]. This bifurcation of antigen-experienced
cells can be observed prior to the development of germinal centres soon after T cell
activation[368]. Therefore, TFH cells and Th cells that enter the tissues may arise
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from separate precursor populations. In terms of the oral potentiation response, it is
possible that populations of OVA-reactive CD4+ T cells that promote IgE production
are distinct from those that control local mastocytosis. However, in the model we used
for experimentation, mice received their first challenge four weeks after their initial
sensitization. In this period, ample time existed for T cell redistribution to multiple
sites. TFH cells can enter tissues, because adoptively transferred IL-21-reporter-
expressing cells are found in the lungs of influenza-infected mice[367]. Furthermore,
in a similar model to the one we used, both CD4+ Th2 cells and IgE producing B
cells have been identified in the colonic lamina propria[58]. While IgE is not sufficient
for mastocytosis on its own, interaction with B cells in the intestine may be required
for Th2m cell function. However, irrespective of local B cell involvement, the data
clearly indicate that CD4+ T cells control local intestinal mast cell infiltration.
5.4.3 The role of CD4+ T cells in disease maintenance
While CD4+ T cell depletion prevented oral potentiation and disease development,
CD4+ T cell depletion was not sufficient to tolerise mice to allergen. In our tem-
porary depletion studies, mice were protected from disease only while their CD4+ T
cells were absent; acute and transient oral allergen-induced diarrhoea was observed
in mice soon (three challenges) after CD4+ T cells emerged in the periphery (Fig-
ure 5.3). It is known that T cells are involved in oral tolerance[137, 143, 458] so
to some extent, this result was to be expected. Sensitized CD4-depleted mice also
remained susceptible to i.v.-induced systemic anaphylaxis (Figure 5.2), so the ini-
tial sensitization was sufficient for systemic, but not intestinally-localised allergic re-
sponses. A similar potentiating role is attributed to CD4+ T cells in the develop-
ment of allergen-induced airways hyperresponsiveness. In sensitized and subsequently
CD4-depleted mice, challenge-induced airways eosinophilia is ablated and subsequent
airways hyperresponsiveness is prevented[459]. Intriguingly, while eosinophilia is ob-
served in lungs of intranasally allergen-challenged mice[294] and in the intestines of
orally allergen-challenged mice[37, 42, 58], neither eosinophils nor IL-5 contribute to
the CD4-dependent respective airways hyperresponsiveness or diarrhoea[37, 294, 459].
The parallels in the processes indicate that the events that permit the triggering of
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an allergic response in the lung or the gut mucosa are separate events from systemic
sensitization.
The processes that maintain disease have also been investigated. IL-4 and IL-13, are
critical in the oral potentiation period, but once disease is established systemic admin-
istration of anti-IL4 or anti-IL-13 antibodies does not prevent disease triggering[295].
Our findings are compatible with these findings. We observed that in the absence of
CD4+ T cells, which are the most likely source of IL-4 and IL-13 required for oral po-
tentiation, most mice remained susceptible to disease (Figure 5.5). Although the oral
potentiation parameters remained elevated, we also observed an eventual diminution
in disease incidence, and reduced mast cell activity in CD4-depleted mice, indicating
that the long-term response was indeed still potentiated by CD4+ T cells (Figure 5.5).
Taken together, the FTY720 studies in which oral potentiation was not inhibited[299],
the partial attenuation in disease we observed following CD4-depletion (Figure 5.5),
and segregation of IgE production from mastocytosis in our potentiation experiments
(Figure 5.4), the data indicate that Th2m cells are required in the intestinal tissue
itself. Although these findings indicate that intestinally localised Th2m cells are re-
quired for optimal oral potentiation, we also demonstrated that once established, the
susceptibility conferred by oral potentiation is reasonably long-lived.
In our experiments, oral potentiation did not increase temperature loss induced by i.v.
allergen administration (Figure 5.7 and 5.16). This contrasts with a previous report
that indicated the severy of anaphylaxis increases in orally primed mice[37]. This may
relate to the contributions of IgG-mediated processes to the anaphylactic response.
While IgE-dependent systemic anaphylaxis is mast cell-dependent[43], IgG-bound ba-
sophils and macrophages can contribute to systemic anaphylaxis[40, 41, 47]. Addi-
tionally, systemic administration of antigen-specific-IgG1 can inhibit IgE-mediated
anaphylactic responses induced orally in mice[67]. It is possible that significant dif-
ferences in hypothermia would have been revealed if IgG-dependent processes were
first neutralised in our studies. We also note that diarrhoea penetrance in the stud-
ies by Brandt et al. generally reached 100 percent within 6 challenges[37], whereas
in our lab it can require ten or more challenges for it to be observed in all mice.
Previous studies also demonstrate that low doses of allergen require more challenges
to invoke diarrhoea[37]. It is possible that oral potentiation could occur faster if
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we used higher challenge doses and may similarly be required for oral potentiation
to heighten the systemic response. We did, however, observe liquid stools and fur
matting 10 to 25 minutes after i.v. allergen challenge of orally primed mice (Figure
5.7), which indicates that the anaphylactic response was more severe in orally-primed
mice, in line with the findings of Brandt et al.[37]. However, as noted in the results
section, although fur matting measurements indicated that it remained ’less severe’
than orally-primed mice, we also observed diarrhea in some i.v. challenged naive
mice (Figure 5.16), indicating that additional non-allergy associated parameters of
the experimental regimen could contribute to the i.v.-induced diarrhea. Determining
whether i.v.-induced intestinal anaphylaxis is severe enough to be observed without
introduction of the rectal probe, and further, whether this requires sensitization, or
is a property for which oral OVA-feeding is sufficient needs to be addressed in future
studies. The heating requirement could be removed if allergen were administered i.p.
instead of i.v. in mice and permit better characterization of the i.v.-induced intestinal
allergic response.
5.4.4 Clarifying the earliest events in the intiation of oral
potentiation
Determining whether the first step involved in oral potentiation requires the presence
of CD4+ T cells or will occur in their absence will also be important to investigate in
future studies. Allergen-reactive CD4+ T cells are recruited to the allergen-exposed
intestine[38, 58], which argues that the local inflammatory milieu promotes CD4+
T cell recruitment. If the earliest events in the oral potentiation process require the
presence of CD4+ T cells, the implications for disease therapy will be different than
if the earliest events that promote CD4+ T cell responses are initiated as a preced-
ing independent process. CD4+ T cell activation in the mesenteric lymph node is
thought to be a key step in the oral potentiation process[38], which predicates aller-
gen and/or antigen-presenting cell transit to the mesenteric lymph node after oral
challenge. OX40L-expressing dendritic cells are demonstrated as Th2-promoting cells
in the intestine[434] and allergen binding to epithelial cells is associated with more
severe intestinal allergic responses[139]. The way innate and non-haematopoeitic cells
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respond to allergen can influence the allergic process, so determining whether these
changes occur in the absence of antigen-specific CD4+ T cells has the potential to
determine the most appropriate targets for therapeutic intervention in atopic individ-
uals.
There are a number of ways of further assessing the requirement for CD4+ T cells
in the initiation of oral potentiation. First, if the CD4+ T cell population was de-
pleted for a short period (two to three challenges), and then allowed to replenish,
examining mastocytosis in the absence of further challenges would indicate whether
or not the potentiation process is initiated by oral exposure in the absence of CD4+
T cells - Without further challenges, do mast cells infiltrate the intestine as CD4+
T cells re-emerge? If they do, this will provide evidence that oral potentiation is
initiated in the absence of CD4+ T cells. As antibody treatment can be leaky, an
adoptive transfer method could also be employed. Studies have demonstrated that
adoptively transferring OVA-specific CD4+ T cells to naive mice, then feeding the
mice OVA induces OVA-specific CD4+ T cell proliferation in mesenteric lymph nodes
and causes their dissemination to the spleen[38]. In future work, mice could be de-
pleted of CD4+ T cells, gavaged with OVA or PBS, and then receive OVA-specific
CD4+ T cells once they were CD4-replete. If the transferred OVA-specific CD4+
T cells were preferentially sequestered to the jejunum, Peyer’s patches or mesenteric
lymph node of the OVA-fed group, this would indicate that their recruitment was
initiated in their absence. Treating naive mice in a similar manner would be plau-
sible, but may be confounded because oral exposure without sensitization inhibits
Th2 polarisation[134, 143, 458]. This may affect the response of the adoptively-
transferred cells. Oral potentiation has been linked to CD4+ T cell α4β7 and CCR-6
expression[38, 299], so monitoring these molecules on emerging CD4+ T cells in CD4-
replete mice could also link intestinal homing to disease. Lastly, it will be desirable
to determine the frequency and activation status of OVA-specific CD4+ T cells in
the gastrointestinal immune system of CD4-replete mice. These studies will have the
potential to determine whether the earliest event in oral potentiation is CD4+ T cell
dependent, or alternatively, if CD4+ T cells are simply a stepping-stone in an already
catalysed process.
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5.4.5 Requirement for oral potentiation for diarrhoea in dif-
ferent contexts
It is important to note that oral potentiation is not required for disease development
in all allergy models. In rats, peripheral sensitization is sufficient to induce an antigen-
specific IgE mediated response in the intestine[44, 54, 59]. The first intestinal exposure
disrupts motility and causes diarrhoea if allergen is intubated directly into the duode-
num or colon[44, 53, 59, 460]. Antigen-specific allergic intestinal responses have also
been observed on first antigen challenge in subcutaneously sensitized mice[140], and
those born to orally-sensitized dammes[20]. In systems very close to the model we
have used, diarrhoea has been observed on the first challenge. In mice with elevated
intestinal mast cell numbers that are predisposed to diarrhoea development, allergic
diarrhoea has been observed without an oral potentiation period, but this is again
rare[67]. There is at least one other report in which diarrhoea was observed on the
first challenge of a mouse[299]. This suggests that in some circumstances, the presence
of IgE and mast cells are sufficient for diarrhoea to develop. However, a direct cor-
relation between intestinal mast cell numbers and the severity of the orally-induced
anaphylactic response has been demonstrated[36], and mast cell numbers increase
significantly following multiple gavages[37, 38]. Further, mice transgenically modified
to have high basal mast cell activity[57] and mice with naturally increased mast cell
numbers[39] demonstrate heightened allergic disease susceptibility. Collectively, these
data suggest that intestinal disease is influenced by the level of mastocytosis, which is
increased during the CD4+ T cell dependent establishment of the diarrhea-permissive
local inflammatory milieu in the intestine.
Our studies have investigated the role of CD4+ T cells in the intestinal allergic pro-
cess. We find that intestinal mast cell recruitment is controlled by local CD4+ T
cell activity. CD4+ T cells also promote systemic IgE production. While these pro-
cesses culminate in intestinally-localised allergic responses, they can be attributed to
independent functions of CD4+ T cells.
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5.4.6 The role of IL-3 in mast cell-dependent Th2 immu-
nity
Once we had determined a causal role for CD4+ T cells in the oral potentiation process
we next investigated the potential involvement of IL-3 in intestinal allergy.
The rationale for investigating IL-3 comes from previous work identifying a role for IL-
3 in Th2-associated intestinal immunity and also in some models of hypersensitivity.
Parenteral allergic responses, including mast cell-dependent[43] IgE-mediated passive
cutaneous anaphylaxis and OVA-induced active systemic anaphylaxis proceed unen-
cumbered in the absence of IL-3[455]. In contrast, symptoms of oxazolone-induced
contact hypersensitivity and IgE-triggered serotonin release are reduced in IL-3-/-
mice[396, 455]. In wild-type mice, systemic administration of IL-3 increases jejunal
mast cell deposition and systemic basophil generation[301, 311, 461], whereas blockade
of IL-3 signaling prevents intestinal mastocytosis in response to parasite infection[462].
Both parasite infection and oral-allergen exposure induce intestinal permeability, mast
cell recruitment and mMCP-1 production in mice[37, 50, 463]. Although IL-3 has been
implicated in the regulation of IgE-mediated allergic reactions, the contribution of this
cytokine to oral allergen-induced intestinal allergic responses has not previously been
explored.
IL-3 is known to be produced by T cells[322, 464] and T cell derived IL-3 is known to
promote mast cell development[465]. When we examined the potential involvement of
IL-3 in a Th2-type response, we observed that culture with IL-4 increased the amount
of IL-3 produced by anti-CD3-stimulated splenocytes. At least in part, this was due
to IL-3 production by CD4+ T cells. Confirming a wealth of previous reports (e.g.,
[465, 466]), we observed mast cell and basophil development from bone marrow cells
cultured with IL-3. In contrast, while TSLP has recently been identified to promote
IL-3-independent, IL-4-producing basophil development[429], only IL-3 gave rise to
mast cells under the same culture conditions. Further, unlike the basophils that were
present in cultures containing IL-3 and/or TSLP, the mast cells that developed did
not express GFP, which reflects IL-4 production in the G4 mouse[273]. From these
data, we conclude that IL-4 promoted IL-3 production by T cells. We also conclude
that CD4+ T cells may contribute to intestinal mastocytosis in Th2 settings through
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the production of IL-3.
5.4.7 The role of IL-3 in intestinal food allergy
IL-3 deficiency impaired the development of an intestinal allergic response in mice.
When we monitored disease development in sensitized and orally challenged IL-3-/-
mice, they neither developed diarrhoea nor lost plasma volume; faecal pellets and
caecal content were also retained. While mastocytosis was diminished in IL-3-/- mice
relative to wild-type mice, oral challenge increased systemic IgE titres, indicating
that CD4-dependent responses still occurred. We also showed that IL-3-deficient mice
remained susceptible to systemic anaphylaxis, as established previously[455]. From
these data, we conclude that IL-3 was specifically required for intestinal allergic mast
cell responses.
When we assessed the relative contribution of IL-3 and IL-9 to intestinal mastocytosis,
our data confirmed that IL-3 was required for intestinal mast cell deposition. Over-
expression of IL-9, which augments mastocytosis in IL-3-sufficient mice[57, 312], also
increased jejunal mast cell numbers in IL-3-deficient mice, but was not sufficient to
permit disease, or bypass the requirement of IL-3 in allergen-induced mastocytosis.
Not only did this confirm that IL-3 was required for allergen-induced intestinal mast
cell recruitment, but it also provided further evidence that antibody production and
intestinal mast cell recruitment were independent processes. Similar observations have
been made in IL-9-deficient settings[57] and support our conclusions. To confirm that
the difference in IgE levels in IL-3-deficient and IL-3-sufficient mice do not underlie
their protection from disease, testing whether IL-3-deficient mice develop disease when
given IL-3 exogenously, as done previously in parasite infection settings[301, 311,
461], will validate the findings of our study. However, as IgE levels were similar in
Tg+/+ and Tg-/- mice, but only Tg+/+ mice presented with diarrhoea, we consider
it unlikely that discrepancies in IgE titres underlie the differences in the intestinal
mast cell response of IL-3+/+ and IL-3-/- mice. From these data, we conclude that
oral allergen-induced mastocytosis is partially dependent on IL-3.
192
5.4.8 The source of IL-3 that drives allergic intestinal mas-
tocytosis
Intestinal CD4+ T cells are a probable source of the IL-3 that promoted the al-
lergic intestinal mastocytosis. Intestinal helminth infection normally induces 1000-
fold increases in IL-3, but if T cells are first depleted, Peyer’s patch IL-3 levels
are 10-fold lower than in naive mice[315]. Both IL-3 and T cells are required for
helminth-induced intestinal mastocytosis, and this expedites the expulsion of some
parasites[307, 309, 311, 314, 462, 467]. Thus, intestinal T cells are a potent source
of mast cell-inducing IL-3. This will, however, need to be validated in a food al-
lergy model, because committed mast cell progenitors are found in the blood and
bone marrow[314, 468, 469]. It is therefore possible that IL-3 is required systemically,
rather than locally, to promote intestinal allergy. Examining mast cell progenitor de-
position in the intestines of IL-3-/- mice, as done previously in disease-resistant IL-9-/-
mice[57], may indicate whether IL-3 is required locally or plays its most important
role before mast cell progenitors reach the intestinal tissue.
The contribution of CD4+ T cell-derived IL-3 to intestinal mastocytosis will be a
focus for future studies. Adoptive transfer of ex vivo-restimulated CD4+ T cells from
diarrhoetic wild-type mice renders otherwise naive mice susceptible to diarrhoea[38].
Transferring IL-3-sufficient or deficient OVA-specific CD4+ T cells to IL-3-deficient
mice would determine whether CD4+ T cells were a sufficient source of IL-3 to promote
mastocytosis and permit disease. DO11.10 mice have an enriched pool of CD4+ T cells
specifically recognising the OVA323-339 epitope[470] and develop allergic diarrhoea in
the model we used[471]. Adoptive transfer of IL-3-sufficient or IL-3-deficient DO11.10
CD4+ T cells to IL-3-/- mice prior to sensitization, then monitoring disease and
mMCP-1 levels in the challenge model will elucidate whether or not CD4+ T cell
IL-3-production is sufficient to promote allergic intestinal mastocytosis.
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5.4.9 Additional potential effects of IL-3 on intestinal mast
cell function
In addition to the reduction in jejunal mast cell numbers in IL-3-/- mice that we ob-
served, it is also possible that IL-3 alters the phenotype of intestinally-localised mast
cells. While mouse mast cells differentiate in response to IL-3, exposure to additional
cytokines, like IL-4 and IL-9, are required for mast cell mMCP-1 expression[472]. In
humans, the process is different. IL-3 promotes the activation, rather than the dif-
ferentiation of pure mast cell populations, and IL-6 and IL-10 synergise with SCF to
promote human mast cell development[314]. IL-6 and IL-10 promote the development
of less differentiated mast cells in mice[314], such that IL-3 may promote the mat-
uration as well as the expansion of intestinal mast cells. Determining the mediator
content of intestinal mast cells and the role of IL-3 in human intestinal allergies will
be important in future studies.
5.5 Summary
We have confirmed a key role for CD4+ T cells in local oral potentiation. We identify
that CD4+ T cells contribute to estalishing the local inflammatory milieu in the je-
junum in a manner that is additional to their role in IgE production. We determined
that the allergic response is optimal in the presence of CD4+ T cells, but oral poten-
tiation is sufficient for continued susceptibility to oral allergen challenge responses.
IL-3 was required for diarrhoea to manifest and was required in addition to IL-9 for
optimal intestinal mastocytosis.
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Chapter 6
Examining milk allergenicity in
Th2 immune response models
6.1 Introduction
6.1.1 Rationale for examining goat milk allergenicity
Milk allergy in the paediatric population is reasonably common. Of the five per-
cent of children in the US that have had an allergic episode, approximately half will
have been triggered by cows milk[9]. A similar incidence is reported in New Zealand
infants[473]. While there are significant similarities in their composition, goat milk is
less allergenic than cow milk in numerous experimental settings. In this, goat milk
offers the potential to be used in a hypoallergenic milk formula that will result in
fewer allergies compared with cow milk-based formulae.
Goat milk has been shown to be a weaker allergen than cow milk in a number of
models. In mice sensitized orally to milks, splenocyte milk-specific IL-4 production
is lower, diarrhoea less frequent and the severity of disease induced by oral feeding
is lower in goat milk-fed mice[234]. In some studies, guinea pigs demonstrate more
severe anaphylactic responses to cow milk than goat milk[141]. Heat-treating goat
milk diminishes its allergenicity in guinea pigs to a greater extent than cow milk[238].
However, goat milk can sensitize, and induce significant allergic responses in both
experimental and clinical settings[221, 238]. Therefore, to develop a hypoallergenic
infant formula, clarification of the specific components of goat milk that contribute
to its allergenicity is required.
In the literature, several milk components have been identified as potential sources
of allergenicity. First, the casein content, and specifically the αs1-casein content,
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influences the allergenicity of milk. This is observed in multiple settings. Milk sourced
from goat breeds in which αs1-casein levels are low results in reduced allergic disease
incidence and lower severity in guinea pig studies[249]. In another study, goat milk
with 10-fold lower αs1-casein content than cow milk also resulted in lower incidences
and less severe allergic responses in mice[234]. One study in mice has shown that
allergenicity of cow milk can be reduced by modifying its casein:whey balance from
80:20 to 60:40[250]. Intriguingly, milks with reduced or naturally low αs1-casein
content generate less BLG-specific antibody and reduce the allergic response triggered
by BLG in the intestine[249, 250]. This suggests that while the casein content of milks
is important, both BLG and caseins are implicated in the differential allergenicity
of cow and goat milks. However, these studies may also indicate that the relative
concentrations of specific proteins, rather than the intrinsic allergenicity of homologues
on a protein-by-protein basis, influence milk allergenicity. Therefore, we sought to
clarify whether differential allergenicity could be attributed to specific components
of goat and cow milk. Finally, we considered that rather than weaker allergenicity,
goat milk may have some additional allergy-suppressing properties that inhibit Th2
responses, including those to milk components. Therefore, in this section, we aimed
to clarify which components and properties of goat milk influence its comparatively
weak allergenicity.
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6.2 Aims
In this chapter we used the models of Th2 immunity characterised in the previous
chapters to evaluate the allergenicity of milk components. Specifically, our objectives
were to determine:
1) If there are differences in the intrinsic allergenicity of homologous cow and goat
milk proteins;
2) If goat milk can suppress Th2 responses;
3) If goat BLG can induce intestinal mast cell responses in sensitized mice;
4) If cow and goat BLG differentially affect orally-induced allergic intestinal mast cell
activity.
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6.3 Results
We began our studies using the pTh2 assay to compare the Th2 response induced
by isolated milk proteins. As αs1-casein and BLG are major milk allergens absent
or low in human milk, we compared the intrinsic allergenicity of these cow and goat
homologues.
6.3.1 Examining pTh2 responses to β-lactoglobulin
In work carried out prior to this study, our lab observed that Th2 responses to food
allergens were generally weak (Figure 1.3). Therefore, we examined whether Th2
responses could be increased if more allergen was administered. In this and all sub-
sequent pTh2 assays, mice were anaesthetised, and then received the stated dose of
allergen intradermally in the ear pinna. Seven days later, the draining lymph node
was excised and the Th2 response was analysed.
First, we examined the Th2 response to either 1 mg or 100 µg of cow BLG. When
we examined the total number of cells infiltrating the lymph node, approximately
twice as many cells were detected when 1 mg was used compared with 100 µg (Figure
6.1A). The number of B cells and CD4+ T cells increased in mice that received 1
mg cow BLG (Figure 6.1B and C). We also observed that 1 mg BLG increased the
proportion of GFP+CD4+ cells, resulting in an approximately 15-fold increase in
Th2 cell numbers which was not observed at 100 µg (Figure 6.1D and E). These data
suggest that 1 mg cow BLG was immunogenic and allergenic in the pTh2 assay, while
0.1 mg was sub-immunogenic.
Next we compared the response for cow and goat BLG. In this assay, we included a
2.5 mg dose. When 1 or 2.5 mg BLG was injected, irrespective of the species source,
we observed increased lymph node cellularity, which could largely be attributed to B
cell and CD4+ T cell hyperplasia (Figure 6.2A-C). We also observed dose-dependent
increases in the proportion and number of Th2 cells, and these increases were similar
for both species (p>0.05 for all parameters; Figure 6.2 A-C, E and F). These data
suggest that cow and goat BLG have equivalent allergenicity in the pTh2 assay.
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6.3.2 Examining pTh2 responses to casein proteins.
Caseins are also major milk allergens, with between 85 and 100 percent of milk al-
lergic individuals exhibiting IgE binding to casein proteins[34, 183]. As significant
IgE binding to one casein protein, αs1-casein, is frequently observed[182], we next
examined the allergenicity of αs1-casein, and that of the whole casein fraction.
In our initial assays, we had difficulties with the solubility of the caseins, so we tested
the amount of protein we were administering using standard protein quantitation
assays. Solubilised HPLC-purified goat αs1-casein generated a lower O.D. reading
compared with the equivalent mass of cow αs1-casein, but gave similar BCA Cu2+
reduction results (Figure 6.3A and B). The same mass of goat αs1-casein and whole
goat caseins gave both similar absorbances and BCA Cu2+ reduction values (Figure
6.3A and B). These aliquots were used directly in one of the three assays used to
compile Figure 6.4. An additional aliquot of goat αs1 casein and the whole casein
fraction were frozen, and subsequently used for the assay shown in figure 6.5. Immu-
nisations were performed based on the weighed mass, rather than results of either of
the protein assays.
When mice were immunized with HPLC-purified αs1-casein, there was a minor in-
crease in total cellularity in response to 1 mg cow and goat αs1-casein (Figure 6.4A),
but only cow reached statistical significance. We did not observe increases in CD4+ T
cell numbers in mice immunised with either cow or goat αs1-casein (Figure 6.4 B). In
the mice that received 1 mg of either protein, we observed statistically non-significant
increases in B cell number, and small, but significant increases in the proportion and
number of Th2 cells (Figure 6.4B, D and E). At no dose did we observe differences
between the two αs1-caseins (<0.05 for all parameters). These data suggest that αs1-
casein isolated from cow, or from goat milk have similar and low allergenicity, in terms
of their ability to initiate Th2 cell development in the absence of adjuvant.
Next we tested whether caseins are more allergenic as a whole, than the isolated αs1-
casein. When we compared 333 µg masses of goat αs1 and whole caseins, we observed
similar immunogenicity, as there were minor, or no difference in the total cell infiltrate,
B cell infiltrate or CD4+ T cell infiltrate in draining lymph nodes (Figure 6.5A-C).
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However, we observed a clear difference in the Th2 response: Equivalent masses of
αs1-casein generated ≈2000 Th2 cells, whereas ≈6000 were induced by the equivalent
mass of the whole casein fraction (Figure 6.5E). Similar relationships were observed
for proportional Th2 responses (Figure 6.5D). These data suggest that wholegoat
caseins have higher intrinsic allergenicity than goat αs1-casein alone.
We next compared the allergenicity of cow and goat whole caseins. When we immu-
nized mice with 1 mg of whole casein fractions we observed pronounced increases in
lymph node hyperplasia, B cell, CD4+ T cell and Th2 cell expansion (Figure 6.6A-E).
Both cow and goat whole caseins increased the proportion and number of Th2 cells
present in lymph nodes compared to non-draining lymph nodes, most significantly
at the highest dose (1 mg; Figure 6.6D and E). While there may have been a small
increase in Th2 proportion for cow over goat at 1 mg, no statistically significant dif-
ference was detected in the proportion or number of Th2 cells at any dose (p>0.05
at all doses). Therefore, these data suggest that cow and goat whole caseins both
induced Th2 cell development and did so to similar extents in the pTh2 assay.
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Figure 6.1: Dose-dependent Th2 response to cow β-lactoglobulin. Mice
(n=3/group) were injected intradermally with 600 dead iL3 N. brasiliensis larvae
(G4/+ L3), 1000 µg cow BLG, or 100 µg cow BLG. Seven days later, draining lymph
nodes were taken, and one non-draining node from each group was taken (nDLN)
and analysed by trypan blue exclusion test for (A) total cell number and after flow
cytometric characterization, the number of (B) B220+ cells, (C) CD4+ T cells and
the (D) proportion and (E) number of CD4+ T cells that were GFP+. Bars show
mean±SEM of groups of (n=3) mice from one of two similar experiments. Data were
compared using One-way ANOVA with Tukey’s post-test. *p<0.05, **p<0.01.
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Figure 6.2: Similar Th2 response to cow and goat β-lactoglobulin. G4/+ mice
(n=5/group) were immunized intradermally with the stated dose of cow (squares) or
goat (circles) BLG. Control +/+ (white triangles) and G4/+ (black triangles) mice
were immunized with 600 dead iL3 N. brasiliensis larvae. Non-draining (nDLN)
lymph nodes (crosses) were used to reflect the assay baseline. (A) Total cell numbers
were calculated by trypan blue exclusion, and the number of (B) B220 and (C) CD4+
T cells were back calculated based on the (D) proportion of live cells that were B220+
(White bars) or CD4+ (Black bars). (E) The proportion and (F) number of CD4+
T cells that expressed GFP, as a surrogate of IL-4 protein induction, were quantified.
Data are shown from a single experiment and the dose response was analysed using
Two-way ANOVA with Bonferroni’s post-test; b p<0.05, bb p<0.01, bbbb p<0.0001
cow BLG vs. nDLN; aa p<0.01, aaaa p<0.0001 goat BLG vs. nDLN.
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Figure 6.3: Comparison of cow and goat casein concentrations by BCA and
nanodrop. Cow αs1-casein (cow as1), goat αs1 casein (goat as1) or goat whole casein
(goat WCF) were dissolved in solution to 1 mg/90 µL (11.111 mg/mL). (A) After
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solution for Cu2+ reduction based on the BCA reduction assay. Three 1/20 dilutions
were prepared from the same stock for nanodrop; BCA data were in duplicate. 600
dead iL3 N. brasiliensis larvae (L3) were also included in the assay (cross). Data
are from a single experiment and were analysed by (A) Student’s t-test, and exact p-
values are shown or (B) Two-way ANOVA with Bonferroni’s post-test; non-significant
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Figure 6.4: Similar Th2 response to cow and goat αs1-casein. Seven days after
intradermal injection of +/+ (white triangles) or G4/+ (black triangles) mice with
600 dead iL3 N. brasiliensis larvae, or cow (squares) or goat (circles) αs1-casein at the
stated dose (in µg), mice were euthanised and auricular cell infiltrates were profiled.
Randomly selected non-draining lymph nodes including samples from all groups were
used as baseline controls (crosses), and in one experiment PBS-immunized mice were
also included (plus symbols). (A) The total number of cells was quantified by trypan
blue exclusion and combined with flow cytometric analysis to determine the number
of (B) B220+ cells, (C) CD4+ cells and the (D) proportion and (E) number of CD4+
T cells that expressed GFP. Symbols represent mean±SEM of data combined from
three separate experiments, each using a different titrating dose; 1000 µg Cow as1,
n=11; 1000 µg Goat as1 n=8; 500 µg Cow as1 n=3; 500 µg goat as1 n=5; 333 µg cow
or goat as1 n=2; 100 µg cow or goat as1 n=5; nDLN n=20; PBS n=4; +/+ L3 n=9;
G4/+ L3 n=11. Dose titrations were compared against the nDLN group using Two-
way ANOVA with Bonferroni’s post-test; aaaa p<0.0001 Goat as1 vs. non-draining,
b p<0.05, bbb p<0.001, bbbb p<0.0001 cow as1 vs. non-draining.
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Figure 6.6: Th2 responses to cow and goat whole caseins are similar. Seven
days after intradermal administration of 1 mg (1000), 0.5 mg (500) or 0.1 mg (100)
cow whole casein fractions (Cow WCF) or goat whole casein fractions (goat WCF),
draining lymph nodes were examined for immune responses compared to non-draining
(nDLN) lymph nodes. +/+ (+/+ L3) and G4/+ (G4/+ L3) mice immunized with
600 dead iL3 N. brasiliensis larvae were used as positive controls. In one experiment
a PBS (PBS) treated group was included as an additional negative control. (A)
Total cell infiltrates, (B) B cell infiltrates, (C) CD4+ T cell infiltrates and (D) the
proportion and (E) number of Th2 cells induced were recorded. Data points represent
mean±SEM of (n=6) mice for N. brasiliensis controls, (n=14) non-draining nodes,
(n=8) draining nodes at 1 mg and (n=4) draining nodes at 0.5 mg and 0.1 mg,
combined from two experiments. a p<0.05, aaaa p<0.0001 goat caseins versus non-
draining nodes, bb p<0.01, bbbb p<0.0001 cow caseins versus non-draining nodes by
Two-way ANOVA with Bonferroni’s post-test.
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6.3.3 Examining the ability of goat milk to suppress Th2 re-
sponses
We used the pTh2 assay to test if goat milk can suppress Th2 responses induced by
other allergens. Mice received 0.1 mg HDM antigen in the presence or absence of 25
µL skim or whole goat milk, in a total volume of 30 µL and seven days later lymph
node cellularity was assessed. We observed increased Total, B cell and CD4+ T cell
infiltration in HDM-immunized mice (Figure 6.7A-C). In terms of both proportion
and number, the pTh2 response was strongest in mice immunised with HDM in the
presence of whole goat milk (Figure 6.7D and E). Therefore, not only were goat milks
unable to significantly suppress HDM-induced Th2 responses, the presence of whole
goat milk increased the Th2 response.
Previous studies have examined the oral allergic response to milks. We next incorpo-
rated the physiological processing component of allergenicity into our investigations.
Using the model developed by Brandt et al.[321], we examined the development of
allergic diarrhoea in mice sensitised to OVA, then fed OVA dissolved in PBS, skim
goat milk or whole goat milk. When mice were challenged perorally with milks alone,
neither skim- nor whole-goat milk caused diarrhoea development in OVA-sensitised
mice (Figure 6.7F). In contrast, when mice were challenged with 50 mg OVA, all
groups began to develop diarrhoea in 3-5 challenges, and disease penetrance reached
100% in all OVA-challenged groups, even those in which the OVA was dissolved in
goat milk. Therefore, allergic diarrhoea in OVA-sensitized mice was neither induced
nor inhibited by the presence of skim or whole goat milk, and there was no apparent
difference of the response in the presence of either skim or whole goat milk.
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Figure 6.7: Neither skim nor whole goat milk prevent Th2 responses. (A-E)
HDM was dissolved and then combined in a 5:25 ratio such that 30 uL contained
100 ug HDM in 5 uL PBS, + 25 µL PBS, 25 µL skim goat milk (SGM) or 25 µL
whole goat milk (WGM). A mock-challenged group was included to set the baseline
(PBS+PBS). Seven days after injection of the stated solution, (A) Total cells were
counted by trypan blue exclusion and flow cytometry proportions were used to back-
calculate the number of (B) B cells, (C) CD4+ T cells, (D) the proportion of CD4+
T cells that expressed GFP and (E) the number of Th2 cells. Data shown are from
one of two similar experiments. (D,E) Data points represent individual mice. (A-C)
Bars show mean±SEM of these same mice. In the second experiment, 30 µL PBS,
SGM or WGM were administered to the ear 36 hours prior to HDM immunization
and gave similar results. (F) OVA-sensitized mice (n=5/group) were i.g. challenged
with 50 mg OVA in PBS, SGM or WGM. Control OVA-sensitised mice received 250
µL skim goat milk (SGM; n=2) or whole goat milk (WGM; n=3) alone during i.g.
challenge. Oral challenge data were generated in a single experiment. (A-E) Data
were compared using One-way ANOVA with Tukey’s post-test; *p<0.05, **p<0.01,
***p<0.001.
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6.3.4 The oral response to milk allergens
Homologous goat and cow milk allergens induced similar Th2 responses, but the pTh2
assay does not examine the full allergic process. Using the model developed by Brandt
et al.[37], we aimed to establish whether oral challenge with goat BLG could initiate
the intestinal mastocytosis associated with oral potentiation.
Mice were sensitised twice, two weeks apart with 50 µg goat BLG with alum, and
then subsequently fed with 50 mg goat BLG, 50 mg OVA, or PBS. A control group
of mice was mock-sensitized, and then fed with 50 mg goat BLG. When we examined
IgE levels, total IgE increased in sensitized mice fed goat BLG (Figure 6.8A). Feeding
goat BLG-sensitised mice with PBS or OVA did not increase the Total IgE above
starting titres (Figure 6.8A). Similarly, mock-sensitised mice fed with goat BLG had
lower IgE than the goat BLG-sensitized, goat BLG-fed group at the experimental
endpoint (Figure 6.8A). We examined antibody binding to goat BLG and observed
minor elevations in the BLG-fed group over other groups for both polyclonal Igs
and IgG1 (Figure 6.8C and E). When we examined these mice for IgG1 binding to
cow BLG, we similarly observed elevations over the other groups (Figure 6.8D and
F). These data indicate that oral challenge with goat BLG increased both goat and
cow BLG-specific antibody titres. Last, we examined serum mMCP-1 levels in these
mice. The only group in which we detected increased mMCP-1 levels was the goat
BLG-sensitised, goat BLG-fed group (Figure 6.8B) with corollary increases in jejunal
mast cell frequencies (Appendix Figure 8.7). From these data, we conclude that oral
potentiation was observed in goat-BLG fed mice. Therefore, goat BLG can both
sensitize and initiate the oral allergic process.
To compare the allergenicity of cow and goat BLG, we used the contracted experi-
mental model in iFABPp-IL-9 transgenic mice. These mice were sensitised to OVA,
goat BLG, cow BLG, BSA or were mock-sensitised with PBS. Seven days later, mice
were orally gavaged with 50 mg of the sensitising allergen nine times. Mice were
bled after the ninth challenge, and sera were analysed for parameters associated with
the intestinal allergic response: mMCP-1, IgE and IgG1 production. Further, be-
cause we previously observed increases in IgG1-ASC numbers in mice sensitised and
orally-primed with OVA, when we killed the mice four days after their final gavage
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challenge, we also examined the number of antigen-specific ASCs in spleens of all
groups of mice.
Before discussing the results of this experiment, it is important to note that in the
early challenges, we observed diarrhoea development in 75 percent of cow BLG-fed
mice after the third challenge (images are shown in the appendices). We attempted
to bleed mice after the third challenge, but blood pressure was low in the cow BLG-
fed group, and we were unable to attain sufficient blood to isolate plasma. In the
preparation of this cow BLG, 2% salt (NaCl) was added to help solubilise it, so to
remove any confounding this may have had, cow BLG was subsequently dialysed
prior to gavage, and thereafter diarrhoea was no longer observed in cow BLG-fed
mice. However, in a repeat experiment, neither sensitised nor unsensitised cow BLG-
fed mice developed diarrhoea using the same mass of undialysed cow BLG; as such
we were unable to reproduce the diarrhoea phenotype, nor were we able to determine
whether it was IgE- and mast cell dependent. Diarrhoea developed in one of three
OVA-fed mice, and in none of the BSA- or goat BLG-fed mice. Therefore, we have
limited our evaluation of the results to the production of mMCP-1 and cross-reactive
IgG1 detection.
When we measured mMCP-1 levels in the OVA, goat BLG, cow BLG and PBS-fed
groups, we observed increases in all three groups of allergen-challenged mice over
PBS-fed mice (Figure 6.9A). While OVA, goat BLG and cow BLG groups were all
elevated over the mock-sensitized group, the OVA-fed group was most significantly
elevated, but not significantly over the two BLG groups (Figure 6.9A). The level of
Total IgE at the experimental endpoint was significantly elevated in the cow BLG
group over mock-sensitised, PBS-fed mice (Figure 6.9B), and similar trends for the
other groups were observed.
We also observed that ASC formation was similar for cow and goat-fed groups (Figure
6.9C-F), and also correlated approximately with the antigen-specific IgG1 titres that
developed (Figure 6.10A-D). When we examined IgG1-binding to the different pro-
teins, cow BLG- and goat BLG-specific antibodies were detected in both cow and goat
BLG sensitized mice, but not OVA-sensitized mice (Figure 6.10B, C, F, G). Somewhat
intriguingly, cow BLG-fed iFABPp-IL-9 transgenic mice had higher cow BLG-specific
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IgG1, and polyclonal Igs than goat BLG-fed mice at the 1/10000 dilution (Figure
6.10B and F). This same relationship was, however, not observed in the spot assay
(Figure 6.9D). Such significant cross-reactivity was not observed between BLG and
either OVA or BSA, in any of polyclonal, antigen-specific IgG1, or spot assays (Fig-
ure 6.9C-F and 6.10A-H). Taken together, these data may indicate that oral challenge
with both cow and goat BLG causes oral potentiation; both homologues drive similar
magnitude increases in mMCP-1 production but may differentially affect the B cell
response. However, further investigation is required to definitively determine whether
the ability of the two BLGs to drive oral potentiation differ.
Taken together, these preliminary findings suggest that the sensitising and response-
evoking capacity of goat BLG and cow BLG were similar, but indicated that cow-BLG
feeding increased BLG-specific IgG1 titres. These studies will benefit from replication
in the future. At this stage, given the similar elevations in the mMCP-1 response,
from these data we conclude that the response-evoking capacity of BLG from cow or
goat milk was similar.
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Figure 6.8: Goat β-lactoglobulin can induce intestinal Th2 responses. Groups
of (n=3/group) mice were sensitized ip to goat BLG with 50 µg goat BLG plus 1 mg
alum (goat BLG/) or mock-sensitized with PBS plus 1 mg alum (PBS/) and then
orally challenged with goat BLG (/goat BPG), OVA (/OVA) or PBS (/PBS) as in-
dicated. Mice were bled for (A) Total IgE before any and after six challenges. (B)
mMCP-1 was analysed in sera after the 6th challenge. (C) goat BLG-specific poly-
clonal Igs, (D) cow BLG-specific polyclonal Igs, (E) goat BLG-specific IgG1 and (F)
cow BLG-specific IgG1 were analysed by ELISA. (B) Data points represent individ-
ual mice or (A, C-F) mean±SEM of these groups. Data were generated in a single
experiment and were analysed using (B) One-way ANOVA with Tukey’s post-test or
(A, C-F) Two-way ANOVA with Bonferroni’s post-test; p<0.05, **p<0.01. mMCP-1
data were log-transformed prior to analysis.
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Figure 6.9: mMCP-1 levels are elevated in orally-challenged sensitized mice.
iFABPp-IL-9 mice were i.p. sensitized, and seven days later began to receive i.g.
challenges with: i) OVA (OVA/OVA), ii) cow BLG (cow BLG/cow BLG), iii) goat
BLG (goat BLG/goat BLG), iv) PBS (PBS/PBS) or v) BSA (BSA). i.p. sensitizations
used 50 µg of the indicated allergen; i.g. challenges used 50 mg of that same allergen
and were given every second day, three times a week for three weeks. Two hours
after the 9th i.g. challenge, mice were bled and (A) serum mMCP-1 and (B) Total
IgE levels were evaluated. (C-F) Antigen-specific IgG1 spot assays were performed
for each allergen. FBS was used to block plates so BSA group was not analysed
in the other spot assays. Data were generated in a single experiment. (A,B) Data
points represent individual mice, (C-F) bars represent mean±SEM of these same
groups. Data were compared using One-way ANOVA with Tukey’s post-test; *p<0.05,
**p<0.01, ***p<0.001. mMCP-1 data were log-transformed prior to analysis.
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Figure 6.10: Cross-reactivity observed between cow and goat β-lactoglobulin
but not other allergens in iFABPp-IL-9 mice. Sera from mice described in
Figure 6.9 were analysed for (A) OVA-specific IgG1, (B) cow BLG-specific IgG1, (C)
goat BLG-specific IgG1, (D) BSA-specific IgG1, (E) OVA-specific polyclonaly Igs, (F)
cow BLG-specific polyclonal Igs, (G) goat BLG-specific polyclonal Igs or (H) BSA-
specific polyclonal Igs. (A, D, E, H) Represent significance against all other groups,
in (B, C, F, G) statistical differences are shown for cow versus goat β-lactoglobulin
groups. Data were generated in a single experiment and compared using Two-way
repeated measures ANOVA with Bonferroni’s post-test; **p<0.01, ****p<0.0001.
214
6.4 Discussion
In this chapter we sought to establish the components of milk that influence its al-
lergenicity. We used the pTh2 assay to compare homologous cow and goat milk
proteins. We examined BLG, αs1-casein, and also the whole casein fraction. We
further investigated the anti-allergic properties of skim and whole goat milks, and
the oral potentiation that follows oral challenge with goat or cow BLG. In the pTh2
assays, we observed similar, dose-dependent Th2 cell development in response to pri-
mary cow and goat BLG, αs1 or whole casein fraction immunisation. These findings
indicated that the intrinsic allergenicity of these goat and cow milk allergens was sim-
ilar. We also found that goat milk itself did not appear to suppress Th2 responses.
Our oral challenge studies identified that goat BLG can induce antigen-specific mast
cell responses in the intestine, and preliminary data indicated that oral challenge with
OVA, cow or goat BLG caused oral potentiation in iFABPp-IL-9 transgenic mice. In
our data we observed no significant difference in the level of potentiation invoked by
either cow or goat BLG.
6.4.1 Evidence for differential allergenicity of goat and cow
milk
Goat and cow milks have been compared previously. Numerous clinical studies have
investigated their allergenicity. Bellioni-Businco et al.[192] observed that a significant
proportion of cow milk allergic individuals were also allergic to goat milk[192]. Ah-
Leung et al. presented evidence of a number of individuals sensitized to goat milk, but
not cow milk[221]. Significant cross-reactivity between milk proteins from different
ruminant species is usually observed[192, 247]. The IgE binding to cow αs1-casein is
also frequently very strong[182]. Ballabio et al. recently observed that goat milk with
low or no αs1-casein induces minimal skin prick positivity in some cow milk sensitized
individuals[236]. There is evidence of cross-reactivity, however, there is also clinical
evidence of cases in which the milks are antigenically distinct.
In experimental systems, comparisons have also been made between cow and goat
milk. McLaughlan et al.[238] ran experiments in guinea pigs. Guinea pigs that were
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given ad libitum access to cow milk became sensitized and demonstrated frequent fatal
anaphylaxis when i.v.-challenged with cow BLG or whole caseins[238]. Guinea pigs
sensitized to goat milk in the same manner also succumbed to the i.v. challenge[238].
However, it was found that if the milks were boiled prior to feeding, the incidence
of fatal i.v.-induced anaphylaxis was reduced, and reduced more markedly for boiled
goat milk[238]. More recently, in a contracted version of the same experiment, the
incidence of fatal anaphylaxis was less frequent in goat milk fed mice[141]. Bevilacqua
et al.[249] observed that when guinea pigs were senstized to whole goat or whole
cows milk, the antibody response was directed against BLG, and milk that had low
αs1-casein content caused less intestinal anaphylaxis[249]; goat milk that had high
αs1-casein caused similar disease severity to cow milk[249]. Similarly, in mice, Lara-
Villoslada et al.[234] demonstrated that mice sensitized orally and challenged i.v. with
skim cow milk released more plasma histamine, had elevated IgG1 titres, had more
severe anaphylactic symptoms and a skewed Th2 cytokine response profile compared
to skim goat milk treated mice[234]. Therefore, there is experimental evidence that
links the allergenicity of goat milk to its αs1-casein content.
6.4.2 αs1-casein as an allergen
Given the evidence in the literature that indicates that αs1-casein is a dominant
allergen, the comparatively low pTh2 response to αs1-casein was surprising. The
αs1-casein content of milk has many times been associated with its allergenicity in
experimental systems[141, 232, 234, 249, 250], and we expected to observe significant
differences. However, not only was there no apparent difference in Th2 development
between cow and goat αs1-casein, both were also poorly immunogenic. In response to
a 1 mg dose, we observed that the total immune cell infiltrate increased by only two-
fold, and the CD4+ T cell population did not observably expand (Figure 6.4).
These findings may indicate that αs1-casein influences the allergenicity of milk through
interaction with other milk components. Caseins form micelles, and αs1-casein influ-
ences the structure and size of the micelle[230]. Johansson et al.[474] argue that the
biasing of monoclonal antibodies that develop against caseins toward κ casein, could
reflect an important role for the supramolecular structure of the casein micelle in its
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immunogenicity[474]. In our studies, we observed that the whole casein fraction was
more immunogenic than αs1-casein in isolation (Figure 6.5), which may support this
finding. Processing of milks can alter their basic physical properties. Heat-treating
milks can induce covalent linkages between BLG peptides and κ casein[475]. The com-
bined effects of caseins and BLG may be important for the allergenicity of milks, and
have been shown to be interrelated in the past[249, 250]. More recently, it has been
shown that milk with high αs1-casein content has larger fat globule diameter[476].
In our studies, we observed that whole milk increased the pTh2 response to HDM
to a greater extent than did skim milk (Figure 6.7); we used low αs1-casein milk in
these studies, but it is possible that higher fat content, or globule size could have
increased the response even more. Although we saw augmented responses to HDM
in the presence of whole milk compared with skim milk in the pTh2 model, we did
not see this same effect in the oral challenge model (Figure 6.7). Side-by-side com-
parisons of cow and goat milk fats on the pTh2 response may reveal some additional
αs1-casein-associated aspects that do not relate to its intrinsic allergenicity or auto-
adjuvanticity.
In the appropriate circumstances, αs1-casein can induce Th2 responses in isolation.
Recently, αs1-casein from goat milk was shown to orally potentiate sensitized mice,
because mMCP-1 levels increase after αs1-casein feeding[394]. In this study, αs1-
casein also triggered increased IgE production, and higher IL-4 and IL-10 release
by splenocytes cultured with αs1-casein[394]. This report indicates that αs1-casein
can act as an allergen in mice. One difference is that this system employed a pre-
sensitization, where mice were administered αs1 casein i.p. with alum adjuvant prior
to i.g. challenge[394]. In our studies, we did observe some Th2 cell development
in response to αs1-casein (Figure 6.4), but the addition of an exogenous adjuvant
is likely to amplify the immune response. These findings may indicate that αs1-
casein has low auto-adjuvanticity, but in the presence of an adjuvant can become a
significant allergen. Natural adjuvants that contribute to sensitization could come in
the form of staphylococcal superantigens[477], or alternatively, may not be required
for sensitization if the allergen was exposed to a mucosal surface (e.g., the lung;[136]).
Additionally, as there are homology differences between cow and human milk proteins,
the absence of an observable effect in the mouse may relate to differences in protein
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homology between cow, goat and mouse milk proteins, in contrast to cow, goat and
human milk proteins. Further studies will be required to determine the comparative
allergenicity of goat αs1-casein to cow αs1-casein in oral challenge models, and test
alternative means by which αs1-casein could sensitize.
6.4.3 The allergenicity of BLG
We investigated BLG allergenicity using the pTh2 assay and in the oral challenge
model. In our pTh2 assays, we observed equivalent allergenicity of cow and goat BLG.
Both proteins induced 15-100-fold increases in Th2 cell development when injected at 1
mg, which indicated that the intact allergens were equivalently allergenic (Figure 6.2).
However, evidence in the literature encouraged us to investigate the response in an oral
challenge model. Goat BLG was shown in the past to induce intestinal responses in
guinea pigs[249]. Cow BLG has been demonstrated to induce mast cell degranulation
in oral challenge models[263]. There is also evidence in the literature that while they
are both stable proteins, the digestibility of the two BLGs differ: 50-80% of goat BLG
is degraded, compared to only 20% of cow BLG when subjected to sequential digestion
in human gastric- and then duodenal juices[185, 478]. We considered that if goat milk
was more digestibile and more rapidly degraded in the murine gastrointestinal tract
the amount of intact antigen available to drive the inflammatory process may be
reduced and result in a similar four-fold differential in their ability to orally prime
and induce mMCP-1 production.
Earlier studies undertaken at AgResearch identified that goat β-lactoglobulin can
drive oral potentiation (Ali Hodgkinson, personal communication). However, mast
cells can produce mMCP-1 in an IgE-independent manner[479], so it was important
to confirm that the oral response only occurs in response to sensitizing antigen. In our
oral challenge studies, we observed that six oral challenges with 50 mg goat BLG was
sufficient to orally potentiate, because mMCP-1 titres increased from ≈20 ng/mL to
≈5000 ng/mL in orally-fed mice (Figure 6.8). We also observed elevated IgE titres,
only in sensitized, allergen-fed mice. Further, feeding goat BLG-sensitized mice with
OVA did not increase mMCP-1 release above mock-challenged and/or sensitized con-
trols. Therefore, oral potentiation induced by goat BLG feeding required sensitization
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and was goat BLG specific.
In the literature, the mast cell response correlates with the development and severity
of oral allergic responses[36, 38]. In our studies in the previous chapter (Chapter 5),
we confirmed that the intestinal mast cell response was a CD4+ T cell-dependent
event. Therefore mMCP-1 production can be used to reflect the allergenicity of an
orally administered protein.
In a preliminary investigation, we used the iFABPp-IL-9 transgenic mice to compare
the allergenicity of OVA, cow and goat BLG. We observed that oral potentiation
occurred when any of OVA, cow or goat BLG were used, because mMCP-1 titres
were elevated compared to PBS-fed mice (Figure 6.9). In terms of their comparative
allergenicity, the low power of the experiment, and unexpected, but unreproducible,
diarrhoea development in cow BLG-sensitized mice prevents us from making defini-
tive conclusions. However, there were trends indicating that OVA induced the most
mMCP-1 release, generated the most frequent splenic IgG1-ASCs, and had high serum
IgG1 titres (Figures 6.9 and 6.10). Similarly, while mMCP-1 levels induced by cow
and goat BLG were similar, the cow BLG-fed group demonstrated increases in serum
cow BLG-specific antibodies that were not observed in the goat-fed group (See Ap-
pendices). Additionally, early in the response, we observed diarrhoea and severe
plasmavolaemia in the cow BLG-fed group. We were unable to repeat this finding,
and further were unable to link this to the allergic process because we could not bleed
these mice post-challenge. However, it does indicate that oral processing may be an
important feature of the differential allergenicity of cow and goat BLG that could be
revealed in follow-up studies using larger experiments.
6.4.4 Future investigations that could clarify goat milk pro-
tein allergenicity
To accurately clarify the role of oral processing in milk protein allergenicity, there
are several potential experiments that would be useful. One of the most informative
tests will be to directly assess antibody cross-reactivity in cow and goat BLG-fed
mice, which could be done using antigen inhibition tests[480]. Lung challenge models
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and alternate oral challenge models have been employed using cow BLG[139, 458].
Cytokine levels produced by splenocytes, intestinal cells or mesenteric lymph node
cells have been compared for other allergens[57, 394]. Examining these responses may
reveal differences in the oral potentiation response, and clarify whether the trend we
observe reflects a true difference, or relates to experimental variation.
The pTh2 studies could also be expanded. Examining the local Th2-mediated B cell
response may indicate additional aspects of protein allergenicity that are not revealed
by measuring Th2 development. While we observe IgG1 switching in the pTh2 assay,
and this correlated with the Th2 response (Chapter 4), distinct mechanisms influence
IgE class switching[279, 306, 445, 481]. Specifically, while both IgE and IgG1 class
switching are both controlled by TFH cells and sensitive to IL-4, they are reciprocally
affected by IL-21[440–443, 482]. Therefore, examining IgE switching may be addi-
tionally informative. While beyond the sensitivity of most current tools, examining
IgE switching may be possible in a modified pTh2 assay using recently developed
IgE-reporter mice[444, 445].
In the course of our studies, we have found no difference in the intrinsic allergenicity,
as defined by primary Th2 cell induction, for BLG, αs1 or whole casein fractions
isolated from cow or goat milks. Future work that analyses milk proteins in isolation,
milk as a complete food and as its casein and whey fractions will have the potential to
clarify the differences in cow and goat milk that render them differentially allergenic
in experimental contexts.
6.5 Summary
Homologous milk allergens derived from cow and goat milk induced similar pTh2 re-
sponses to each other. αs1-casein was shown to have low allergenicity in isolation.
The presence of milk fat increased the pTh2 response but did not expedite disease in
the oral challenge model. Goat milk did not demonstrate strong anti-allergic proper-
ties in the models tested. Further investigation of how oral processing influences milk
protein allergenicity is warranted.
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Chapter 7
General Discussion
7.1 Summary of findings
During the course of this work we uncovered some novel aspects of Th2 cell devel-
opment and function. In Chapter 3, we determined that biallelic IL-4 production
occurs more frequently than is predicted for a monoallelic, stochastic gene expression
event. In Chapter 4, we identified IL-4-independent and -dependent phases of Th2
cell development, and also found that the biallelic IL-4-producing potential is impor-
tant for allergen-specific Th2 immunity. In Chapter 5, we uncovered an important
role for IL-3, and established the causal role of CD4+ T cells in allergen-induced in-
testinal mastocytosis. We further determined that this function of CD4+ T cells was
required additional to their contribution to IgE production. Our final results chapter
defined the Th2-inducing capacity of goat and cow milk components. It additionally
provided preliminary information about the ability of goat BLG to induce intestinal
mast cell activity. The findings of this thesis reaffirm the central role of CD4+ T cells
in IgE-mediated allergic disease.
7.1.1 Checkpoints along the road to allergy
The inter-related aspects of Th2 immunity investigated in this project allow us to draw
a more comprehensive picture of the experimental allergic process that ultimately
results in diarrhoea. We identified numerous points of potential disease intervention
in mice that warrant investigation in clinical settings based on current knowledge and
the findings of this thesis. These concepts are summarised in figure 7.1. Taken as a
whole, we consider that there are multiple points for disease intervention, however,
the further along the process, the more difficult disease will become to treat.
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7.1.2 Future research directions
Evaluating Biallelic Th2 cell function in vivo
In this thesis, we examined Th2 cell development and function, largely using IL-4
haplo-insufficient, or IL-4-deficient reporter mice. We infer information about the reg-
ulation of IL-4 production from our data, namely that biallelic IL-4 production is more
frequent than is expected based on the proposed model[401]. Determining whether
this is important for specific aspects of allergic Th2 cell function, and whether this
truly occurs in wild-type mice (and humans) in vivo, requires further investigation.
The presence of biallelic IL-4 production in wild-type cells could be evaluated at the
transcriptional level using single cell PCR analysis from in vivo-generated Th2 cells
with distinguishable, but wild-type IL-4 alleles[389]. Additionally, the specific involve-
ment of biallelic IL-4 production in Th2 immunity could be examined at a functional
level. Deletion of an IL-4-silencer site results in non-specific IL-4 production[380],
which could override the potential imbalance in the absolute concentration of IL-4
in IL-4 heterozygous mice. These mice would then be deficient only in biallelic IL-4
production. Examining IgG1 class-switching, the generation of IgE, and the devel-
opment of allergic diarrhoea could make some headway into the role of biallelic IL-4
producing Th2 cells in the allergic immune process.
Establishing the functional or physical divergence of Th2m
and TFH cells
The data in the oral allergen challenge model provides evidence for the existence of
Th2m cells. However, it is unknown whether Th2m cells are a separate population
from IgE-inducing cells. In addition to IgE production at systemic sites[444], antibody
can be produced in high amounts in local tissues. Specifically, Kweon et al. iden-
tify IgE-producing B cells in the colonic intestinal lamina propria of orally-sensitized
mice[58]. In this case, it is plausible that Th2m cells are also the cells involved in
the amplification of systemic IgE following oral exposure, and contribute to both
processes simultaneously. Determining the existence of divergent, or overlapping Th2
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cell functions in the intestinal allergic process may indicate whether targeting multiple
CD4+ T cell populations will be required for effective disease intervention. Addition-
ally, establishing the importance of IL-3 in other oral allergen-challenge models, and
eventually in clinical contexts will clarify the overall involvement of IL-3 in the in-
testinal allergic process. Simple experiments could evaluate IL-3-deficient mice in the
cholera toxin model[58, 140, 483], the superantigen oral allergic disease model[456],
or use IL-3R-deficient mice to validate our findings in the model we used[113]. For
clinical application, initial animal experiments could also examine whether anti-IL-3
antibodies can inhibit disease development in mice.
Targeting adaptive immunity for disease intervention
The most informative experiment that will follow our oral potentiation studies in
Chapter 5 arises from the CD4-depletion work. We observed that while CD4+ T cells
were not required for disease maintenance, the underlaying inflammatory process was
diminished following their depletion. Clinically, anti-IgE therapies are effective at
desensitizing, but not necessarily tolerizing allergic individuals (permitting long-term
disease resolution). However, the CD4+ T cell response wanes in anti-IgE treated
individuals[83]. Concomitant CD4-depletion along with administration of anti-IgE
in mice (using anti-IgE hybridomas like EM-95[37]), could potentially ablate, and
prevent the re-establishment of disease. This may uncover the basic processes that
underlie long-term disease susceptibility and eventually lead to a combined therapy
that targets allergen-reactive CD4+ T cells and IgE-producing B cells.
It would be ill-advised to use a pan-CD4-depleting antibody (like GK1.5) to treat
allergic diseases, because subsets of CD4+ T cells contribute to the adaptive immune
response against essentially every pathogen that causes human disease. Therefore,
establishing novel ways in which allergen-reacted CD4+ T cells can be targeted will
be a second required step that will precede the arrival of potential therapies in the
clinic.
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Addressing the ”localness” of local responses
One key aspect that remains to be addressed is the extent to which oral potentiation
requires local exposure. Allergen is detected in the intestines of naive allergen-fed
mice, but oral challenge of sensitized mice increases intestinal permeability[37, 57] and
results in 1000-fold higher (to µg/mL concentrations) levels of allergen in the blood[68,
149]. Furthermore, in sensitized mice, systemic anaphylactic responses, in some cases,
are caused by oral allergen administration[67], and response severity correlates with
the administered allergen dose, and the amount that is absorbed[67, 68]. While the
intestinal response requires multiple gavages to become manifest, the dissemination of
allergen that follows intestinal allergen exposure argues against complete segregation
of each tissue in the common mucosal immune system. In line with the concept of
systemic potentiation, oral allergen challenge also increases lung mast cell numbers
and exaccerbates the severity of the response evoked by distinct sensitizing allergens in
both the lung and the intestine[67, 149, 321]. Clarifying whether the exaccerbation of
the lung response requires allergen to reach the lung, or is a general feature of the Th2
response would improve our understanding of the post-sensitization CD4-dependent
allergic process. Stabilizing mast cells prior to oral allergen exposure prevents the
leaky gut phenotype in iIFABP -IL-9 mice. This could be used to distinguish between
systemic potentiation via the oral route and lung potentiation induced by systemic
allergen dissemination. This will be an important direction for follow up work to our
studies examining oral potentiation of the intestine.
Reflecting allergenicity as a function of Th2 cell development
In our aim to clarify immunological differences between cow and goat milk, we were
unable to identify quantitative differences in the Th2 response to specific proteins.
However, closer analysis of the whole casein fraction may identify important aspects
of milk allergenicity that our assays have not examined. Specifically, we did not
analyse whole caseins in the oral challenge model; ruminant caseins demonstrate sig-
nificant species-to-species cross-reactivity in humans[34] and this may be an important
attribute of their ability to cause allergies. Simply comparing mMCP-1 production
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in the oral challenge model using cow and goat casein fractions, or whole milks in
this model, could indicate the ability of milk from each source to promote intestinal
allergy. Additionally, in our suppression assays, we examined the ability of milks to
suppress the allergic response to an environmental, rather than a food allergen. Fu-
ture studies would also benefit from analysis of the Th2 response to food allergens in
the presence- or absence of milk protein.
The cause of sensitization
The pathways that initiate sensitization after birth are unclear. Clarifying which as-
pects of the allergic process are modelled in the two Th2 immune response models
examined in this thesis will help us understand how a protein becomes an allergen.
In the G4 reporter pTh2 assay, two components should be examined in the near fu-
ture. First, the influence of adjuvant on the Th2 response should be explored. While
we examined the intrinsic allergenicity of homologous proteins in milks, the complex
composition of milks may require multiple components to initiate the allergic process.
Addition of an adjuvant may amplify Th2 responses to some proteins to a great ex-
tent than others. Similarly, cooking processes can modify the structure of isolated
proteins and of whole foods[139, 160, 161, 475]; determining whether specific modi-
fications to weak allergens can influence their allergenicity may clarify the processes
that contribute to allergic sensitization in future studies. The third aspect implicated
in allergic sensitization is the exposure site, and this is not necessarily reflected in the
pTh2 assay. Examining allergenicity of primary allergen exposure in the lung, which
models inhaled allergen exposure, has been shown to induce Th2-type responses in
mice[136]. Using G4 reporter mice it may be possible to quantitate Th2 induction
following the first intranasal allergen exposure, and in this reveal additional aspects
of the Th2 response to allergens. While this may be below the sensitivity of the initial
Th2 response, sufficient Th2 cells may develop, and thus help clarify how allergic Th2
immunity is initiated.
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7.1.3 Evaluating the success of this project
In this thesis, ”Development of Th2 immune response models to evaluate allergenicity
of milk proteins”, I aimed to develop assays that could be used to examine the com-
parative allergenicity of cow and goat milks. While I was unable to identify specific
anti-allergic goat milk components, or those with intrinsically lower allergenicity than
their homologous cow milk components, I was able to use the PTh2 assay and the
oral allergen-induced intestinal anaphylaxis model to test the allergenicity of multiple
milk proteins. The findings in chapters three, four and five provide good grounding
for the investigations undertaken in these assays. In retrospect, generating empirical
data for the mMCP-1 release studies could be informative in determination of the
size of the experiments required to observe a predictably ’physiologically relevant’
difference in ’allergenicity’ in the oral challenge model. Thus, while I was unable to
identify immunologic features that result in the reduced allergenicity of goat milk, the
studies in this thesis provide clear evidence of how the PTh2 assay and oral challenge
model can be used in synchrony as a framework in which multiple features of protein
allergenicity can be evaluated.
7.1.4 Final conclusions
In this dissertation, I have used literature and experimental evidence to argue for a
multi-phase inflammatory process that leads to allergic response susceptibility. The
initial allergen exposure initiates IL-4-independent Th2 cell development. These cells
are then expanded in the presence of IL-4, facillitate IgE production and are addition-
ally involved in an oral potentiation phase that permits allergic response triggering
in the intestine. These processes can be initiated by many individual proteins, but
these vary by orders of magnitude, depending on the specific allergen involved. In this
manner, allergic disease can be considered an unbalanced sum of factors: Disease is
influenced by the inflammatory environment, properties of the allergen and the host
that ultimately result in allergic response susceptibility.
The findings used to create this thesis can be summarised in four statements. First,
primary allergen immunisation induces IL-4-independent Th2 cell development which
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is followed by an IL-4-dependent phase. Second, IL-4 heterozygous mice are hap-
loinsufficient for IL-4 in allergic disease contexts. Third, CD4+ T cells are critical
mediators of IL-3-dependent oral allergen-induced intestinal mastocytosis. Lastly, the
low allergenicity of goat milk compared to cow milk relates to its absolute composi-
tion, or changes occurring during physiological processing, rather than differences in
the intrinsic allergenicity of its dominant protein components.
Despite some significant advances made in recent times, fuller understanding is re-
quired before allergies will become manageable maladies that are considered afflictions
of the past. The most critical question that remains to be addressed is what permits
persistent, consistently deleterious immune responses to normal, everyday proteins
and foods. The aetiology of allergic disease is, and should remain at the forefront of
scientific research until we have the answer.
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Chapter 8
Appendices
8.1 Supporting data
8.1.1 References for figure 1.1
1Finkelman, 2007. J Allergy Clin Immunol. 120:506-515.
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3Strait et al., 2003. J Immunol. 170:3835-3842.
4Feyerabend et al., 2011. Immunity 35:1-13.
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Figure 8.1: References for figure 1.1. These references relate specifically to figure
1.1 in the introduction section.
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8.1.2 Genotyping of IL-3 and IL-9 transgene
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Figure 8.2: Genotype testing of IL-3 and IL-9. (A) Mice were tested for the
presence of the wild-type IL-9 and the IL-9 transgene. (B) Mice were tested for the
presence of the wild-type IL-3 gene. Primer pairs can be found in the methods section.
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8.1.3 Flow Cytometry reagents
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Specificity Fluorophore Clone Source
B220 Horizon V450 Ra3-6B2 BD Pharmingen
PE-Texas Red Ra3-6B2 BD Pharmingen
CD3 Alexafluor R© 488 500A2 Invitrogen Molecular Probes
CD4 Allophycocyanin (APC) RM4-5 BD Pharmingen
APC/H7 GK1.5 BD Pharmingen
Fluorescein Isothiocyanate (FITC) GK1.5 In house
Phycoerythrin (PE) GK1.5 BD Pharmingen
Peridinin Chlorophyll Protein (Percp) RM4-5 BD Pharmingen
Quantum dot605 R© RM4-5 invitrogen Molecular Probes
CD8a Alexafluor R© 700 536.7 Biolegend
PE-Cy7 53-6.7 BD Pharmingen
CD19 APC-H7 ID3 BD Pharmingen
CD44 PE IM7 BD Pharmingen
CD45 Pacific Blue R© 30F11 Biolegend
CD62L Biotin MEL-14 BD Pharmingen
Pacific Blue R© MEL-14 Biolegend
CD117) APC 2B8 BD Pharmingen
FceRI PE Mar-1 eBioscience
CD16/32 FITC 2.4G2 BD Pharmingen
human CD2 APC RPA2.10 BD Pharmingen
I-A/I-E PE-Cy7 M51114.15.2 Biolegend
IL-3 PE MP2-8F8 BD Pharmingen
IL-4 APC 11B11 BD Pharmingen
PE 11B11 BD Pharmingen
IL-5 PE TRFK-5 BD Pharmingen
IL-10 PE JES5-16E3 BD Pharmingen
IL-13 PE eBio13A eBioscience
IgD PE 11-26c.2a BD Pharmingen
IgE biotin R35-118 BD Pharmingen
IgG1 biotin A85.1 BD Pharmingen
CD49b PE-Cy7 DX5 eBioscience
Biotin APC Streptavidin BD Pharmingen
FITC Streptavidin BD Pharmingen
PE Streptavidin BD Pharmingen
PE-Texas Red R© Streptavidin BD Pharmingen
7-Amino Actinomycin D (7-AAD) BD Pharmingen
4,6-diaminidino-2-phenylindole (DAPI) Invitrogen Molecular Probes
Live/Dead R© fixable blue Invitrogen Molecular Probes
Golgistop (with Monensin) BD Pharmingen
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8.1.4 Flow cytometers
282
Cytometer Laser Filter and position Reagents
LSRII-SORP Ultraviolet (355 nm) 450/50B DAPI
Live/Dead fixable blue
Violet (405 nm) 450/50F Brilliant Violet 421
Pacific Blue R©
Horizon R©V450
605/40C Qdot605
Blue (488 nm) 705/70A Percp
515/20B GFP
FITC
Alexafluor488
488/10C Side Scatter (SSC)
Green (532 nm) 780/60A PE-Cy7
660/40C 7-AAD
610/20D PE-Texas Red R©
575/26E PE
Red (633/640 nm) 780/60A APC-Cy7
780/60A APC-H7
710/50B Alexafluor R© 700
670/14C APC
BD FACSCallibur Blue (488 nm) 530/30 (FL-1) FITC
Alexafluor R©488
GFP
585/42 (FL-2) PE
670LP (FL-3) 7-AAD
661/16 (FL-4) APC
FACSDiva Blue (488 nm) 530/30 (FL-1)
585/42 (FL-2) PE
670LP (FL-3)
Red (633 nm) 661/16 (FL-4) APC
780/60 (FL-5)
Ultraviolet (355 nm) 450/50 (FL-6) DAPI
620LP (FL-8)
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8.1.5 Supplementary data
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Figure 8.3: GFP and hCD2 medFI are lower in KN2/G4 cells than G4/+,
KN2/+, G4/G4 and KN2/KN2 cells. Ten days after intradermal immunization
with 100 µg HDM, auricular lymph nodes were excised. (A) The GFP median fluo-
rescence intensity of total GFP+ CD4+ cells was examined. (B) The hCD2 median
fluorescence intensity of total hCD2+ CD4+ cells was examined. Data are shown from
one of the experiments used to compile data in figures 4.2 and 4.3. AFU=Arbitrary
Fluorescence Units.
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Figure 8.5: Cytokine production by OVA or PBS-stimulated splenocytes
from IL-3 sufficient and deficient mice. Mice were sensitized to OVA plus alum
twice by ip injection and then were mock-challenged with PBS 10 times. Spleens
were excised and cultured with OVA (OVA) or medium alone (PBS). After four days
supernatants were collected and examined for (A) IL-3, (B) IL-4, (C) IL-5 and (D)
IL-13 production using a bioplex assay. Data bars show mean + SEM of individually
cultured spleens (n=5/group). **p<0.01, ****p<0.0001 by Two-way ANOVA with
Bonferroni’s post-test.
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Figure 8.6: Cytokine production by OVA or PBS-stimulated mesenteric
lymph node cells from Tg+/+, Tg-/- and nTg-/- mice. Mice were sensitized
to OVA plus alum twice by ip injection and then were mock-challenged with PBS
11 times. Mesenteric lymph nodes were excised and cells were cultured with OVA.
After three days supernatants were collected and examined for (A) IFN-γ, (B) IL-3,
(C) IL-4 and (D) IL-5 and (E) IL-13 production by ELISA. Data bars show mean +
SEM of individually cultured MLNs (n=3/group). Data were compared by One-way
ANOVA with Tukey’s post-test. Dashed lines represent the assay limit. ND, none
detected.
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Figure 8.7: Mastocytosis in caprine BLG sensitized mice. Jejunal mast cell
frequencies were determined by CAE staining at the experimental endpoint in mice
from Figure 6.8. NA not analysed.
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Figure 8.8: Liquid stool at 60 minutes post-challenge three in intestinally
atopic mice fed different allergens. 60 minutes after the third oral gavage with
sensitizing antigen (day 13), iIFABPp-IL-9 mice were photographed. Diarrhoea was
not observed in any mice in a second experiment in which sensitized or naive mice
were fed three times with 50 mg cow BLG.
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